0001628280-24-021088.txt : 20240507 0001628280-24-021088.hdr.sgml : 20240507 20240507160934 ACCESSION NUMBER: 0001628280-24-021088 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 81 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: agilon health, inc. CENTRAL INDEX KEY: 0001831097 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 371915147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40332 FILM NUMBER: 24921896 BUSINESS ADDRESS: STREET 1: 6210 E HWY 290 STREET 2: SUITE 450 CITY: AUSTIN STATE: TX ZIP: 78723 BUSINESS PHONE: 562-256-3800 MAIL ADDRESS: STREET 1: 6210 E HWY 290 STREET 2: SUITE 450 CITY: AUSTIN STATE: TX ZIP: 78723 FORMER COMPANY: FORMER CONFORMED NAME: Agilon Health Topco, Inc. DATE OF NAME CHANGE: 20201103 10-Q 1 agl-20240331.htm 10-Q agl-20240331
0001831097December 312024Q1falsehttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent7600018310972024-01-012024-03-3100018310972024-05-01xbrli:shares00018310972024-03-31iso4217:USD00018310972023-12-31iso4217:USDxbrli:shares0001831097us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-03-310001831097us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310001831097agl:MedicalServicesRevenueMember2024-01-012024-03-310001831097agl:MedicalServicesRevenueMember2023-01-012023-03-310001831097agl:OtherOperatingRevenueMember2024-01-012024-03-310001831097agl:OtherOperatingRevenueMember2023-01-012023-03-3100018310972023-01-012023-03-310001831097us-gaap:CommonStockMember2023-12-310001831097us-gaap:AdditionalPaidInCapitalMember2023-12-310001831097us-gaap:RetainedEarningsMember2023-12-310001831097us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001831097us-gaap:NoncontrollingInterestMember2023-12-310001831097us-gaap:RetainedEarningsMember2024-01-012024-03-310001831097us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001831097us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001831097us-gaap:CommonStockMember2024-01-012024-03-310001831097us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001831097us-gaap:CommonStockMember2024-03-310001831097us-gaap:AdditionalPaidInCapitalMember2024-03-310001831097us-gaap:RetainedEarningsMember2024-03-310001831097us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001831097us-gaap:NoncontrollingInterestMember2024-03-310001831097us-gaap:CommonStockMember2022-12-310001831097us-gaap:AdditionalPaidInCapitalMember2022-12-310001831097us-gaap:RetainedEarningsMember2022-12-310001831097us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001831097us-gaap:NoncontrollingInterestMember2022-12-3100018310972022-12-310001831097us-gaap:RetainedEarningsMember2023-01-012023-03-310001831097us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001831097us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001831097us-gaap:CommonStockMember2023-01-012023-03-310001831097us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001831097us-gaap:CommonStockMember2023-03-310001831097us-gaap:AdditionalPaidInCapitalMember2023-03-310001831097us-gaap:RetainedEarningsMember2023-03-310001831097us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001831097us-gaap:NoncontrollingInterestMember2023-03-3100018310972023-03-31agl:member0001831097agl:PayorAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-03-31xbrli:pure0001831097agl:PayorAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-03-310001831097us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberagl:PayorBMember2024-01-012024-03-310001831097us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberagl:PayorBMember2023-01-012023-03-310001831097us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberagl:PayorCMember2024-01-012024-03-310001831097us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberagl:PayorCMember2023-01-012023-03-310001831097us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberagl:PayorDMember2023-01-012023-03-310001831097agl:PayorAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-03-310001831097agl:PayorAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001831097us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberagl:PayorBMember2024-01-012024-03-310001831097us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberagl:PayorBMember2023-01-012023-12-310001831097us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberagl:PayorCMember2024-01-012024-03-310001831097us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberagl:PayorDMember2024-01-012024-03-310001831097us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberagl:PayorDMember2023-01-012023-12-310001831097us-gaap:CorporateDebtSecuritiesMember2024-03-310001831097us-gaap:CorporateDebtSecuritiesMember2023-12-310001831097us-gaap:USTreasurySecuritiesMember2024-03-310001831097us-gaap:USTreasurySecuritiesMember2023-12-310001831097us-gaap:OtherDebtSecuritiesMember2024-03-310001831097us-gaap:OtherDebtSecuritiesMember2023-12-310001831097us-gaap:DebtSecuritiesMember2024-01-012024-03-310001831097us-gaap:CashAndCashEquivalentsMember2024-01-012024-03-310001831097us-gaap:DebtSecuritiesMember2023-01-012023-03-310001831097us-gaap:CashAndCashEquivalentsMember2023-01-012023-03-310001831097us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2024-03-310001831097us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-03-310001831097us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2024-03-310001831097us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001831097us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001831097us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001831097us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2024-03-310001831097us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-03-310001831097us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2024-03-310001831097us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2023-12-310001831097us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310001831097us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2023-12-310001831097us-gaap:FairValueInputsLevel1Memberus-gaap:OtherDebtSecuritiesMember2024-03-310001831097us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-03-310001831097us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001831097us-gaap:FairValueInputsLevel1Memberus-gaap:OtherDebtSecuritiesMember2023-12-310001831097us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001831097us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001831097us-gaap:FairValueInputsLevel1Member2024-03-310001831097us-gaap:FairValueInputsLevel2Member2024-03-310001831097us-gaap:FairValueInputsLevel3Member2024-03-310001831097us-gaap:FairValueInputsLevel1Member2023-12-310001831097us-gaap:FairValueInputsLevel2Member2023-12-310001831097us-gaap:FairValueInputsLevel3Member2023-12-310001831097us-gaap:SegmentContinuingOperationsMember2024-01-012024-03-310001831097us-gaap:SegmentContinuingOperationsMember2023-01-012023-03-310001831097us-gaap:SegmentDiscontinuedOperationsMember2024-01-012024-03-310001831097us-gaap:SegmentDiscontinuedOperationsMember2023-01-012023-03-310001831097us-gaap:UnassertedClaimMember2023-12-310001831097us-gaap:UnassertedClaimMember2024-03-310001831097agl:SecuredTermLoanFacilityMember2021-02-180001831097agl:SecuredRevolvingFacilityMember2021-02-180001831097us-gaap:StandbyLettersOfCreditMember2021-02-180001831097agl:SecuredTermLoanFacilityMember2021-02-182021-02-180001831097agl:SecuredTermLoanFacilityMember2024-03-310001831097agl:SecuredRevolvingFacilityMember2024-03-310001831097us-gaap:StandbyLettersOfCreditMember2024-03-310001831097us-gaap:StandbyLettersOfCreditMember2024-01-012024-03-310001831097srt:MaximumMemberagl:SecuredTermLoanFacilityMemberagl:SecuredOvernightFinancingRateSOFRMember2023-05-252023-05-250001831097agl:SecuredTermLoanFacilityMemberagl:SecuredOvernightFinancingRateSOFRMembersrt:MinimumMember2023-05-252023-05-250001831097srt:MaximumMemberagl:SecuredTermLoanFacilityMemberus-gaap:BaseRateMember2023-05-252023-05-250001831097agl:SecuredTermLoanFacilityMemberus-gaap:FederalFundsEffectiveSwapRateMember2023-05-252023-05-250001831097agl:SecuredTermLoanFacilityMemberagl:SecuredOvernightFinancingRateSOFRMember2023-05-252023-05-250001831097agl:SecuredTermLoanFacilityMembersrt:MinimumMemberus-gaap:BaseRateMember2023-05-252023-05-250001831097srt:MinimumMemberagl:SecuredRevolvingFacilityMember2023-05-252023-05-250001831097us-gaap:SuretyBondMember2024-03-310001831097us-gaap:SuretyBondMember2023-12-3100018310972024-02-012024-03-31agl:lawsuit0001831097us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001831097us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001831097us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001831097us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001831097agl:MphrxMember2023-02-282023-02-280001831097agl:MphrxMemberagl:DevelopedTechnologyMember2023-02-282023-02-280001831097us-gaap:CustomerRelationshipsMemberagl:MphrxMember2023-02-2800018310972023-02-282023-02-28agl:entity0001831097us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-03-31agl:investment0001831097us-gaap:SuretyBondMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-03-310001831097us-gaap:SuretyBondMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310001831097agl:OtherEquityMethodInvestmentsMember2024-03-310001831097agl:OtherEquityMethodInvestmentsMember2023-12-310001831097agl:ACOREACHMember2024-03-310001831097agl:ACOREACHMember2023-12-310001831097us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-01-012024-03-31agl:partneragl:geography0001831097us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMemberagl:MedicalServicesRevenueMember2024-01-012024-03-310001831097us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMemberagl:MedicalServicesRevenueMember2023-01-012023-03-310001831097agl:OtherOperatingRevenueMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-01-012024-03-310001831097agl:OtherOperatingRevenueMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-01-012023-03-310001831097us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-01-012024-03-310001831097us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-01-012023-03-310001831097us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-03-310001831097us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-12-310001831097us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberagl:MedicalServicesRevenueMember2024-01-012024-03-310001831097us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberagl:MedicalServicesRevenueMember2023-01-012023-03-310001831097us-gaap:ProductAndServiceOtherMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-01-012024-03-310001831097us-gaap:ProductAndServiceOtherMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-01-012023-03-310001831097us-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-01-012024-03-310001831097us-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-01-012023-03-310001831097agl:VeeralDesaiMember2024-01-012024-03-310001831097agl:VeeralDesaiMember2024-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________________________
FORM 10-Q
_______________________________________________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended March 31, 2024
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from           to           
Commission file number 001-40332
_______________________________________________________
agilon health, inc.
(Exact name of registrant as specified in its charter)
Delaware37-1915147
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
6210 E Hwy 290, Suite 450
Austin, TX 78723
(Address of principal executive offices)
(562) 256-3800
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, $0.01 par value
AGL
New York Stock Exchange
_______________________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x NO o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
xAccelerated Filero
Non-accelerated FileroSmaller Reporting Companyo
  Emerging Growth Companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YES o NO x
At May 1, 2024, there were 411,261,609 shares of the registrant’s $0.01 par value common stock outstanding.

agilon health, inc.
INDEX
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
Other Information
 
  
2
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
agilon health, inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
 March 31,
2024		December 31,
2023
 (unaudited)   
ASSETS
Current assets:
Cash and cash equivalents$111,706 $107,570 
Restricted cash and equivalents6,844 6,759 
Marketable securities307,359 380,773 
Receivables, net1,571,143 942,461 
Prepaid expenses and other current assets, net39,757 42,513 
Total current assets2,036,809 1,480,076 
Property and equipment, net27,539 27,576 
Intangible assets, net72,076 63,769 
Goodwill24,133 24,133 
Other assets155,906 145,312 
Total assets$2,316,463 $1,740,866 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Medical claims and related payables$1,266,651 $737,724 
Accounts payable and accrued expenses252,497 233,182 
Current portion of long-term debt7,500 6,250 
Total current liabilities1,526,648 977,156 
Long-term debt, net of current portion29,834 32,308 
Other liabilities71,495 70,381 
Total liabilities1,627,977 1,079,845 
Commitments and contingencies
Stockholders' equity (deficit):
Common stock, $0.01 par value: 2,000,000 shares authorized; 410,843 and 406,387 shares issued and outstanding, respectively
4,108 4,064 
Additional paid-in capital2,020,803 1,986,899 
Accumulated deficit(1,332,890)(1,326,826)
Accumulated other comprehensive income (loss)(2,747)(2,298)
Total agilon health, inc. stockholders' equity (deficit)689,274 661,839 
Noncontrolling interests(788)(818)
Total stockholders’ equity (deficit)688,486 661,021 
Total liabilities and stockholders’ equity (deficit)$2,316,463 $1,740,866 
The condensed consolidated balance sheets include assets and liabilities of consolidated variable interest entities (“VIEs”) as agilon health, inc., together with its consolidated subsidiaries and VIEs (the “Company”), is the primary beneficiary of these VIEs. The condensed consolidated balance sheets include total assets that can only be used to settle obligations of the Company’s consolidated VIEs totaling $1.71 billion and $1.07 billion as of March 31, 2024 and December 31, 2023, respectively, and total liabilities of the Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $1.49 billion and $930.60 million as of March 31, 2024 and December 31, 2023, respectively. See Note 14 for additional details.
See accompanying Notes to the Condensed Consolidated Financial Statements.
3
agilon health, inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
 Three Months Ended
March 31,
 20242023
Revenues:
Medical services revenue$1,601,195 $1,053,119 
Other operating revenue3,159 1,193 
Total revenues1,604,354 1,054,312 
Expenses:
Medical services expense1,443,842 897,572 
Other medical expenses85,424 83,617 
General and administrative (including noncash stock-based compensation expense of $16,909 and $13,585, respectively)
76,422 69,752 
Depreciation and amortization5,844 2,954 
Total expenses1,611,532 1,053,895 
Income (loss) from operations(7,178)417 
Other income (expense):
Income (loss) from equity method investments5,684 1,376 
Other income (expense), net5,892 7,892 
Interest expense(1,284)(1,493)
Income (loss) before income taxes3,114 8,192 
Income tax benefit (expense)133 1,759 
Income (loss) from continuing operations3,247 9,951 
Discontinued operations:
Income (loss) before gain (loss) on sales(518)6,008 
Gain (loss) on sales of assets, net(8,763)— 
Total discontinued operations(9,281)6,008 
Net income (loss)(6,034)15,959 
Noncontrolling interests’ share in (earnings) loss(30)63 
Net income (loss) attributable to common shares$(6,064)$16,022 
 
Net income (loss) per common share, basic and diluted
Continuing operations$0.01 $0.02 
Discontinued operations$(0.02)$0.02 
Weighted average shares outstanding
Basic408,938413,136
Diluted413,437426,586
See accompanying Notes to the Condensed Consolidated Financial Statements.
4
agilon health, inc.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands)
(unaudited)
 Three Months Ended
March 31,
 20242023
Net income (loss)$(6,034)$15,959 
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable securities, net of tax(457)1,896 
Foreign currency translation adjustment8 115 
Total comprehensive income (loss)(6,483)17,970 
Comprehensive (income) loss attributable to noncontrolling interests(30)63 
Total comprehensive income (loss) attributable to agilon health, inc.$(6,513)$18,033 
See accompanying Notes to the Condensed Consolidated Financial Statements.
5
agilon health, inc.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(in thousands)
(unaudited)
For the three months ended March 31, 2024:
Total Stockholders’ Equity
Common StockAdditional
Paid-In
Capital 		Accumulated
 Deficit 		Accumulated Other Comprehensive
Income (loss) 		Noncontrolling
 Interest 		Total
Stockholders’
Equity
(Deficit)
Shares Amount
January 1, 2024406,387$4,064 $1,986,899 $(1,326,826)$(2,298)$(818)$661,021 
Net income (loss)—— — (6,064)— 30 (6,034)
Other comprehensive income (loss)— — — — (449)— (449)
Exercise of stock options1,43414 2,441 — — — 2,455 
Vesting of restricted stock units1,17011 (11)— — — — 
Shares withheld related to net share settlement(122)(1)(645)— — — (646)
Issuance of common stock1,97420 15,210 — — — 15,230 
Stock-based compensation expense—— 16,909 — — — 16,909 
March 31, 2024410,843$4,108 $2,020,803 $(1,332,890)$(2,747)$(788)$688,486 
For the three months ended March 31, 2023:
Total Stockholders’ Equity
Common StockAdditional
Paid-In
Capital 		Accumulated
 Deficit 		Accumulated Other Comprehensive
Income (loss) 		Noncontrolling
 Interest 		Total
Stockholders’
Equity
(Deficit)
Shares Amount
January 1, 2023412,385$4,124 $2,106,886 $(1,064,230)$(5,560)$(611)$1,040,609 
Net income (loss)—— — 16,022 — (63)15,959 
Other comprehensive income (loss)— — — — 2,011 — 2,011 
Exercise of stock options2,00220 9,597 — — — 9,617 
Vesting of restricted stock units791 (1)— — — — 
Shares withheld related to net share settlement(1)— (28)— — — (28)
Stock-based compensation expense—— 13,672 — — — 13,672 
March 31, 2023414,465$4,145 $2,130,126 $(1,048,208)$(3,549)$(674)$1,081,840 


6
agilon health, inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
 Three Months Ended March 31,
 20242023
Cash flows from operating activities:
Net income (loss)$(6,034)$15,959 
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization5,844 4,189 
Stock-based compensation expense16,909 13,672 
Loss (income) from equity method investments(5,684)(1,376)
(Gain) loss on sale of assets, net4,996 — 
Other noncash items(472)(1,785)
Changes in operating assets and liabilities:(63,335)(91,470)
Net cash provided by (used in) operating activities(47,776)(60,811)
Cash flows from investing activities:
Purchase of property and equipment(3,139)(3,717)
Purchase of intangible assets(11,438)— 
Funding of loans receivable and other(8,508)(1,301)
Investments in marketable securities— (29,969)
Proceeds from maturities of marketable securities and other74,523 28,540 
Net cash paid in business combination— (44,367)
Net cash provided by (used in) investing activities51,438 (50,814)
Cash flows from financing activities:
Proceeds from equity issuances, net1,809 9,589 
Repayments of long-term debt(1,250)(1,250)
Net cash provided by (used in) financing activities559 8,339 
Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents4,221 (103,286)
Cash, cash equivalents and restricted cash and equivalents from continuing operations, beginning of period114,329 475,912 
Cash, cash equivalents and restricted cash and equivalents from discontinued operations, beginning of period— 31,768 
Cash, cash equivalents and restricted cash and equivalents, beginning of period114,329 507,680 
Cash, cash equivalents and restricted cash and equivalents from continuing operations, end of period118,550 397,023 
Cash, cash equivalents and restricted cash and equivalents from discontinued operations, end of period— 7,371 
Cash, cash equivalents and restricted cash and equivalents, end of period$118,550 $404,394 
See accompanying Notes to the Condensed Consolidated Financial Statements.
7
agilon health, inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1. Business
Description of Business
agilon health, inc., through its partnerships and platform, provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. As of March 31, 2024, the Company, through its contracted physician networks, provided care to approximately 522,800 Medicare Advantage members enrolled with private health plans. Beginning January 1, 2024, the Company expanded its operations into: (i) Lexington, Kentucky and (ii) Augusta, Georgia, along with additional partnerships in the Company’s existing Texas, Pennsylvania, and Michigan markets. Additionally, beginning January 1, 2024, the Company began participating in the Centers for Medicare & Medicaid Services' (“CMS”) Shared Savings Program (“MSSP”), along with its existing participation in the Accountable Care Organization Realizing Equity, Access, and Community Health (“ACO REACH”) Model, (collectively, “CMS ACO Models”).
See Note 14 for additional discussions related to the Company’s involvement with VIEs.
The Company’s largest shareholder is an investment fund associated with Clayton Dubilier & Rice, LLC (“CD&R”), a private equity firm. All funds affiliated with CD&R are considered related parties.
NOTE 2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and both joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The accompanying condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Use of Estimates
Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (“IBNR”) claims), and valuation of long-lived assets, goodwill and intangible assets (acquired in business combinations and analysis of impairment). Management’s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.
Property and Equipment
As of March 31, 2024 and December 31, 2023, the Company’s gross carrying amount of property and equipment was $44.3 million and $41.9 million, with accumulated depreciation of $16.8 million and $14.3 million, respectively. For the three months ended March 31, 2024 and 2023, the Company recognized $2.8 million and $1.7 million, respectively, in
8
depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.
Income Taxes
The Company determines the income tax provision for interim periods using an estimate of the Company’s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.
Recent Accounting Pronouncements
In November of 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting—Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which amends certain reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. Additionally, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The amendments in ASU 2023-07 are required to be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-07 on the disclosures in its condensed consolidated financial statements.
In December of 2023, the FASB issued ASU 2023-09, Income Taxes—Improvements to Income Tax Disclosures (“ASU 2023-09”), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on the disclosures in its condensed consolidated financial statements.
NOTE 3. Revenue, Receivables, and Concentration of Credit Risk
Medical Services Revenue
Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (“payors”). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (“PMPM”) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (“members”) attributed to the Company’s contracted primary care physicians. PMPM fees are determined as a percent of the premium payors receive from the Centers for Medicare & Medicaid Services’ (“CMS”) for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers (“ASC 606”), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.
The transaction price for the Company’s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS’s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member’s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available
9
diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company’s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved.
Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.
Receivables
Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management’s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized.
Concentration
The Company contracts with various payors whereby the Company is entitled to monthly PMPM fees to provide a defined range of healthcare services for members attributed to its contracted primary care physicians. The Company generally accepts full financial risk for such members and therefore is responsible for the cost of all healthcare services required by them. Substantially all of the Company’s receivable balances are from a small number of payors. Revenue from Medicare Advantage payors constitutes substantially all of the Company’s total revenue for the three months ended March 31, 2024 and 2023.
The following table provides the Company’s revenue concentration with respect to major payors as a percentage of the Company’s total revenues:
 Three Months Ended
March 31,
 20242023
Payor A22 %20 %
Payor B15 %17 %
Payor C14 %13 %
Payor D*10 %
___________________________________________
*Less than 10% of total revenues.
The following table provides the Company’s concentration of credit risk with respect to major payors as a percentage of receivables, net:
 March 31,
2024		December 31,
2023
Payor A14 %13 %
Payor B14 %11 %
Payor C12 % *
Payor D13 %21 %
___________________________________________
*Less than 10% of total receivables.
10
NOTE 4. Marketable Securities and Fair Value Measurements
Marketable Securities
The following table summarizes the Company’s marketable securities (in thousands):
 March 31, 2024December 31, 2023
 Amortized CostGross Unrealized GainsGross Unrealized Losses Fair ValueAmortized CostGross Unrealized GainsGross Unrealized Losses Fair Value
Marketable securities:
Corporate debt securities$184,107 $63 $(1,547)$182,623 $234,821 $180 $(1,604)$233,397 
U.S. Treasury notes126,085 53 (1,402)124,736 138,329 261 (1,206)137,384 
Other— — — — 10,000 — (8)9,992 
 $310,192 $116 $(2,949)$307,359 $383,150 $441 $(2,818)$380,773 
For the three months ended March 31, 2024, the Company recognized total interest income of $5.4 million, of which $4.0 million was related to its marketable securities investments and $1.4 million was related to interest on cash and cash equivalent balances. For the three months ended March 31, 2023, the Company recognized total interest income of $8.3 million, of which $4.9 million was related to its marketable securities investments and $3.4 million was related to interest on cash and cash equivalent balances.
The following table summarizes the Company’s marketable securities maturity as of March 31, 2024 (in thousands):
YearAmortized CostFair Value
2024$92,005 $91,495 
2025176,926 174,802 
202641,261 41,062 
 $310,192 $307,359 
The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of March 31, 2024 (in thousands):
Less Than 12 Months12 Months or Greater
Fair ValueGross Unrealized Losses Fair ValueGross Unrealized Losses
Marketable securities:
Corporate debt securities$50,514 $212 $101,513 $1,335 
U.S. Treasury notes49,359 615 63,494 787 
$99,873 $827 $165,007 $2,122 

11
The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December 31, 2023 (in thousands):
Less Than 12 Months12 Months or Greater
Fair ValueGross Unrealized Losses Fair ValueGross Unrealized Losses
Marketable securities:
Corporate debt securities$55,343 $167 $126,189 $1,437 
U.S. Treasury notes37,486 303 75,980 903 
Other9,992 8 — — 
$102,821 $478 $202,169 $2,340 
The Company’s unrealized losses from marketable securities as of March 31, 2024 and December 31, 2023 were caused primarily by interest rate increases. The Company does not intend to sell marketable securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. There was no allowance for credit losses on available-for-sale marketable securities at March 31, 2024 and December 31, 2023.
Fair Value Measurements
The Company’s financial instruments consist of cash and cash equivalents, restricted cash and cash equivalents, marketable securities, receivables, other liabilities, accounts payable, certain accrued expenses, and borrowings which consist of a term loan and a revolving credit facility. The carrying values of the financial instruments classified as current in the consolidated balance sheets approximate their fair values due to their short-term maturities. The Company's cash and cash equivalents are classified within Level 1 of the fair value hierarchy. The Company may be required, from time to time, to measure its loans to physician partner groups, primarily in connection with taxes payable on shares distributed to them upon completion of the Company's initial public offering ("IPO"), at fair value on a nonrecurring basis. Such measurements are classified within Level 2 of the fair value hierarchy. The carrying values of the term loan and revolving credit facility are a reasonable estimate of fair value because the interest rates on such borrowings approximate market rates as of the reporting date. Such borrowings are classified within Level 2 of the fair value hierarchy. During the three months ended March 31, 2024 and 2023, there were no material transfers of financial assets or liabilities within the fair value hierarchy.
The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy:
•Level 1—quoted prices for identical instruments in active markets;
•Level 2—quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
•Level 3—fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
12
The table below summarizes the Company’s financial instruments measured at fair value on a recurring basis (in thousands):
 March 31, 2024December 31, 2023
 Level 1Level 2Level 3Level 1Level 2Level 3
Marketable securities:
Corporate debt securities$— $182,623 $— $— $233,397 $— 
U.S. Treasury notes124,736 — — 137,384 — — 
Other— — — 9,992 — — 
 $124,736 $182,623 $— $147,376 $233,397 $— 
NOTE 5. Other Assets
The following table summarizes the Company’s other assets (in thousands):
 March 31,
2024		December 31,
2023
Loans to physician partners$71,561 $71,862 
Health plan deposits2,051 2,051 
Equity method investments(1)
53,672 44,753 
Right-of-use lease assets13,092 13,411 
Other15,530 13,235 
 $155,906 $145,312 
___________________________________________
(1)See Note 14 for additional discussion related to the Company's equity method investments.
Loans to Physician Partners
Loans to physician partners primarily represent loans in connection with taxes payable on shares distributed to them in connection with the IPO. These loans mature between 2026 and 2031 with nominal interest compounding annually and no prepayment penalties. Such loans are stated at the amount expected to be collected.
NOTE 6. Medical Claims and Related Payables
Medical services expense represents costs incurred for medical services provided to members by physicians, hospitals and other ancillary providers for which the Company is financially responsible and that are paid either directly by the Company or by payors with whom the Company has contracted. Medical services expenses are recognized in the period in which services are provided and include estimates of claims that have been incurred but have either not yet been received, processed, or paid and as such, not reported.
Such estimates are developed using actuarial methods commonly used by health insurance actuaries that include a number of factors and assumptions including medical service utilization trends, changes in membership, observed medical cost trends, historical claim payment patterns and other factors. Generally, for the most recent months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average PMPM medical costs incurred in prior months for which more complete claims data are available.
Each period, the Company re-examines previously established medical claims payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claims information becomes available, the Company adjusts its estimates and recognizes those changes in estimates in the period in which the change is identified. The difference between the estimated liability and the actual settlements of claims is recognized in the period the claims are settled. The Company’s medical claims payable balance represents management’s best estimate of its liability for unpaid medical costs as of March 31, 2024 and 2023. The Company uses judgment to determine the appropriate assumptions for developing the required estimates.
13
The following table presents the components of changes in medical claims and related payables (in thousands):
 March 31,
 20242023
Medical claims and related payables, beginning of the year$723,071 $339,749 
Components of incurred costs related to:
Current year1,427,328 872,973 
Prior years16,514 24,599 
Discontinued operations - current year— 71,333 
Discontinued operations - prior years— 3,922 
 1,443,842 972,827 
Claims paid related to:
Current year(316,779)(223,425)
Prior years(595,250)(278,688)
Discontinued operations - current year— (34,793)
Discontinued operations - prior years— (42,140)
 (912,029)(579,046)
Medical claims and related payables, end of the period$1,254,884 $733,530 
Medical claims and related payables also include $11.8 million and $14.7 million, as of March 31, 2024 and December 31, 2023, respectively, that is recoverable from other parties under risk sharing arrangements and is presented as prepaid expenses and other current assets, net in the condensed consolidated balance sheets. Medical claims and related payables presented in the periods above include immaterial balances related to claims liabilities associated with certain divested California businesses for which the Company has retained the liability for claims incurred prior to the date of divestiture.
NOTE 7. Other Liabilities
The following table summarizes the Company’s other liabilities (in thousands):
 March 31,
2024		December 31,
2023
Other long-term contingencies$49,000 $49,000 
Lease liabilities, long-term10,618 10,905 
Equity method liabilities – CMS ACO Models2,284 1,199 
Other9,593 9,277 
 $71,495 $70,381 
As of both March 31, 2024 and December 31, 2023, the Company’s accruals for contingent liabilities related to unasserted claims were $49.0 million. The accrued amounts represent the Company’s estimate of probable losses in accordance with ASC Topic 450, Contingencies.
See Note 14 for equity method liabilities related to the Company's CMS ACO Models investments.
NOTE 8. Debt
On February 18, 2021, the Company executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the “Credit Facility”). The Credit Facility includes: (i) a $100.0 million secured term loan (the “Secured Term Loan Facility”) and (ii) a $100.0 million senior secured revolving credit facility (the “Secured Revolving Facility”) with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $100.0 million. Subject to specified
14
conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $50.0 million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of the Company’s indebtedness. The maturity date of the Credit Facility is February 18, 2026.
As of March 31, 2024, the Company had $37.5 million outstanding under the Secured Term Loan Facility and availability under the Secured Revolving Facility was $60.7 million, as the Company had outstanding letters of credit totaling $39.3 million. The standby letters of credit are automatically extended without amendment for one-year periods, unless the Company notifies the institution in advance of the expiration date that the letter will be terminated. No amounts have been drawn on the outstanding letters of credit as of March 31, 2024.
Effective with the Second Amendment to Credit Agreement on May 25, 2023, the Company transitioned to the Secured Overnight Financing Rate ("SOFR") as a benchmark interest rate used in the Credit Agreement. At the Company’s option, borrowings under the Credit Agreement can be either: (i) SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans. Daily Simple SOFR Rate Loans and SOFR Rate Loans bear interest at a rate equal to the sum of 3.50% and the higher of (a) SOFR, as defined in the credit agreement, and (b) 0%. Base Rate Loans bear interest at a rate equal to the sum of 2.50% and the highest of: (a) 0.50% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus 1.00% and (d) 0%. Additionally, the Company pays a commitment fee on the unfunded Secured Revolving Facility amount of 0.375%. The Company must also pay customary letter of credit fees. As of March 31, 2024, the effective interest rate on the Secured Term Loan Facility was 9.394%.
The Credit Facility is guaranteed by certain of the Company’s subsidiaries, including those identified as VIEs, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios. Failure to meet any of these covenants could result in an event of default under the Credit Agreement. If an event of default occurs, the lenders could elect to declare all amounts outstanding under the Credit Agreement to be immediately due and payable. The Company was in compliance with all covenants under the Credit Facilities.
As of both March 31, 2024 and December 31, 2023, the Company had $25.1 million outstanding surety bonds related to health plan payor risk-bearing capital contributions.
NOTE 9. Commitments and Contingencies
Legal Proceedings
From time to time, the Company is a party to, or has a significant relationship to, legal proceedings, lawsuits, and other claims that arise in the ordinary course of the Company's business. Except as described in this Note 9, the Company is not aware of any other legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company's business, prospects, financial condition, results of operations or cash flows. The Company’s policy is to expense legal costs as they are incurred.
In February and March 2024, three putative class action lawsuits, (1) New England Teamsters Pension Fund v. agilon health, inc. et al., 1:24-cv-00297 (W.D. Tex., March 19, 2024); (2) Hope v. agilon health, inc. et al., 1:24-cv-00305 (W.D. Tex., March 25, 2024); and (3) Indiana Public Retirement System v. agilon health et al., 1:24-cv-02506 (S.D.N.Y., April 2, 2024), were filed. The lawsuits name the Company and certain current and former members of the Company’s executive team and Board of Directors as defendants. The lawsuits generally assert securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended, in connection with statements made in the Company’s annual and quarterly reports and earnings releases related to, among other things, the Company’s medical utilization and claims rates, medical margin, incurred but not reported reserve, and profit margins between April 2021 to February 2024. The lawsuits seek compensatory damages, attorney’s fees and other unspecified equitable and/or injunctive relief. The Company is unable to estimate the ultimate individual or aggregate amount of monetary liability or financial impact due to the early stages of the litigation.
15
NOTE 10. Common Stock
Common Stock
2024. During the three months ended March 31, 2024, the Company issued approximately 2.5 million shares of common stock primarily in connection with exercises and vesting of stock-based awards. Additionally, during the three months ended March 31, 2024, the Company issued approximately 2.0 million shares of common stock to settle liabilities related to the exchange of common stock for reduced physician partner compensation percentage in certain ACO REACH entities.
2023. During the three months ended March 31, 2023, the Company issued approximately 2.1 million shares of common stock primarily in connection with exercises and vesting of stock-based awards.
NOTE 11. Net Income (Loss) Per Common Share
Basic net income (loss) per common share (“EPS”) is computed based upon the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed based upon the weighted average number of common shares outstanding plus the impact of common shares issuable from the assumed conversion of stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on basic net income (loss) per share are included in diluted net income (loss) per share during the periods presented.
The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):
 Three Months Ended
March 31,
 20242023
Numerator
Income (loss) from continuing operations$3,247 $9,951 
Noncontrolling interests’ share in (earnings) loss from continuing operations(30)63 
Net income (loss) attributable to common stockholders before discontinued operations3,217 10,014 
Income (loss) from discontinued operations(9,281)6,008 
Net income (loss) attributable to common stockholders$(6,064)$16,022 
Denominator
Weighted average shares outstanding – basic408,938413,136
Weighted average shares outstanding – diluted413,437426,586
Net income (loss) per share attributable to common stockholders
Net income (loss) per common share from continuing operations, basic and diluted$0.01 $0.02 
Net income (loss) per common share from discontinued operations, basic and diluted$(0.02)$0.02 
The following table provides the weighted-average potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):
 March 31,
 20242023
Stock options6,6162,098
Restricted stock units9,6574,592
16
NOTE 12. Goodwill and Amortizable Intangible Assets
As of both March 31, 2024 and December 31, 2023, the Company’s goodwill balance was $24.1 million. There were no events or circumstances that warranted an interim impairment test for goodwill during the three months ended March 31, 2024.
As of March 31, 2024 and December 31, 2023, the Company’s gross carrying amount of amortizable intangible assets was $119.2 million and $108.0 million, with accumulated amortization of $47.1 million and $44.2 million, respectively. For the three months ended March 31, 2024 and 2023, the Company recognized $2.9 million and $1.3 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.
Acquisition
On February 28, 2023, the Company completed the acquisition of My Personal Health Record Express, Inc. (the “Acquisition”), a leading provider of value-based care technology and interoperability solutions for cash consideration of $45.3 million, net of cash acquired and subject to certain post-closing adjustments. The Company accounted for the Acquisition utilizing the acquisition method of accounting, which requires assets and liabilities to be recognized based on estimates of their acquisition date fair values. The determination of the values of the acquired assets and assumed liabilities, including other intangible assets and deferred taxes, requires significant judgment. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, the Company estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Measurement period adjustments are recorded in the period in which they are determined, as if they had been completed at the acquisition date. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within the Company's consolidated results of operations. The following allocation of the purchase price related to the Acquisition based upon the fair value of assets, which primarily included developed technology of $27.5 million, and assumed net liabilities of $3.8 million, with the residual amount being recorded as goodwill of $21.6 million. The intangible assets acquired have a weighted-average life of 10 years.
NOTE 13. Supplemental Cash Flow Information
The following table provides supplemental cash flow information (in thousands):
 Three Months Ended
March 31,
 20242023
Supplemental cash flow information:
Interest paid$1,069 $1,352 
Income taxes paid227 171 
Supplemental disclosure of non-cash investing and financing activities:  
Right-of-use asset obtained in exchange for new operating lease liability326 435 
Settlement of liabilities through issuance of stock15,230 — 
The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):
 March 31,
2024		December 31,
2023
Cash and cash equivalents$111,706 $107,570 
Restricted cash and equivalents(1)
6,844 6,759 
Cash, cash equivalents and restricted cash equivalents$118,550 $114,329 
___________________________________________
(1)Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.
17
NOTE 14. Variable Interest Entities
Consolidated Variable Interest Entities
agilon health, inc.’s consolidated assets and liabilities as of March 31, 2024 and December 31, 2023 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to agilon health, inc.
agilon health, inc.’s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):
 March 31,
2024		December 31,
2023
Assets
Cash and cash equivalents$59,680 $62,154 
Restricted cash equivalents6,842 6,757 
Receivables, net1,569,319 940,618 
Prepaid expenses and other current assets, net21,926 21,907 
Property and equipment, net1,636 1,754 
Intangible assets, net46,578 25,561 
Other assets, net6,144 6,334 
Liabilities
Medical claims and related payables1,266,651 737,724 
Accounts payable and accrued expenses219,407 188,671 
Other liabilities5,062 4,184 
Risk-bearing Entities. At March 31, 2024, the Company operates 34 wholly-owned risk-bearing entities (“RBEs”) for the purpose of entering into risk-bearing contracts with payors. Each RBE’s equity at risk is considered insufficient to finance its activities without additional support, and, therefore, each RBE is considered a VIE. The Company consolidates the RBEs as it has determined that it is the primary beneficiary because it has: (i) the ability to control the activities that most significantly impact the RBEs’ economic performance; and (ii) the obligation to absorb losses or right to receive benefits that could potentially be significant to the RBEs. Specifically, the Company has the unilateral ability and authority, through the RBE governance and management agreements, to make significant decisions about strategic and operating activities of the RBEs, including negotiating and entering into risk-bearing contracts with payors, and approving the RBEs’ annual operating budgets. The Company also has the obligation to fund losses of the RBEs and the right to receive a significant percentage of any financial surplus generated by the RBEs. The assets of the RBEs primarily consist of cash and cash equivalents, receivables, net, intangible assets, net, and other assets. Its obligations primarily consist of medical claims and related payables as well as operating expenses of the RBEs (accounts payable and accrued expenses), including incentive compensation obligations to the Company’s physician partners. On February 18, 2021, the Company executed the Credit Facility, which is guaranteed by certain of the Company’s VIEs. Assets generated by the RBEs (primarily from medical services revenues) may be used, in certain limited circumstances, to settle the Company’s contractual debt obligations.
Unconsolidated Variable Interest Entities
As of March 31, 2024, the Company had 11 equity method investees that were deemed to be VIEs. The Company has determined that the activities that most significantly impact the performance of these VIEs consist of the allocation of resources to and other decisions related to clinical activities and provider contracting decisions. Because the Company does not have the ability to control these activities due to another party’s control of the VIEs’ board of directors, the Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs. The Company provided support to assist its CMS ACO Models investments in obtaining surety bonds related to risk-bearing capital contributions to CMS. As of March 31, 2024 and December 31, 2023, the ACOs had $103.0 million and $38.5 million outstanding surety bonds. The Company's maximum loss exposure as a result of the Company’s involvement with the VIEs cannot be quantified as the Company has the obligation to provide ongoing operational support to the unconsolidated VIEs, as needed.
18
Equity Method Investments
The following table summarizes the Company’s equity method investees (in thousands):
 March 31,
2024		December 31,
2023
Equity method investments - Other(1)
$9,477 $9,148 
Equity method investments - CMS ACO Models(1)
44,195 35,605 
Equity method liabilities - CMS ACO Models(2)
(2,284)(1,199)
___________________________________________
(1)Included in Other assets, net in the condensed consolidated balance sheets.
(2)Included in Other liabilities in the condensed consolidated balance sheets.
The Company is a partner in 10 wholly-owned CMS ACO Models entities in collaboration with 15 of its physician group partners operating in 13 geographies. The combined summarized operating results of the Company’s CMS ACO Models entities are as follows (in thousands):
 Three Months Ended
March 31,
 20242023
Medical services revenue$440,160 $280,529 
Medical services expense(398,792)(257,477)
Other medical expenses(1)
(25,405)(15,744)
Income (loss) from operations9,532 2,001 
Net income (loss)(2)
5,631 1,334 
___________________________________________
(1)For the three months ended March 31, 2024 and 2023, includes physician incentive expenses of $16.7 million and $9.7 million, respectively.
(2)Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.
The combined summarized balance sheet of the Company’s CMS ACO Models entities are as follows (in thousands):
 March 31,
2024		December 31,
2023
Current assets$294,399 $174,967 
Noncurrent assets3,341 3,341 
Total assets297,740 178,308 
Current and total liabilities255,829 142,027 
NOTE 15. Discontinued Operations
Discontinued operations is a component of an entity that has either been disposed of or is deemed held-for-sale and, (i) the operations and cash flows of the component have been or will be eliminated from ongoing operations as a result of the disposal transaction, and (ii) the entity will not have any significant continuing involvement in the operations of the component after the disposal transaction. On October 31, 2023, the Company completed the disposition of MDX Hawaii, Inc. and its related operations. The Company’s decision to exit Hawaii and the Independent Practice Association line of business represents a strategic shift that will have a major effect on its operations and financial results. As such, the Company’s Hawaii operations are reflected in the consolidated financial statements as discontinued operations for all periods presented.
19
The results of discontinued operations are as follows (in thousands):
Three Months Ended
March 31,
20242023
Revenues:
Medical services revenue$— $81,711 
Other operating revenue— 124 
Total revenues— 81,835 
Expenses:
Medical services expense— 75,255 
Other medical expenses— 2,407 
General and administrative518 (2,906)
Depreciation and amortization— 1,235 
Income (loss) from operations(518)5,844 
Other income (expense), net— 204 
Gain (loss) on sales of assets, net(8,763)— 
Interest expense— (40)
Net income (loss) from discontinued operations attributable to common shares$(9,281)$6,008 
The following table provides significant non-cash operating items for discontinued operations that are included in the consolidated statements of cash flows for the three months ended March 31, 2023 (in thousands):
Non-cash operating activities from discontinued operations:
Depreciation and amortization$1,235 
Stock-based compensation expense87 


20
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
All references in this report to “agilon,” “the Company”, “we,” “us” or “our” mean agilon health, inc., together with its consolidated subsidiaries. Unless the context suggests otherwise, references to “agilon health, inc.” mean the parent company without its subsidiaries.
Cautionary Language Regarding Forward-Looking Statements
Statements in this Quarterly Report on Form 10-Q (the “Report”) that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Some of the forward-looking statements can be identified by the use of forward-looking terms such as “believes,” “expects,” “may,” “will,” “shall,” “should,” “would,” “could,” “seeks,” “aims,” “projects,” “is optimistic,” “intends,” “plans,” “estimates,” “anticipates” or the negative versions of these words or other comparable terms. Forward-looking statements include, without limitation, all matters that are not historical facts. They appear in a number of places throughout this Report and include, without limitation, statements regarding our intentions, beliefs, assumptions or current expectations concerning, among other things, our financial position, results of operations, cash flows, prospects, and growth strategies.
Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be outside our control. We caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of the market in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this Report. In addition, even if our results of operations, financial condition, and cash flows, and the development of the market in which we operate, are consistent with the forward-looking statements contained in this Report, those results or developments may not be indicative of results or developments in subsequent periods. A number of important factors, including, without limitation, the risks and uncertainties discussed under Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, could cause actual results and outcomes to differ materially from those reflected in the forward-looking statements. As explained in greater detail under Item 9A. “Controls and Procedures” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, we are undertaking a broad range of remedial procedures to address the material weaknesses in our internal control over financial reporting identified as of December 31, 2023. Our efforts to improve our internal controls are ongoing. Furthermore, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Report. Factors that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, without limitation:
•our history of net losses and the expectation that our expenses will increase in the future;
•failure to identify and develop successful new geographies, physician partners and payors, or execute upon our growth initiatives;
•success in executing our operating strategies or achieving results consistent with our historical performance;
•medical expenses incurred on behalf of our members may exceed revenues we receive;
•our ability to secure contracts with Medicare Advantage (“MA”) payors;
•our ability to grow new physician partner relationships sufficient to recover startup costs;
•availability of additional capital, on acceptable terms or at all, to support our business in the future;
•significant reduction in our membership;
•transition to a Total Care Model may be challenging for physician partners;
•public health crises, such as COVID-19, could adversely affect us;
•inaccuracy in estimates of our members’ risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts;
•the impact of restrictive clauses or exclusivity provisions in some of our contracts with physician partners;
•our ability to hire and retain qualified personnel;
21
•our ability to realize the full value of our intangible assets;
•security breaches, cybersecurity attacks, loss of data and other disruptions to our information systems;
•our ability to protect the confidentiality of our know-how and other proprietary and internally developed information;
•reliance on our subsidiaries to perform and fund their operations;
•environmental, social, and governance issues;
•our reliance on a limited number of key payors;
•the limited terms of contracts with our payors and our ability to renew them upon expiration;
•reliance on our payors, physician partners and other providers to operate our business;
•our ability to obtain accurate and complete diagnosis data;
•reliance on third-party software, data, infrastructure and bandwidth;
•consolidation and competition in the healthcare industry;
•the impact of changes to, and dependence on, federal government healthcare programs;
•uncertain or adverse economic and macroeconomic conditions, including a downturn or decrease in government expenditures;
•regulation of the healthcare industry and our physician partners’ ability to comply with such laws and regulations;
•federal and state investigations, audits and enforcement actions;
•repayment obligations arising out of payor audits;
•negative publicity regarding the managed healthcare industry generally;
•our use, disclosure and processing of personally identifiable information, protected health information, and de-identified data;
•our failure to obtain or maintain an insurance license, a certificate of authority or an equivalent authorization;
•lawsuits not covered by insurance;
•changes in tax laws and regulations, or changes in related judgments or assumptions;
•our indebtedness and our potential to incur more debt;
•dependence on our subsidiaries for cash to fund all of our operations and expenses;
•provisions in our governing documents;
•ability to achieve a return on investment depends on appreciation in the price of our common stock;
•the material weakness in our internal control over financial reporting and our ability to remediate such material weakness; and
•risks related to other factors discussed under Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.
The information set forth in this Item 2 is intended to provide readers with an understanding of our financial condition, changes in financial condition, and results of operations. We will discuss and provide our analysis in the following order:
•Overview and Recent Developments
•Key Financial and Operating Metrics
•Key Components of Our Results of Operations
22
•Results of Operations
•Non-GAAP Financial Measures
•Liquidity and Capital Resources
•Critical Accounting Policies and Estimates
•Recent Accounting Pronouncements
Overview and Recent Developments
Our business is transforming healthcare by empowering the primary care physicians (“PCPs”) to be the agent for change in the communities they serve. We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost, and patient experience when provided with the right infrastructure and payment model. Through our combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, we are poised to revolutionize healthcare for seniors across communities throughout the United States. Our purpose-built model provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. Our model operates by forming risk-bearing entities (“RBEs”) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of our physician partners’ attributed patients (or, global capitation arrangements). The RBEs also contract with agilon to perform certain functions and enter into long-term professional service agreements with one or more anchor physician groups pursuant to which the anchor physician groups receive a base compensation rate and share in the savings from successfully improving quality of care and reducing costs.
Our business model is differentiated by its focus on existing community-based physician groups and is built around three key elements: (1) agilon’s platform; (2) agilon’s long-term physician partnership approach; and (3) agilon’s network. With our model, our goal is to remove the barriers that prevent community-based physicians from evolving to a Total Care Model, where the physician is empowered to manage health outcomes and the total healthcare needs of their attributed Medicare patients.
First Quarter 2024 Results:
•Medicare Advantage members of approximately 522,800 as of March 31, 2024 increased 43% from March 31, 2023.
•CMS ACO Models attributed beneficiaries of approximately 131,000 as of March 31, 2024 increased 48% from March 31, 2023.
•Total revenue of $1.6 billion increased 52% from the first quarter of 2023.
•Gross profit of $75 million, compared to $73 million in the first quarter of 2023.
•Medical margin of $157 million, compared to $156 million in the first quarter of 2023.
•Net loss of $6 million, compared to net income of $16 million in the first quarter of 2023.
•Adjusted EBITDA of $29 million in the first quarter compared to $24 million in the first quarter 2023.
Membership Details
Medicare Advantage members increased 43% from March 31, 2023, which includes contributions from new geographies and growth within geographies existing prior to 2023. Total members live on the platform includes 522,800 Medicare Advantage members and 131,000 attributed CMS ACO Models beneficiaries.
Average Medicare Advantage membership was 518,400 during the first quarter of 2024.
23
Key Financial and Operating Metrics
All of our key metrics exclude historical results from our Hawaii operations (which are included as discontinued operations in our condensed consolidated financial statements).
We monitor the following key financial and operating metrics to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. We believe the following key metrics are useful in evaluating our business (dollars in thousands):
As of and For the
Three Months Ended March 31,
20242023% Change
MA members522,800365,70043 
Medical services revenue$1,601,195 $1,053,119 52 
Gross profit$75,088 $73,123 3 
Medical margin(1)
$157,353 $155,547 1 
Platform support costs$45,712 $43,292 6 
Net income (loss)$(6,034)$15,959 (138)
Adjusted EBITDA(1)
$29,054 $24,038 21 
___________________________________________
(1)Medical margin and Adjusted EBITDA are non-GAAP financial measures. Gross profit is the most directly comparable financial measure calculated in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) to medical margin. Net income (loss) is the most directly comparable financial measure calculated in accordance with U.S. GAAP to Adjusted EBITDA. See “—Non-GAAP Financial Measures" for additional information.
Medicare Advantage Members
Our MA members include all individuals enrolled in an MA plan that are attributed to the PCPs on our platform at the end of a given period.
Medical Services Revenue
Our medical services revenue consists of capitation revenue under contracts with various payors. Under the typical capitation arrangement, we are entitled to per member per month ("PMPM") fees to provide a defined range of healthcare services for MA health plan members through our contracted physician partners and affiliated PCPs. Such fees are typically based on a defined percentage of corresponding premium that payors receive from the Centers for Medicare & Medicaid Services' (“CMS”). We recognize capitation revenue over the period eligible members are entitled to receive healthcare services.
Gross Profit
Gross profit represents the amount earned from total revenues less medical services expense and other medical expenses. Total revenues include medical services revenue and other operating revenue. The Company’s costs of revenues consist of medical services expense and other medical expenses, which represents the costs that are directly related to providing the services that generate revenue.
The following table presents our gross profit (dollars in thousands):
Three Months Ended
March 31,
20242023
Total revenues$1,604,354 $1,054,312 
Medical services expense(1,443,842)(897,572)
Other medical expenses(1)
(85,424)(83,617)
Gross profit$75,088 $73,123 
___________________________________________
24
(1)Represents physician compensation expense related to surplus sharing and other care management expenses that help to create medical cost efficiency. Includes costs in geographies that are in implementation and are not yet generating revenue and investments to grow existing markets. For the three months ended March 31, 2024 and 2023, costs incurred in implementing geographies were $0.6 million and $2.3 million, respectively.
Medical Margin
We define medical margin as medical services revenue after medical services expense is deducted. Medical services expense represents costs incurred for medical services provided to our members. As our platform matures over time, we expect medical margin to increase in absolute dollars. However, medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM.
See “—Non-GAAP Financial Measures” for information regarding our use of medical margin and a reconciliation of gross profit to medical margin.
Platform Support Costs
Our platform support costs, which include regionally-based support personnel and other operating costs to support our geographies, are expected to decrease over time as a percentage of revenue as our physician partners add members and our revenue grows. Our operating expenses at the enterprise level include resources and technology to support payor contracting, clinical program development, quality, data management, finance, and legal and compliance functions.
The table below represents costs to support our live geographies and enterprise functions, which are included in general and administrative expenses (dollars in thousands):
Three Months Ended
March 31,
20242023
Platform support costs$45,712 $43,292 
% of Revenue3 %4 %
Net Income (Loss) and Adjusted EBITDA
Net income (loss) is the most directly comparable U.S. GAAP measure to Adjusted EBITDA. We define Adjusted EBITDA as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) stock-based compensation expense, (vi) severance and related costs, and (vii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We reflect our share of Adjusted EBITDA for equity method investments by applying our actual ownership percentage for the period to the applicable reconciling items on an entity-by-entity basis.
See “—Non-GAAP Financial Measures” for information regarding our use of Adjusted EBITDA and a reconciliation of net income (loss) to Adjusted EBITDA.
Key Components of Our Results of Operations
Revenues
Medical Services Revenue
Our medical services revenue consists of capitation revenue under contracts with various payors. Under the typical capitation arrangement, we are entitled to PMPM fees to provide a defined range of healthcare services for MA health plan members through our contracted physician partners and affiliated PCPs. Such fees are typically based on a defined percentage of corresponding premium that payors receive from CMS. We recognize capitation revenue over the period eligible members are entitled to receive healthcare services.
Medical services revenue constitutes substantially all of our total revenue for the three months ended March 31, 2024 and 2023.
25
Operating Expenses
Medical Services Expense
In each of our geographies, a network of physicians, hospitals, and other healthcare providers provide care to our members. Medical services expense represents costs incurred for medical services provided to our members. Our medical services expense trends primarily relate to changes in per visit costs incurred by our members, along with changes in health system and provider utilization of services. Medical services expenses are recognized in the period in which services are provided and include estimates of our obligations for medical services that have been rendered by third parties but for which claims have either not yet been received, processed, or paid.
Other Medical Expenses
Other medical expenses include: (i) partner physician compensation expense and (ii) other provider costs. Partner physician compensation expense represents obligations to our physician partners corresponding to a portion of the surplus generated in our geographies, which is a function of medical services revenues less the sum of medical services expenses, other provider costs and market operating costs, for the respective geography. Physician payment obligations are reconciled quarterly, and settlement payments are typically issued to providers on an annual basis in arrears, with interim payments issued periodically. Other provider costs include payments to support physician-patient engagement, certain other medical costs, and other care management expenses that help to create medical cost efficiency. Other provider costs include costs incurred for geographies that are in implementation and are not yet generating revenue.
General and Administrative
General and administrative expenses consist of market-based support personnel and other operating costs to support our geographies, personnel and other operating costs to support our enterprise functions, and investments to support development and expansion of our physician partners. Our enterprise functions include salaries and related expenses, stock-based compensation (including shares issued under partner physician group equity agreements), operational support expenses, technology infrastructure, finance, and legal, as well as other costs associated with the continued growth of our platform. For the purposes of calculating physician partner incentive expense, we allocate a portion of our enterprise general and administrative expenses to our geographies. General and administrative expenses also include severance and accruals for unasserted claims.
Depreciation and Amortization
Depreciation and amortization expenses are associated with our property and equipment and acquired intangible assets. Depreciation includes expenses associated with buildings, computer equipment and software, furniture and fixtures, and leasehold improvements. Amortization primarily includes expenses associated with acquired intangible assets.
Other Income (Expense)
Income (loss) from equity method investments
Income (loss) from equity method investments consists primarily of income associated with our participation in the CMS Shared Savings Program (“MSSP”), along with its existing participation in the Accountable Care Organization Realizing Equity, Access, and Community Health (“ACO REACH”) Model, (collectively, “CMS ACO Models”).
Other Income (Expense), Net
Other income (expense), net includes interest income, which consists primarily of interest earned on our cash and cash equivalents, restricted cash and cash equivalents, and marketable securities, including amortization/accretion of discount/premium.
Interest Expense
Interest expense consists primarily of interest expense associated with our outstanding debt, including amortization of debt discounts and costs.
26
Income Tax Benefit (Expense)
We are subject to corporate U.S. federal, state, and local income taxation. Deferred tax assets are reduced by a valuation allowance to the extent management believes it is not more likely than not to be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income. Management makes estimates and judgments about future taxable income based on assumptions that are consistent with our plans and estimates.
Total Discontinued Operations
Total discontinued operations consist of the results of our Hawaii operations. For certain of our divestiture transactions, we continue to be responsible for any liabilities arising from the business that were incurred prior to the closing date of such transaction, including any fines, penalties, and other sanctions, the payment of claims for medical services incurred prior to the effective date of each transaction, a liability for unrecognized tax benefits for which we are indemnified, and other contingent liabilities that we currently believe are remote. For additional discussion, see Note 15 to the Condensed Consolidated Financial Statements.
Results of Operations
The following table summarizes key components of our results of operations (dollars in thousands):
Three Months Ended
March 31,
20242023
Revenues:
Medical services revenue$1,601,195 $1,053,119 
Other operating revenue3,159 1,193 
Total revenues1,604,354 1,054,312 
Expenses:
Medical services expense1,443,842 897,572 
Other medical expenses85,424 83,617 
General and administrative (including noncash stock-based compensation expense of $16,909 and $13,585, respectively)
76,422 69,752 
Depreciation and amortization5,844 2,954 
Total expenses1,611,532 1,053,895 
Income (loss) from operations(7,178)417 
Other income (expense):
Income (loss) from equity method investments5,684 1,376 
Other income (expense), net5,892 7,892 
Interest expense(1,284)(1,493)
Income (loss) before income taxes3,114 8,192 
Income tax benefit (expense)133 1,759 
Income (loss) from continuing operations3,247 9,951 
Discontinued operations:
Income (loss) before gain (loss) on sales(518)6,008 
Gain (loss) on sales of assets, net(8,763)— 
Total discontinued operations(9,281)6,008 
Net income (loss)(6,034)15,959 
Noncontrolling interests’ share in (earnings) loss(30)63 
Net income (loss) attributable to common shares$(6,064)$16,022 
27
The following table summarizes our results of operations as a percentage of total revenues:
Three Months Ended
March 31,
20242023
Revenues:
Medical services revenue100 %100 %
Other operating revenue— — 
Total revenues100 100 
Expenses:
Medical services expense90 85 
Other medical expenses5 8 
General and administrative (including noncash stock-based compensation expense of 1% and 1%, respectively)
5 7 
Depreciation and amortization— — 
Total expenses100 100 
Income (loss) from operations— — 
Other income (expense):
Income (loss) from equity method investments— — 
Other income (expense), net— 1 
Interest expense— — 
Income (loss) before income taxes— 1 
Income tax benefit (expense)— — 
Income (loss) from continuing operations— 1 
Discontinued operations:
Income (loss) before gain (loss) on sales— 1 
Gain (loss) on sales of assets, net(1)— 
Total discontinued operations(1)1 
Net income (loss)— 2 
Noncontrolling interests’ share in (earnings) loss— — 
Net income (loss) attributable to common shares— %2 %
Comparison of the Three Months Ended March 31, 2024 to the Three Months Ended March 31, 2023
Medical Services Revenue
Three Months Ended
March 31,		Change
(dollars in thousands)20242023$%
Medical services revenue$1,601,195 $1,053,119 $548,076 52 %
% of total revenues100 %100 %
Medical services revenue increased for the three months ended March 31, 2024 due primarily to growth in average membership of 43%, which was attributable to seven new geographies that began to generate revenue in 2024 and growth
28
in our existing geographies. The increase in medical services revenue for the three months ended March 31, 2024 was also driven, to a lesser extent, by an increase in PMPM capitation rates of 7%.
Medical Services Expense
Three Months Ended
March 31,		Change
(dollars in thousands)20242023$%
Medical services expense$1,443,842 $897,572 $546,270 61 %
% of total revenues90 %85 %
Medical services expense increased for the three months ended March 31, 2024 due primarily to growth in average membership of 43%, which was attributable to seven new geographies that became operational in 2024 and growth in our existing geographies. The increase in medical services expense for the three months ended March 31, 2024 was also driven, to a lesser extent, by an increase in average medical services expense per member of 13%.
Other Medical Expenses
Three Months Ended
March 31,		Change
(dollars in thousands)20242023$%
Other medical expenses$85,424 $83,617 $1,807 2 %
% of total revenues5 %8 %
Other medical expenses increased by $1.8 million, or 2%, for the three months ended March 31, 2024 compared to 2023. Partner physician incentive expense decreased by $7.9 million to $49.8 million in 2024 compared to $57.7 million in 2023. Other provider costs increased by $11.4 million to $35.0 million in 2024 compared to $23.6 million in 2023, resulting from the increase in the number of geographies and members on our platform. Other provider costs for the three months ended March 31, 2024 include $0.6 million of costs related to geographies that are expected to become operational in January 2025, while other provider costs for the three months ended March 31, 2023 include $2.3 million of costs related to geographies that became operational in 2024.
General and Administrative
Three Months Ended
March 31,		Change
(dollars in thousands)20242023$%
General and administrative$76,422 $69,752 $6,670 10 %
% of total revenues5 %7 %
General and administrative expenses increased $6.7 million, or 10%, for the three months ended March 31, 2024 compared to 2023. Operating costs to support our live geographies and enterprise functions (platform support costs) increased by $2.4 million to $45.7 million in 2024 compared to $43.3 million in 2023 due primarily to growth in operating costs incurred to support geographies that became operational in 2024. Operating costs to support our live geographies and enterprise functions as a percentage of revenue decreased to 3% for the three months ended March 31, 2024 compared to 4% for the same period in 2023. Investments to support geography entry increased to $10.5 million in 2024, compared to $9.3 million in 2023 due to increased costs associated with our geographies that are expected to become operational in the following calendar year and expansion into existing geographies. Stock-based compensation expense increased $3.3 million in 2024 primarily due to the granting of certain stock-based instruments to third parties after the first quarter of 2023.
29
Income (loss) from equity method investments
Three Months Ended
March 31,		Change
(dollars in thousands)20242023$%
Income (loss) from equity method investments$5,684 $1,376 $4,308 313 %
% of total revenues— %— %
Income (loss) from equity method investments increased $4.3 million, or 313%, for the three months ended March 31, 2024 compared to 2023 primarily from two new equity investments that began to generate revenue in 2024 and growth in our existing CMS ACO Models investments.
Other income (expense), net
Three Months Ended
March 31,		Change
(dollars in thousands)20242023$%
Other income (expense), net$5,892 $7,892 $(2,000)(25)%
% of total revenues— %1 %
Other income (expense), net decreased $2.0 million, or 25%, for the three months ended March 31, 2024 compared to 2023 primarily from interest income as a result of the maturities of various marketable securities investments.
Total Discontinued Operations
Three Months Ended
March 31,		Change
(dollars in thousands)20242023$%
Total discontinued operations$(9,281)$6,008 $(15,289)(254)%
% of total revenues(1)%1 %
Total discontinued operations is related to the sale of our Hawaii operations in October 2023. Total discontinued operations for the three months ended March 31, 2024 is primarily related to loss on sale of our Hawaii operations compared to income from discontinued operations for the three months ended March 31, 2023.
Non-GAAP Financial Measures
In addition to providing results that are determined in accordance with U.S. GAAP, we present medical margin and Adjusted EBITDA, which are non-GAAP financial measures.
We define medical margin as medical services revenue after medical services expense is deducted. Medical services expense represents costs incurred for medical services provided to our members. As our platform matures over time, we expect medical margin to increase in absolute dollars. However, medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM. We believe this metric provides insight into the economics of our capitation arrangements as it includes all medical services expense directly associated with our members’ care.
We define Adjusted EBITDA as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) stock-based compensation expense, (vi) severance and related costs, and (vii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We reflect our share of Adjusted EBITDA for equity method investments by applying our actual ownership percentage for the period to the applicable reconciling items on an entity-by-entity basis.
30
Gross profit is the most directly comparable U.S. GAAP measure to medical margin. Net income (loss) is the most directly comparable U.S. GAAP measure to Adjusted EBITDA.
We believe medical margin and Adjusted EBITDA help identify underlying trends in our business and facilitate evaluation of period-to-period operating performance of our operations by eliminating items that are variable in nature and not considered by us in the evaluation of ongoing operating performance, allowing comparison of our recurring core business operating results over multiple periods. We also believe medical margin and Adjusted EBITDA provide useful information about our operating results, enhance the overall understanding of our past performance and future prospects, and allow for greater transparency with respect to key metrics we use for financial and operational decision-making. We believe medical margin and Adjusted EBITDA or similarly titled non-GAAP measures are widely used by investors, securities analysts, ratings agencies, and other parties in evaluating companies in our industry as a measure of financial performance. Other companies may calculate medical margin and Adjusted EBITDA or similarly titled non-GAAP measures differently from the way we calculate these metrics. As a result, our presentation of medical margin and Adjusted EBITDA may not be comparable to similarly titled measures of other companies, limiting their usefulness as comparative measures.
Adjusted EBITDA is not considered a measure of financial performance under U.S. GAAP, and the items excluded therefrom are significant components in understanding and assessing our financial performance. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as an alternative to such U.S. GAAP measures as net income (loss), cash flows provided by or used in operating, investing, or financing activities or other financial statement data presented in our consolidated financial statements as an indicator of financial performance or liquidity. Some of these limitations are:
•Adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;
•Adjusted EBITDA does not reflect interest expense or the requirements necessary to service interest or principal payments on debt;
•Adjusted EBITDA does not reflect income tax expense (benefit) or the cash requirements to pay taxes;
•Adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;
•Although depreciation and amortization charges are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; and
•The expenses and other items that we exclude in our calculation of Adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from similarly titled non-GAAP financial measures.
The following table sets forth a reconciliation of gross profit to medical margin using data derived from our condensed consolidated financial statements for the periods indicated (dollars in thousands):
Three Months Ended
March 31,
20242023
Gross profit(1)
$75,088 $73,123 
Other operating revenue(3,159)(1,193)
Other medical expenses85,424 83,617 
Medical margin$157,353 $155,547 
___________________________________________
(1)Gross profit is defined as total revenues less medical services expense and other medical expenses.
31
The following table sets forth a reconciliation of net income (loss) to Adjusted EBITDA using data derived from our condensed consolidated financial statements for the periods indicated (dollars in thousands):
Three Months Ended
March 31,
20242023
Net income (loss)$(6,034)$15,959 
(Income) loss from discontinued operations, net of income taxes9,281 (6,008)
Interest expense1,284 1,493 
Income tax expense (benefit)(133)(1,759)
Depreciation and amortization5,844 2,954 
Severance and related costs2,415 188 
Stock-based compensation expense16,909 13,585 
EBITDA adjustments related to equity method investments3,902 1,967 
Other(1)
(4,414)(4,341)
Adjusted EBITDA$29,054 $24,038 
___________________________________________
(1)Includes interest income and transaction-related costs.

Liquidity and Capital Resources
We have historically financed our operations primarily through funds generated from our capitation arrangements with payors, issuances of equity securities, and borrowings under credit agreements. We generally invest any excess cash in money market accounts, which are classified as cash equivalents, and marketable securities. Our investment strategies are designed to provide safety and preservation of capital, sufficient liquidity to meet the cash flow needs of our business operations, and attainment of a competitive return. As of March 31, 2024, we had cash and cash equivalents and restricted cash and equivalents of $118.6 million and investments in marketable securities of $307.4 million.
We expect to continue to incur operating losses and generate negative cash flows from operations for the foreseeable future due to the investments we intend to continue to make in expanding our business and additional general and administrative costs we expect to incur related to our operation as a public company. As a result, we may require additional capital resources in the future to execute strategic initiatives to grow our business.
Our primary uses of cash include payments for medical claims and other medical expenses, general and administrative expenses, costs associated with the development of new geographies and expansion of existing geographies, debt service, and capital expenditures. Final reconciliation and receipt of amounts due from payors are typically settled in arrears, following completion of the contractual program year.
Based on our planned operations, we believe that our existing cash and cash equivalents, investments in marketable securities, as well as available borrowing capacity under the Credit Facility (defined below), will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months, though we may require additional capital resources in the future. We have based these estimates on assumptions that may prove to be wrong and we could utilize our available capital resources sooner than we expect.
We may require additional financing in the future to fund working capital and pay our obligations. We may seek to raise any necessary additional capital through a combination of public or private equity offerings and/or debt financings. There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us, if at all. If adequate funds are not available on acceptable terms when needed, we may be required to significantly reduce operating expenses, which may have a material adverse effect on our business, financial condition, cash flows, and results of operations. If we do raise additional capital through public or private equity, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.
32
Our ability to pay dividends to holders of our common stock is significantly limited as a practical matter by our growth plans as well as the Credit Facility insofar as we may seek to pay dividends out of funds made available to us by agilon health management, inc. (“agilon management”) or its subsidiaries because the Credit Facility restricts agilon management’s ability to pay dividends or make loans to us. The borrower on the Credit Facility is agilon management, our wholly-owned subsidiary. The Credit Facility is guaranteed by certain of our subsidiaries, including those identified as variable interest entities, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios.
As of March 31, 2024, we had $25.1 million outstanding surety bonds related to health plan payor risk-bearing capital contributions.
Cash Flows
The following summary discussion of our cash flows is based on the condensed consolidated statements of cash flows. The following table sets forth changes in cash flows (dollars in thousands):
Three Months Ended March 31,
20242023Change
Net cash provided by (used in) operating activities$(47,776)$(60,811)$13,035 
Net cash provided by (used in) investing activities51,438 (50,814)102,252 
Net cash provided by (used in) financing activities559 8,339 (7,780)
Net Cash Provided By (Used In) Operating Activities
Net cash used in operating activities was $47.8 million for the three months ended March 31, 2024 compared to $60.8 million for the three months ended March 31, 2023. The decrease in net cash used in operating activities was primarily as a result of the timing of settlements with payors from new and existing geographies. Our cash flow from operations is dependent upon the number of members on our platform, the timing of settlements with payors, and the level of operating and general and administrative expenses necessary to operate and grow our business, among other factors.
Net Cash Provided By (Used In) Investing Activities
Net cash provided by investing activities was $51.4 million for the three months ended March 31, 2024 compared to net cash used in investing activities of $50.8 million for the three months ended March 31, 2023. During the three months ended March 31, 2024, we received proceeds from the maturities of marketable securities of $74.5 million. During the three months ended March 31, 2023, we completed the acquisition of My Personal Health Record Express, Inc. for $44.4 million.
Net Cash Provided By (Used In) Financing Activities
Net cash provided by financing activities was $0.6 million for the three months ended March 31, 2024 compared to $8.3 million for the three months ended March 31, 2023. During the three months ended March 31, 2024, we received proceeds from stock option exercises of $1.8 million compared to $9.6 million for the three months ended March 31, 2023.
Debt Obligations
On February 18, 2021, we executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the “Credit Facility”). The Credit Facility includes: (i) a $100.0 million senior secured term loan (the “Secured Term Loan Facility”) and (ii) a $100.0 million senior secured revolving credit facility (the “Secured Revolving Facility”) with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $100.0 million. Subject to specified conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $50.0 million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of our indebtedness. The maturity date of the Credit Facility was extended to February 18, 2026.
33
Effective with the Second Amendment to Credit Agreement on May 25, 2023, we transitioned to the Secured Overnight Financing Rate ("SOFR") as a benchmark interest rate used in the Credit Agreement. At our option, borrowings under the Credit Facilities, as defined in the credit agreement, can be either: (i) SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans. Daily Simple SOFR Rate Loans and SOFR Rate Loans bear interest at a rate equal to the sum of 3.50% and the higher of (a) SOFR, as defined in the credit agreement, and (b) 0%. Base Rate Loans bear interest at a rate equal to the sum of 2.50% and the highest of: (a) 0.50% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus 1.00% and (d) 0%. Additionally, we pay a commitment fee on the unfunded 2021 Revolving Credit Facility amount of 0.375%. We must also pay customary letter of credit fees.
The Credit Facility contains customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios.
For additional discussion on our debt obligations, see Note 8 to the Condensed Consolidated Financial Statements for additional information about our outstanding debt.
Equity
As of March 31, 2024, we had 410.8 million shares of common stock outstanding. See Note 10 to the Condensed Consolidated Financial Statements for additional information about our equity transactions.
Critical Accounting Estimates
Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our historical experience, known trends and events, and various other assumptions that we believe are reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our condensed consolidated financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. A summary of our critical accounting policies is included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 in Part II, Item 7 “Management’s Discussion and Analysis of Financial Conditions and Results of Operations - Critical Accounting Policies” and Note 2 to the Condensed Consolidated Financial Statements. There have been no significant changes to our critical accounting policies during 2024.
Recent Accounting Pronouncements
For the impact of new accounting standards, see Note 2 to the Condensed Consolidated Financial Statements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to various market risks, including the potential loss arising from adverse changes in interest rates. We do not use derivative financial instruments in the normal course of business or for speculative or trading purposes.
Our exposures to market risk for changes in interest expense relate primarily to the Credit Facility. Indebtedness under the Credit Facility is floating rate debt and is carried at amortized cost. Therefore, fluctuations in interest rates will impact our consolidated financial statements. A rising interest rate environment will increase the amount of interest paid on this debt. A hypothetical 100 basis point change in interest rates would not have a material impact on our interest expense.
We held cash, cash equivalents, restricted cash equivalents, and marketable securities of $425.9 million and $495.1 million as of March 31, 2024 and December 31, 2023, respectively, consisting of bank deposits, certificates of deposits, money market funds, U.S. Treasury notes, and corporate debt securities. Such interest-earning instruments carry a
34
degree of interest rate risk. A hypothetical 100 basis point change in interest rates would not have a material impact on the fair value of our marketable securities. Declines in interest rates over time will reduce our investment income. The goals of our investment policy are liquidity and capital preservation. We do not enter into investments for trading or speculative purposes.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures. Our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), with the assistance of other members of management, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Our disclosure controls and procedures are intended to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s (“SEC”) rules and forms and (2) accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. Based on this review, although we continue to work to remediate the material weakness in internal control over financial reporting as described in our Annual Report on Form 10-K for the year ended December 31, 2023, and progress has been made to date, our CEO and CFO have concluded that the disclosure controls and procedures related to this material weakness were not effective as of March 31, 2024.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect every misstatement. An evaluation of effectiveness is subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may decrease over time.
Changes in Internal Control Over Financial Reporting. Under applicable SEC rules (Exchange Act Rules 13a-15(d) and 15d-15(d)), management is required to evaluate any change in internal control over financial reporting that occurred during each fiscal quarter that had materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. There were no changes in our internal control over financial reporting that occurred during our most recently completed fiscal quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting
As explained in greater detail under Part II, Item 9A. “Controls and Procedures” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, we are undertaking a broad range of remedial procedures to address the material weakness in our internal control over financial reporting identified as of December 31, 2023. Our efforts to improve our internal controls are ongoing. Therefore, while we determined, with the participation of our CEO and CFO, that there have been no changes in our internal control over financial reporting in the three-month period ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, we continue to monitor the operation of these remedial measures through the date of this report.
35
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
See the “Legal Proceedings” section of Note 9 to the Condensed Consolidated Financial Statements for information regarding legal proceedings, which information is incorporated by reference in this Item 1.
Item 1A. Risk Factors
In addition to the information set forth in this Form 10-Q, you should carefully consider the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. There have been no material changes to the risk factors disclosed in the Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a)
None.
(b)
None.
(c)
None.
Item 5. Other Information
On March 15, 2024, Veeral Desai, the registrant’s Chief Strategy and Development Officer, adopted a Rule 10b5-1 plan intended to satisfy the affirmative defense of SEC Rule 10b5-1(c). The trading plan commences June 15, 2024, ends August 30, 2024 and covers 1,000,000 options to purchase common stock of the registrant.
36

Item 6. Exhibits
Exhibit
Number
Description
31.1
  
31.2
  
32.1
  
32.2
  
101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.*
  
101.SCHInline XBRL Taxonomy Extension Schema Document.*
  
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.*
  
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.*
  
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.*
  
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.*
  
104Cover Page Interactive Data File (embedded within the Inline XBRL document).*
___________________________________________
*Filed herewith.
**Furnished herewith.
37
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 7, 2024
agilon health, inc.
  
 (Registrant)
  
 /s/ TIMOTHY S. BENSLEY
 Timothy S. Bensley
 Chief Financial Officer
 (Principal Financial Officer)
38
 EX-31.1 2 agl-20240331xexx311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Steven J. Sell, certify that:
1.I have reviewed this quarterly report on Form 10-Q of agilon health, inc. for the period ended March 31, 2024;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 7, 2024
By:/s/ STEVEN J. SELL
 Steven J. Sell
 Chief Executive Officer
 (Principal Executive Officer)

 EX-31.2 3 agl-20240331xexx312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Timothy S. Bensley, certify that:
1.I have reviewed this quarterly report on Form 10-Q of agilon health, inc. for the period ended March 31, 2024;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 7, 2024
By:/s/ TIMOTHY S. BENSLEY
 Timothy S. Bensley
 Chief Financial Officer
 (Principal Financial Officer)

 EX-32.1 4 agl-20240331xexx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of agilon health, inc. (the “Company”) on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven J. Sell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 7, 2024
By:/s/ STEVEN J. SELL
Steven J. Sell
Chief Executive Officer
(Principal Executive Officer)

 EX-32.2 5 agl-20240331xexx322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of agilon health, inc. (the “Company”) on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy S. Bensley, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 7, 2024
By:/s/ TIMOTHY S. BENSLEY
Timothy S. Bensley
Chief Financial Officer
(Principal Financial Officer)

 EX-101.SCH 6 agl-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Marketable Securities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Other Assets link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Medical Claims and Related Payables link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Other Liabilities link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Net Income (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Goodwill and Amortizable Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Variable Interest Entities link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Marketable Securities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Medical Claims and Related Payables (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Net Income (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Variable Interest Entities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Business (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Marketable Securities and Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Marketable Securities and Fair Value Measurements - Summarizes Marketable Securities Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Marketable Securities, Unrealized Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Medical Claims and Related Payables - Summary Changes in Medical Claims and Related Payables (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Medical Claims and Related Payables - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Other Liabilities - Summary of Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Other Liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Net Income (Loss) Per Common Share - Computation of Basic and Diluted EPS (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Goodwill and Amortizable Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Supplemental Cash Flow Information - Summary of Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Supplemental Cash Flow Information - Summary of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Variable Interest Entities - Summary of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Variable Interest Entities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Variable Interest Entities - Schedule of Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Variable Interest Entities - Summary of Operating Results (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Variable Interest Entities - Summarized Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Discontinued Operations - Summary of Results of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Discontinued Operations - Summary of Significant Non-Cash Operating Items for Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 agl-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 agl-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 agl-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Consolidated Entities Consolidated Entities [Axis] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate Variable Rate [Domain] Noncontrolling interests’ share in (earnings) loss Noncontrolling interests’ share in (earnings) loss from continuing operations Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Interest expense Disposal Group, Including Discontinued Operation, Interest Expense Statistical Measurement Statistical Measurement [Domain] Credit facility remaining borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Underlying Security Market Price Change Underlying Security Market Price Change, Percent All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Debt Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Related payables associated with retained liability Liability For Claims And Claims Adjustment Expense, Amounts Recoverable Liability For Claims And Claims Adjustment Expense, Amounts Recoverable under risk sharing arrangements Variable Interest Entity, Primary Beneficiary Variable Interest Entity Variable Interest Entity, Primary Beneficiary [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Corporate debt securities Corporate Debt Securities [Member] Other income (expense), net Nonoperating Income (Expense) Commitments and contingencies Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Common Stock Equity [Text Block] Proceeds from equity issuances, net Proceeds from Issuance of Common Stock Medical claims and related payables Liability for Claims and Claims Adjustment Expense Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Summary of Other Liabilities Other Liabilities [Table Text Block] Concentration Risk [Line Items] Concentration Risk [Line Items] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Amortized Cost Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract] Fair Value Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Total outstanding letters of credit Letters of Credit Outstanding, Amount Restricted cash and equivalents Restricted Cash Equivalents, Current Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Debt Securities Debt Securities [Member] Net income (loss) attributable to common shares Net income (loss) Net Income (Loss) Total current liabilities Liabilities, Current Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Schedule of Cash and Cash Equivalents from Continuing Operations Schedule of Cash and Cash Equivalents [Table Text Block] Gross carrying amount of amortizable intangible assets Intangible Assets, Gross (Excluding Goodwill) Other Equity Methods Other Equity Method Investments [Member] Other Equity Method Investments LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Liabilities and Equity [Abstract] Overnight Federal Funds Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Other Other Assets, Miscellaneous, Noncurrent Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Other Assets [Abstract] Other Assets [Abstract] Summery of Net Income (Loss) Per Share Attributable to Common Stockholder Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Receivables Receivable [Policy Text Block] Executive Category: Executive Category [Axis] Weighted-average life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Goodwill Goodwill Line of credit facility, accordion feature, increase limit Line Of Credit Facility, Accordion Feature, Increase Limit Line Of Credit Facility, Accordion Feature, Increase Limit Equity Components Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Revenues Disposal Group, Including Discontinued Operation, Revenue Extended term of letters of credit Extended Term Of Letters Of Credit Extended term of letters of credit. Current year Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year Underlying Securities Award Underlying Securities Amount Fair Value Debt Securities, Held-to-Maturity, Fair Value, Maturity [Abstract] Entity Small Business Entity Small Business Weighted average shares outstanding Denominator Weighted Average Number of Shares Outstanding, Basic [Abstract] Prior years Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Receivables Accounts Receivable [Member] Lease liabilities, long-term Operating Lease, Liability, Noncurrent Components of incurred costs related to: Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract] Restricted stock units Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation expense Depreciation Summary of Marketable Securities Marketable Securities [Table Text Block] Discontinued operations: Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Other Other Sundry Liabilities, Noncurrent Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Shares withheld related to net share settlement Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Schedule of Equity Method Investments Equity Method Investments [Table Text Block] Schedule of Antidilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Standby Letters of Credit Standby Letters of Credit [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Award Type Award Type [Axis] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Claims paid related Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Assets acquired Finite-Lived Intangible Assets Acquired Gross carrying amount of property and equipment Property, Plant and Equipment, Gross Right-of-use asset obtained in exchange for new operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Summary of Operating Results Schedule of Other Operating Cost and Expense, by Component [Table Text Block] Entity File Number Entity File Number Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Number of medicare advantage members enrolled with private health plans Number Of Medicare Advantage Members Enrolled With Private Health Plans Number of Medicare Advantage members enrolled with private health plans. Schedule of Other Assets Schedule of Other Assets [Table Text Block] Amortization expense Amortization of Intangible Assets Proceeds from maturities of marketable securities and other Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash and equivalents from continuing operations, beginning of period Cash, cash equivalents and restricted cash and equivalents from continuing operations, end of period Cash, cash equivalents and restricted cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Asset Class [Axis] Asset Class [Axis] Insurance [Abstract] Insurance [Abstract] Equity Method Investment, Nonconsolidated Investee or Group of Investees Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] 12 Months or Greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued (in shares) Common Stock, Shares, Issued Security Exchange Name Security Exchange Name Long-term debt Long-Term Debt Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Stock options Employee Stock Option [Member] 2026 Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Three Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Three Business Business Description and Accounting Policies [Text Block] Income (loss) before gain (loss) on sales Discontinued Operations Income (Loss) Before Impairments Gain (Loss) On Sales And Income Taxes Discontinued operations income loss before impairments gain loss on Sales and income taxes. Total expenses Costs and Expenses Maximum Maximum [Member] Total comprehensive income (loss) attributable to agilon health, inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Expenses Expenses Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other noncash items Other Noncash Income (Expense) Business Acquisition [Axis] Business Acquisition [Axis] Medicare Advantage Payors Customer Concentration Risk [Member] Variable Rate Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Equity method liabilities – CMS ACO Models Equity Method Liabilities, Noncurrent Equity Method Liabilities, Noncurrent Title of 12(b) Security Title of 12(b) Security Income (loss) from operations Disposal Group, Including Discontinued Operation, Operating Income (Loss) Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Loss Contingency, Nature Loss Contingency, Nature [Domain] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] 2025 Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Two Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Two Secured Term Loan Facility Secured Term Loan Facility [Member] Secured Term Loan Facility [Member] Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Summary Changes in Medical Claims and Related Payables Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Equity method investments Equity Method Investments Expenses Disposal Group, Including Discontinued Operation, Operating Expense Investments in marketable securities Payments to Acquire Marketable Securities Statistical Measurement Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] General and administrative Disposal Group, Including Discontinued Operation, General And Administrative Expense, Net Of Adjustments Disposal Group, Including Discontinued Operation, General And Administrative Expense, Net Of Adjustments Operating Activities [Domain] Operating Activities [Domain] Other Liabilities [Abstract] Other Liabilities [Abstract] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Supplemental disclosure of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Summarized Balance Sheet Condensed Balance Sheet [Table Text Block] Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] mphrX mphrX [Member] mphrX [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Medical Services Revenue Revenue from Contract with Customer [Policy Text Block] Other Other Debt Obligations [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Prior years Prior Year Claims and Claims Adjustment Expense Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Cash, cash equivalents and restricted cash and equivalents from discontinued operations, beginning of period Cash, cash equivalents and restricted cash and equivalents from discontinued operations, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Continuing operations, basic (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Debt Securities [Abstract] Debt Securities [Abstract] Net unrealized gain (loss) on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance, (in shares) Common Stock, Shares, Outstanding Payor D Payor D [Member] Payor D. PEO PEO [Member] Payor A Payor A [Member] Payor A. Noncurrent assets Assets, Noncurrent Liability For Claims And Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Income (loss) from continuing operations Income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 2025 Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Two Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Two Asset Class [Domain] Asset Class [Domain] Stock-based compensation expense Disposal Group, Including Discontinued Operation, Shared Based Payment Arrangement, Expense Disposal Group, Including Discontinued Operation, Shared Based Payment Arrangement, Expense Schedule Of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Payor C Payor C [Member] Payor C. Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] ACO REACH ACO REACH [Member] ACO REACH Net income (loss) attributable to common stockholders before discontinued operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Credit Facility Credit Facility [Axis] Total liabilities Liabilities Current and total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accumulated Other Comprehensive Income (loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount All Executive Categories All Executive Categories [Member] Payor B Payor B [Member] Payor B. Number of equity method investments for VIEs Number Of Equity Method Investments Number of equity method investments. Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Operating Activities [Axis] Operating Activities [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Liability For Claims And Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Net income (loss) per common share, basic and diluted Earnings Per Share [Abstract] Summary of Consolidated Asset and Liabilities Include VIE Assets and Liabilities Schedule of Variable Interest Entities [Table Text Block] Common stock, $0.01 par value: 2,000,000 shares authorized; 410,843 and 406,387 shares issued and outstanding, respectively Common Stock, Value, Issued Less Than 12 Months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months General and administrative (including noncash stock-based compensation expense of $16,909 and $13,585, respectively) General and Administrative Expense Allowances for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest Organization, Consolidation and Presentation of Financial Statements [Abstract] Discontinued Operations Discontinued Operations [Member] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Total current assets Current assets Assets, Current Investment income Investment Income, Net Number of direct contracting entities Number Of Direct Contracting Entities Number of Direct Contracting Entities. Schedules of Concentration of Risk as a Percentage of Revenues and Receivables Schedules of Concentration of Risk, by Risk Factor [Table Text Block] All Individuals All Individuals [Member] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Other liabilities Other Liabilities Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Goodwill and Amortizable Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Marketable Securities and Fair Value Measurements Cash, Cash Equivalents, and Marketable Securities [Text Block] PEO Name PEO Name Equity method liabilities Equity Method Liabilities Equity Method Liabilities Concentration risk, percentage Concentration Risk, Percentage Base Rate Loans Base Rate [Member] Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Funding of loans receivable and other Payments to Acquire Loans Receivable Depreciation and amortization Depreciation, Depletion and Amortization Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total agilon health, inc. stockholders' equity (deficit) Equity, Attributable to Parent Number of wholly-owned risk-bearing entities Number Of Wholly Owned Risk Bearing Entities Number of wholly-owned risk-bearing entities. Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Concentration Risk Type Concentration Risk Type [Axis] Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Variable Interest Entities Variable Interest Entity Disclosure [Text Block] Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] Purchase of intangible assets Payments to Acquire Intangible Assets Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Loss contingency, new claims filed Loss Contingency, New Claims Filed, Number Other Assets Other Assets Disclosure [Text Block] Level 2 Fair Value, Inputs, Level 2 [Member] Current year Current Year Claims and Claims Adjustment Expense Health plan deposits Health Plan Deposits, Noncurrent Health Plan Deposits, Noncurrent Entity Emerging Growth Company Entity Emerging Growth Company Veeral Desai [Member] Veeral Desai Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Disposal Group Classification Disposal Group Classification [Domain] Continuing Operations Continuing Operations [Member] Net liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Marketable securities Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current Document Fiscal Period Focus Document Fiscal Period Focus Marketable debt securities [Line Items] Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] Credit facility remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Individual: Individual [Axis] Discontinued operations, basic (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Income (Loss) Per Common Share Earnings Per Share [Text Block] Product and Service Product and Service [Axis] Medical Claims and Related Payables Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Weighted average effective interest rate Debt, Weighted Average Interest Rate Marketable Securities [Table] Marketable Securities [Table] Total stockholders’ equity (deficit) Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Other Liabilities [Line Items] Other Liabilities [Line Items] Other liabilities. Depreciation and amortization Depreciation and amortization Disposal Group, Including Discontinued Operation, Depreciation and Amortization Minimum Minimum [Member] Property and equipment, net Property, Plant and Equipment, Net Receivables, net Receivables, Net, Current Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Disposal Group Classification Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Incurred cost related to claims Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Other Operating Product and Service, Other [Member] Liabilities Liabilities [Abstract] Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income (loss) from discontinued operations attributable to common shares Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income taxes paid Income Taxes Paid, Net U.S. Treasury notes US Treasury Securities [Member] Number of geographies Number of Geographical Location Number of geographical location. Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Summary of Fair Value Assets Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Continuing operations, diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Accumulated Deficit Retained Earnings [Member] Current portion of long-term debt Long-Term Debt, Current Maturities Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders’ equity (deficit) Liabilities and Equity Other income (expense): Nonoperating Income (Expense) [Abstract] Other assets Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Right-of-use lease assets Operating Lease, Right-of-Use Asset Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] (Gain) loss on sale of assets, net Gain (Loss) on Disposition of Assets Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Arrangement Duration Trading Arrangement Duration Summary of Marketable Securities, Unrealized Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Gain (loss) on sales of assets, net Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Summary of Restricted Cash Equivalents from Continuing Operations Restrictions on Cash and Cash Equivalents [Table Text Block] Settlement of liabilities through issuance of stock Stock Issued Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Non-cash operating activities from discontinued operations: Discontinued Operation, Alternative Cash Flow Information [Abstract] Termination Date Trading Arrangement Termination Date Restricted cash equivalents Restricted Cash Equivalents Common stock, shares authorized (in shares) Common Stock, Shares Authorized Other operating revenue Other Operating Revenue [Member] Other operating revenue. Claims paid related to: Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] Medical services revenue Medical Services Revenue [Member] Medical services revenue. Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract] Secured Revolving Facility Secured Revolving Facility [Member] Secured Revolving Facility [Member] Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] 2024 Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Comprehensive (income) loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Other long-term contingencies Loss Contingency, Accrual, Noncurrent Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table] Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table] Surety Bond Surety Bond [Member] Supplemental Cash Flow Information Cash Flow, Supplemental Disclosures [Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Prepaid expenses and other current assets, net Prepaid Expense and Other Assets, Current Insider Trading Arrangements [Line Items] Other assets, net Other Assets Number of shares issued under share-based awards (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Award Timing Method Award Timing Method [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Other Liabilities [Table] Other Liabilities [Table] Other liabilities. Adjustment to Compensation, Amount Adjustment to Compensation Amount Noncontrolling interests Equity, Attributable to Noncontrolling Interest Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Accumulated amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Repayments of long-term debt Repayments of Long-Term Debt Entity Central Index Key Entity Central Index Key Revenue, Receivables, and Concentration of Credit Risk Concentration Risk Disclosure [Text Block] Stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Net income (loss) per share attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Loss Contingency Nature Loss Contingency Nature [Axis] Income tax benefit (expense) Income Tax Expense (Benefit) Other income (expense), net Disposal Group, Including Discontinued Operation, Other Income (Expense) Disposal Group, Including Discontinued Operation, Other Income (Expense) Loans to physician partners Loans To Physicians Partners Loans To Physicians Partners Name Trading Arrangement, Individual Name Cash and Cash Equivalents [Abstract] 12 Months or Greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Issuance of common stock Stock Issued During Period, Value, New Issues Equity [Abstract] Equity [Abstract] Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Revenues Medical services revenue Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Less Than 12 Months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Net cash paid in business combination Net cash paid in business combination Payments to Acquire Businesses, Net of Cash Acquired Shares withheld related to net share settlement (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) 2024 Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Credit Facility Credit Facility [Domain] Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Number of shares issued to settle liabilities (in shares) Stock Issued During Period, Shares, Issued for Services Debt instrument, basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Numerator Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Long-term debt, net of current portion Long-Term Debt, Excluding Current Maturities Diluted (in shares) Weighted average shares outstanding – diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Physician compensation expense Physician Compensation Expense Physician compensation expense. 2026 Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Three Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Three Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Summary of Financial Statements Related to Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Expenses: Operating Expenses [Abstract] Medical claims and related payables, beginning of the year Medical claims and related payables, end of the period Liability For Claims And Claims Adjustment Expense, Including Amounts Recoverable Liability For Claims And Claims Adjustment Expense, Including Amounts Recoverable Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-In Capital Additional Paid-in Capital [Member] Unasserted Claim Unasserted Claim [Member] Cash, cash equivalents and restricted cash and equivalents, beginning of period Cash, cash equivalents and restricted cash and equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Total assets Assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Income (loss) from equity method investments Loss (income) from equity method investments Income (Loss) from Equity Method Investments Cover [Abstract] Cover [Abstract] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Other Liabilities Other Liabilities Disclosure [Text Block] Other liabilities Other liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Summary of Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Subsidiary Sale Of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Number of physician group partners Number Of Physician Group Partners Number of physician group partners. Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted average shares outstanding – basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type Concentration Risk Type [Domain] Income (loss) from operations Income (loss) from operations Operating Income (Loss) Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Revenues: Revenues [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents [Member] Consolidated Entities Consolidated Entities [Domain] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Developed Technology Developed Technology [Member] Developed Technology [Member] Line of credit facility, unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Statement [Line Items] Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer Relationships Customer Relationships [Member] Discontinued operations, diluted (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Stockholders' equity (deficit): Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Noncontrolling Interest Noncontrolling Interest [Member] Total discontinued operations Income (loss) from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent EX-101.PRE 10 agl-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
 3 Months Ended
Mar. 31, 2024
May 01, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-40332  
Entity Registrant Name agilon health, inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 37-1915147  
Entity Address, Address Line One 6210 E Hwy 290  
Entity Address, Address Line Two Suite 450  
Entity Address, City or Town Austin  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 78723  
City Area Code (562)  
Local Phone Number 256-3800  
Title of 12(b) Security Common stock, $0.01 par value  
Trading Symbol AGL  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   411,261,609
Entity Central Index Key 0001831097  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 111,706 $ 107,570
Restricted cash and equivalents 6,844 6,759
Marketable securities 307,359 380,773
Receivables, net 1,571,143 942,461
Prepaid expenses and other current assets, net 39,757 42,513
Total current assets 2,036,809 1,480,076
Property and equipment, net 27,539 27,576
Intangible assets, net 72,076 63,769
Goodwill 24,133 24,133
Other assets 155,906 145,312
Total assets 2,316,463 1,740,866
Current liabilities:    
Medical claims and related payables 1,266,651 737,724
Accounts payable and accrued expenses 252,497 233,182
Current portion of long-term debt 7,500 6,250
Total current liabilities 1,526,648 977,156
Long-term debt, net of current portion 29,834 32,308
Other liabilities 71,495 70,381
Total liabilities 1,627,977 1,079,845
Commitments and contingencies
Stockholders' equity (deficit):    
Common stock, $0.01 par value: 2,000,000 shares authorized; 410,843 and 406,387 shares issued and outstanding, respectively 4,108 4,064
Additional paid-in capital 2,020,803 1,986,899
Accumulated deficit (1,332,890) (1,326,826)
Accumulated other comprehensive income (loss) (2,747) (2,298)
Total agilon health, inc. stockholders' equity (deficit) 689,274 661,839
Noncontrolling interests (788) (818)
Total stockholders’ equity (deficit) 688,486 661,021
Total liabilities and stockholders’ equity (deficit) $ 2,316,463 $ 1,740,866
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 2,000,000,000 2,000,000,000
Common stock, shares issued (in shares) 410,843,000 406,387,000
Common stock, shares outstanding (in shares) 410,843,000 406,387,000
Assets $ 2,316,463 $ 1,740,866
Liabilities 1,627,977 1,079,845
Variable Interest Entity, Primary Beneficiary    
Assets 1,710,000 1,070,000
Liabilities $ 1,490,000 $ 930,600
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:    
Revenues $ 1,604,354 $ 1,054,312
Expenses:    
General and administrative (including noncash stock-based compensation expense of $16,909 and $13,585, respectively) 76,422 69,752
Depreciation and amortization 5,844 2,954
Total expenses 1,611,532 1,053,895
Income (loss) from operations (7,178) 417
Other income (expense):    
Income (loss) from equity method investments 5,684 1,376
Other income (expense), net 5,892 7,892
Interest expense (1,284) (1,493)
Income (loss) before income taxes 3,114 8,192
Income tax benefit (expense) 133 1,759
Income (loss) from continuing operations 3,247 9,951
Discontinued operations:    
Income (loss) before gain (loss) on sales (518) 6,008
Gain (loss) on sales of assets, net (8,763) 0
Total discontinued operations (9,281) 6,008
Net income (loss) (6,034) 15,959
Noncontrolling interests’ share in (earnings) loss (30) 63
Net income (loss) attributable to common shares $ (6,064) $ 16,022
Net income (loss) per common share, basic and diluted    
Continuing operations, basic (in dollars per share) $ 0.01 $ 0.02
Continuing operations, diluted (in dollars per share) 0.01 0.02
Discontinued operations, basic (in dollars per share) (0.02) 0.02
Discontinued operations, diluted (in dollars per share) $ (0.02) $ 0.02
Weighted average shares outstanding    
Basic (in shares) 408,938 413,136
Diluted (in shares) 413,437 426,586
Medical services revenue    
Revenues:    
Revenues $ 1,601,195 $ 1,053,119
Expenses:    
Expenses 1,443,842 897,572
Other operating revenue    
Revenues:    
Revenues 3,159 1,193
Expenses:    
Expenses $ 85,424 $ 83,617
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Stock-based compensation expense $ 16,909 $ 13,585
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net income (loss) $ (6,034) $ 15,959
Other comprehensive income (loss):    
Net unrealized gain (loss) on marketable securities, net of tax (457) 1,896
Foreign currency translation adjustment 8 115
Total comprehensive income (loss) (6,483) 17,970
Comprehensive (income) loss attributable to noncontrolling interests (30) 63
Total comprehensive income (loss) attributable to agilon health, inc. $ (6,513) $ 18,033
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (loss)
Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2022   412,385        
Beginning balance at Dec. 31, 2022 $ 1,040,609 $ 4,124 $ 2,106,886 $ (1,064,230) $ (5,560) $ (611)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) 15,959     16,022   (63)
Other comprehensive income (loss) 2,011       2,011  
Exercise of stock options (in shares)   2,002        
Exercise of stock options 9,617 $ 20 9,597      
Vesting of restricted stock units (in shares)   79        
Vesting of restricted stock units 0 $ 1 (1)      
Shares withheld related to net share settlement (in shares)   (1)        
Shares withheld related to net share settlement (28)   (28)      
Stock-based compensation expense 13,672   13,672      
Ending balance, (in shares) at Mar. 31, 2023   414,465        
Ending balance at Mar. 31, 2023 $ 1,081,840 $ 4,145 2,130,126 (1,048,208) (3,549) (674)
Beginning balance (in shares) at Dec. 31, 2023 406,387 406,387        
Beginning balance at Dec. 31, 2023 $ 661,021 $ 4,064 1,986,899 (1,326,826) (2,298) (818)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) (6,034)     (6,064)   30
Other comprehensive income (loss) (449)       (449)  
Exercise of stock options (in shares)   1,434        
Exercise of stock options 2,455 $ 14 2,441      
Vesting of restricted stock units (in shares)   1,170        
Vesting of restricted stock units 0 $ 11 (11)      
Shares withheld related to net share settlement (in shares)   (122)        
Shares withheld related to net share settlement (646) $ (1) (645)      
Issuance of common stock (in shares)   1,974        
Issuance of common stock 15,230 $ 20 15,210      
Stock-based compensation expense $ 16,909   16,909      
Ending balance, (in shares) at Mar. 31, 2024 410,843 410,843        
Ending balance at Mar. 31, 2024 $ 688,486 $ 4,108 $ 2,020,803 $ (1,332,890) $ (2,747) $ (788)
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net income (loss) $ (6,034) $ 15,959
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 5,844 4,189
Stock-based compensation expense 16,909 13,672
Loss (income) from equity method investments (5,684) (1,376)
(Gain) loss on sale of assets, net 4,996 0
Other noncash items (472) (1,785)
Changes in operating assets and liabilities: (63,335) (91,470)
Net cash provided by (used in) operating activities (47,776) (60,811)
Cash flows from investing activities:    
Purchase of property and equipment (3,139) (3,717)
Purchase of intangible assets (11,438) 0
Funding of loans receivable and other (8,508) (1,301)
Investments in marketable securities 0 (29,969)
Proceeds from maturities of marketable securities and other 74,523 28,540
Net cash paid in business combination 0 (44,367)
Net cash provided by (used in) investing activities 51,438 (50,814)
Cash flows from financing activities:    
Proceeds from equity issuances, net 1,809 9,589
Repayments of long-term debt (1,250) (1,250)
Net cash provided by (used in) financing activities 559 8,339
Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents 4,221 (103,286)
Cash, cash equivalents and restricted cash and equivalents from continuing operations, beginning of period 114,329 475,912
Cash, cash equivalents and restricted cash and equivalents from discontinued operations, beginning of period 0 31,768
Cash, cash equivalents and restricted cash and equivalents, beginning of period 114,329 507,680
Cash, cash equivalents and restricted cash and equivalents from continuing operations, end of period 118,550 397,023
Cash, cash equivalents and restricted cash and equivalents from discontinued operations, end of period 0 7,371
Cash, cash equivalents and restricted cash and equivalents, end of period $ 118,550 $ 404,394
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business
NOTE 1. Business
Description of Business
agilon health, inc., through its partnerships and platform, provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. As of March 31, 2024, the Company, through its contracted physician networks, provided care to approximately 522,800 Medicare Advantage members enrolled with private health plans. Beginning January 1, 2024, the Company expanded its operations into: (i) Lexington, Kentucky and (ii) Augusta, Georgia, along with additional partnerships in the Company’s existing Texas, Pennsylvania, and Michigan markets. Additionally, beginning January 1, 2024, the Company began participating in the Centers for Medicare & Medicaid Services' (“CMS”) Shared Savings Program (“MSSP”), along with its existing participation in the Accountable Care Organization Realizing Equity, Access, and Community Health (“ACO REACH”) Model, (collectively, “CMS ACO Models”).
See Note 14 for additional discussions related to the Company’s involvement with VIEs.
The Company’s largest shareholder is an investment fund associated with Clayton Dubilier & Rice, LLC (“CD&R”), a private equity firm. All funds affiliated with CD&R are considered related parties.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
NOTE 2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and both joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The accompanying condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Use of Estimates
Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (“IBNR”) claims), and valuation of long-lived assets, goodwill and intangible assets (acquired in business combinations and analysis of impairment). Management’s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.
Property and Equipment
As of March 31, 2024 and December 31, 2023, the Company’s gross carrying amount of property and equipment was $44.3 million and $41.9 million, with accumulated depreciation of $16.8 million and $14.3 million, respectively. For the three months ended March 31, 2024 and 2023, the Company recognized $2.8 million and $1.7 million, respectively, in
depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.
Income Taxes
The Company determines the income tax provision for interim periods using an estimate of the Company’s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.
Recent Accounting Pronouncements
In November of 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting—Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which amends certain reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. Additionally, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The amendments in ASU 2023-07 are required to be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-07 on the disclosures in its condensed consolidated financial statements.
In December of 2023, the FASB issued ASU 2023-09, Income Taxes—Improvements to Income Tax Disclosures (“ASU 2023-09”), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on the disclosures in its condensed consolidated financial statements.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue, Receivables, and Concentration of Credit Risk
 3 Months Ended
Mar. 31, 2024
Risks and Uncertainties [Abstract]  
Revenue, Receivables, and Concentration of Credit Risk
NOTE 3. Revenue, Receivables, and Concentration of Credit Risk
Medical Services Revenue
Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (“payors”). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (“PMPM”) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (“members”) attributed to the Company’s contracted primary care physicians. PMPM fees are determined as a percent of the premium payors receive from the Centers for Medicare & Medicaid Services’ (“CMS”) for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers (“ASC 606”), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.
The transaction price for the Company’s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS’s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member’s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available
diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company’s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved.
Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.
Receivables
Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management’s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized.
Concentration
The Company contracts with various payors whereby the Company is entitled to monthly PMPM fees to provide a defined range of healthcare services for members attributed to its contracted primary care physicians. The Company generally accepts full financial risk for such members and therefore is responsible for the cost of all healthcare services required by them. Substantially all of the Company’s receivable balances are from a small number of payors. Revenue from Medicare Advantage payors constitutes substantially all of the Company’s total revenue for the three months ended March 31, 2024 and 2023.
The following table provides the Company’s revenue concentration with respect to major payors as a percentage of the Company’s total revenues:
 Three Months Ended
March 31,
 20242023
Payor A22 %20 %
Payor B15 %17 %
Payor C14 %13 %
Payor D*10 %
___________________________________________
*Less than 10% of total revenues.
The following table provides the Company’s concentration of credit risk with respect to major payors as a percentage of receivables, net:
 March 31,
2024		December 31,
2023
Payor A14 %13 %
Payor B14 %11 %
Payor C12 % *
Payor D13 %21 %
___________________________________________
*Less than 10% of total receivables.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Fair Value Measurements
 3 Months Ended
Mar. 31, 2024
Debt Securities [Abstract]  
Marketable Securities and Fair Value Measurements
NOTE 4. Marketable Securities and Fair Value Measurements
Marketable Securities
The following table summarizes the Company’s marketable securities (in thousands):
 March 31, 2024December 31, 2023
 Amortized CostGross Unrealized GainsGross Unrealized Losses Fair ValueAmortized CostGross Unrealized GainsGross Unrealized Losses Fair Value
Marketable securities:
Corporate debt securities$184,107 $63 $(1,547)$182,623 $234,821 $180 $(1,604)$233,397 
U.S. Treasury notes126,085 53 (1,402)124,736 138,329 261 (1,206)137,384 
Other— — — — 10,000 — (8)9,992 
 $310,192 $116 $(2,949)$307,359 $383,150 $441 $(2,818)$380,773 
For the three months ended March 31, 2024, the Company recognized total interest income of $5.4 million, of which $4.0 million was related to its marketable securities investments and $1.4 million was related to interest on cash and cash equivalent balances. For the three months ended March 31, 2023, the Company recognized total interest income of $8.3 million, of which $4.9 million was related to its marketable securities investments and $3.4 million was related to interest on cash and cash equivalent balances.
The following table summarizes the Company’s marketable securities maturity as of March 31, 2024 (in thousands):
YearAmortized CostFair Value
2024$92,005 $91,495 
2025176,926 174,802 
202641,261 41,062 
 $310,192 $307,359 
The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of March 31, 2024 (in thousands):
Less Than 12 Months12 Months or Greater
Fair ValueGross Unrealized Losses Fair ValueGross Unrealized Losses
Marketable securities:
Corporate debt securities$50,514 $212 $101,513 $1,335 
U.S. Treasury notes49,359 615 63,494 787 
$99,873 $827 $165,007 $2,122 
The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December 31, 2023 (in thousands):
Less Than 12 Months12 Months or Greater
Fair ValueGross Unrealized Losses Fair ValueGross Unrealized Losses
Marketable securities:
Corporate debt securities$55,343 $167 $126,189 $1,437 
U.S. Treasury notes37,486 303 75,980 903 
Other9,992 8 — — 
$102,821 $478 $202,169 $2,340 
The Company’s unrealized losses from marketable securities as of March 31, 2024 and December 31, 2023 were caused primarily by interest rate increases. The Company does not intend to sell marketable securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. There was no allowance for credit losses on available-for-sale marketable securities at March 31, 2024 and December 31, 2023.
Fair Value Measurements
The Company’s financial instruments consist of cash and cash equivalents, restricted cash and cash equivalents, marketable securities, receivables, other liabilities, accounts payable, certain accrued expenses, and borrowings which consist of a term loan and a revolving credit facility. The carrying values of the financial instruments classified as current in the consolidated balance sheets approximate their fair values due to their short-term maturities. The Company's cash and cash equivalents are classified within Level 1 of the fair value hierarchy. The Company may be required, from time to time, to measure its loans to physician partner groups, primarily in connection with taxes payable on shares distributed to them upon completion of the Company's initial public offering ("IPO"), at fair value on a nonrecurring basis. Such measurements are classified within Level 2 of the fair value hierarchy. The carrying values of the term loan and revolving credit facility are a reasonable estimate of fair value because the interest rates on such borrowings approximate market rates as of the reporting date. Such borrowings are classified within Level 2 of the fair value hierarchy. During the three months ended March 31, 2024 and 2023, there were no material transfers of financial assets or liabilities within the fair value hierarchy.
The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy:
•Level 1—quoted prices for identical instruments in active markets;
•Level 2—quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
•Level 3—fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
The table below summarizes the Company’s financial instruments measured at fair value on a recurring basis (in thousands):
 March 31, 2024December 31, 2023
 Level 1Level 2Level 3Level 1Level 2Level 3
Marketable securities:
Corporate debt securities$— $182,623 $— $— $233,397 $— 
U.S. Treasury notes124,736 — — 137,384 — — 
Other— — — 9,992 — — 
 $124,736 $182,623 $— $147,376 $233,397 $— 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Assets
 3 Months Ended
Mar. 31, 2024
Other Assets [Abstract]  
Other Assets
NOTE 5. Other Assets
The following table summarizes the Company’s other assets (in thousands):
 March 31,
2024		December 31,
2023
Loans to physician partners$71,561 $71,862 
Health plan deposits2,051 2,051 
Equity method investments(1)
53,672 44,753 
Right-of-use lease assets13,092 13,411 
Other15,530 13,235 
 $155,906 $145,312 
___________________________________________
(1)See Note 14 for additional discussion related to the Company's equity method investments.
Loans to Physician Partners
Loans to physician partners primarily represent loans in connection with taxes payable on shares distributed to them in connection with the IPO. These loans mature between 2026 and 2031 with nominal interest compounding annually and no prepayment penalties. Such loans are stated at the amount expected to be collected.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Medical Claims and Related Payables
 3 Months Ended
Mar. 31, 2024
Insurance [Abstract]  
Medical Claims and Related Payables
NOTE 6. Medical Claims and Related Payables
Medical services expense represents costs incurred for medical services provided to members by physicians, hospitals and other ancillary providers for which the Company is financially responsible and that are paid either directly by the Company or by payors with whom the Company has contracted. Medical services expenses are recognized in the period in which services are provided and include estimates of claims that have been incurred but have either not yet been received, processed, or paid and as such, not reported.
Such estimates are developed using actuarial methods commonly used by health insurance actuaries that include a number of factors and assumptions including medical service utilization trends, changes in membership, observed medical cost trends, historical claim payment patterns and other factors. Generally, for the most recent months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average PMPM medical costs incurred in prior months for which more complete claims data are available.
Each period, the Company re-examines previously established medical claims payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claims information becomes available, the Company adjusts its estimates and recognizes those changes in estimates in the period in which the change is identified. The difference between the estimated liability and the actual settlements of claims is recognized in the period the claims are settled. The Company’s medical claims payable balance represents management’s best estimate of its liability for unpaid medical costs as of March 31, 2024 and 2023. The Company uses judgment to determine the appropriate assumptions for developing the required estimates.
The following table presents the components of changes in medical claims and related payables (in thousands):
 March 31,
 20242023
Medical claims and related payables, beginning of the year$723,071 $339,749 
Components of incurred costs related to:
Current year1,427,328 872,973 
Prior years16,514 24,599 
Discontinued operations - current year— 71,333 
Discontinued operations - prior years— 3,922 
 1,443,842 972,827 
Claims paid related to:
Current year(316,779)(223,425)
Prior years(595,250)(278,688)
Discontinued operations - current year— (34,793)
Discontinued operations - prior years— (42,140)
 (912,029)(579,046)
Medical claims and related payables, end of the period$1,254,884 $733,530 
Medical claims and related payables also include $11.8 million and $14.7 million, as of March 31, 2024 and December 31, 2023, respectively, that is recoverable from other parties under risk sharing arrangements and is presented as prepaid expenses and other current assets, net in the condensed consolidated balance sheets. Medical claims and related payables presented in the periods above include immaterial balances related to claims liabilities associated with certain divested California businesses for which the Company has retained the liability for claims incurred prior to the date of divestiture.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Liabilities
 3 Months Ended
Mar. 31, 2024
Other Liabilities [Abstract]  
Other Liabilities
NOTE 7. Other Liabilities
The following table summarizes the Company’s other liabilities (in thousands):
 March 31,
2024		December 31,
2023
Other long-term contingencies$49,000 $49,000 
Lease liabilities, long-term10,618 10,905 
Equity method liabilities – CMS ACO Models2,284 1,199 
Other9,593 9,277 
 $71,495 $70,381 
As of both March 31, 2024 and December 31, 2023, the Company’s accruals for contingent liabilities related to unasserted claims were $49.0 million. The accrued amounts represent the Company’s estimate of probable losses in accordance with ASC Topic 450, Contingencies.
See Note 14 for equity method liabilities related to the Company's CMS ACO Models investments.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Debt
NOTE 8. Debt
On February 18, 2021, the Company executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the “Credit Facility”). The Credit Facility includes: (i) a $100.0 million secured term loan (the “Secured Term Loan Facility”) and (ii) a $100.0 million senior secured revolving credit facility (the “Secured Revolving Facility”) with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $100.0 million. Subject to specified
conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $50.0 million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of the Company’s indebtedness. The maturity date of the Credit Facility is February 18, 2026.
As of March 31, 2024, the Company had $37.5 million outstanding under the Secured Term Loan Facility and availability under the Secured Revolving Facility was $60.7 million, as the Company had outstanding letters of credit totaling $39.3 million. The standby letters of credit are automatically extended without amendment for one-year periods, unless the Company notifies the institution in advance of the expiration date that the letter will be terminated. No amounts have been drawn on the outstanding letters of credit as of March 31, 2024.
Effective with the Second Amendment to Credit Agreement on May 25, 2023, the Company transitioned to the Secured Overnight Financing Rate ("SOFR") as a benchmark interest rate used in the Credit Agreement. At the Company’s option, borrowings under the Credit Agreement can be either: (i) SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans. Daily Simple SOFR Rate Loans and SOFR Rate Loans bear interest at a rate equal to the sum of 3.50% and the higher of (a) SOFR, as defined in the credit agreement, and (b) 0%. Base Rate Loans bear interest at a rate equal to the sum of 2.50% and the highest of: (a) 0.50% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus 1.00% and (d) 0%. Additionally, the Company pays a commitment fee on the unfunded Secured Revolving Facility amount of 0.375%. The Company must also pay customary letter of credit fees. As of March 31, 2024, the effective interest rate on the Secured Term Loan Facility was 9.394%.
The Credit Facility is guaranteed by certain of the Company’s subsidiaries, including those identified as VIEs, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios. Failure to meet any of these covenants could result in an event of default under the Credit Agreement. If an event of default occurs, the lenders could elect to declare all amounts outstanding under the Credit Agreement to be immediately due and payable. The Company was in compliance with all covenants under the Credit Facilities.
As of both March 31, 2024 and December 31, 2023, the Company had $25.1 million outstanding surety bonds related to health plan payor risk-bearing capital contributions.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
NOTE 9. Commitments and Contingencies
Legal Proceedings
From time to time, the Company is a party to, or has a significant relationship to, legal proceedings, lawsuits, and other claims that arise in the ordinary course of the Company's business. Except as described in this Note 9, the Company is not aware of any other legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company's business, prospects, financial condition, results of operations or cash flows. The Company’s policy is to expense legal costs as they are incurred.
In February and March 2024, three putative class action lawsuits, (1) New England Teamsters Pension Fund v. agilon health, inc. et al., 1:24-cv-00297 (W.D. Tex., March 19, 2024); (2) Hope v. agilon health, inc. et al., 1:24-cv-00305 (W.D. Tex., March 25, 2024); and (3) Indiana Public Retirement System v. agilon health et al., 1:24-cv-02506 (S.D.N.Y., April 2, 2024), were filed. The lawsuits name the Company and certain current and former members of the Company’s executive team and Board of Directors as defendants. The lawsuits generally assert securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended, in connection with statements made in the Company’s annual and quarterly reports and earnings releases related to, among other things, the Company’s medical utilization and claims rates, medical margin, incurred but not reported reserve, and profit margins between April 2021 to February 2024. The lawsuits seek compensatory damages, attorney’s fees and other unspecified equitable and/or injunctive relief. The Company is unable to estimate the ultimate individual or aggregate amount of monetary liability or financial impact due to the early stages of the litigation.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Common Stock
NOTE 10. Common Stock
Common Stock
2024. During the three months ended March 31, 2024, the Company issued approximately 2.5 million shares of common stock primarily in connection with exercises and vesting of stock-based awards. Additionally, during the three months ended March 31, 2024, the Company issued approximately 2.0 million shares of common stock to settle liabilities related to the exchange of common stock for reduced physician partner compensation percentage in certain ACO REACH entities.
2023. During the three months ended March 31, 2023, the Company issued approximately 2.1 million shares of common stock primarily in connection with exercises and vesting of stock-based awards.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Income (Loss) Per Common Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Net Income (Loss) Per Common Share
NOTE 11. Net Income (Loss) Per Common Share
Basic net income (loss) per common share (“EPS”) is computed based upon the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed based upon the weighted average number of common shares outstanding plus the impact of common shares issuable from the assumed conversion of stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on basic net income (loss) per share are included in diluted net income (loss) per share during the periods presented.
The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):
 Three Months Ended
March 31,
 20242023
Numerator
Income (loss) from continuing operations$3,247 $9,951 
Noncontrolling interests’ share in (earnings) loss from continuing operations(30)63 
Net income (loss) attributable to common stockholders before discontinued operations3,217 10,014 
Income (loss) from discontinued operations(9,281)6,008 
Net income (loss) attributable to common stockholders$(6,064)$16,022 
Denominator
Weighted average shares outstanding – basic408,938413,136
Weighted average shares outstanding – diluted413,437426,586
Net income (loss) per share attributable to common stockholders
Net income (loss) per common share from continuing operations, basic and diluted$0.01 $0.02 
Net income (loss) per common share from discontinued operations, basic and diluted$(0.02)$0.02 
The following table provides the weighted-average potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):
 March 31,
 20242023
Stock options6,6162,098
Restricted stock units9,6574,592
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Amortizable Intangible Assets
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Amortizable Intangible Assets
NOTE 12. Goodwill and Amortizable Intangible Assets
As of both March 31, 2024 and December 31, 2023, the Company’s goodwill balance was $24.1 million. There were no events or circumstances that warranted an interim impairment test for goodwill during the three months ended March 31, 2024.
As of March 31, 2024 and December 31, 2023, the Company’s gross carrying amount of amortizable intangible assets was $119.2 million and $108.0 million, with accumulated amortization of $47.1 million and $44.2 million, respectively. For the three months ended March 31, 2024 and 2023, the Company recognized $2.9 million and $1.3 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.
Acquisition
On February 28, 2023, the Company completed the acquisition of My Personal Health Record Express, Inc. (the “Acquisition”), a leading provider of value-based care technology and interoperability solutions for cash consideration of $45.3 million, net of cash acquired and subject to certain post-closing adjustments. The Company accounted for the Acquisition utilizing the acquisition method of accounting, which requires assets and liabilities to be recognized based on estimates of their acquisition date fair values. The determination of the values of the acquired assets and assumed liabilities, including other intangible assets and deferred taxes, requires significant judgment. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, the Company estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Measurement period adjustments are recorded in the period in which they are determined, as if they had been completed at the acquisition date. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within the Company's consolidated results of operations. The following allocation of the purchase price related to the Acquisition based upon the fair value of assets, which primarily included developed technology of $27.5 million, and assumed net liabilities of $3.8 million, with the residual amount being recorded as goodwill of $21.6 million. The intangible assets acquired have a weighted-average life of 10 years.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Cash Flow Information
 3 Months Ended
Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information
NOTE 13. Supplemental Cash Flow Information
The following table provides supplemental cash flow information (in thousands):
 Three Months Ended
March 31,
 20242023
Supplemental cash flow information:
Interest paid$1,069 $1,352 
Income taxes paid227 171 
Supplemental disclosure of non-cash investing and financing activities:  
Right-of-use asset obtained in exchange for new operating lease liability326 435 
Settlement of liabilities through issuance of stock15,230 — 
The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):
 March 31,
2024		December 31,
2023
Cash and cash equivalents$111,706 $107,570 
Restricted cash and equivalents(1)
6,844 6,759 
Cash, cash equivalents and restricted cash equivalents$118,550 $114,329 
___________________________________________
(1)Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Variable Interest Entities
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Variable Interest Entities
NOTE 14. Variable Interest Entities
Consolidated Variable Interest Entities
agilon health, inc.’s consolidated assets and liabilities as of March 31, 2024 and December 31, 2023 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to agilon health, inc.
agilon health, inc.’s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):
 March 31,
2024		December 31,
2023
Assets
Cash and cash equivalents$59,680 $62,154 
Restricted cash equivalents6,842 6,757 
Receivables, net1,569,319 940,618 
Prepaid expenses and other current assets, net21,926 21,907 
Property and equipment, net1,636 1,754 
Intangible assets, net46,578 25,561 
Other assets, net6,144 6,334 
Liabilities
Medical claims and related payables1,266,651 737,724 
Accounts payable and accrued expenses219,407 188,671 
Other liabilities5,062 4,184 
Risk-bearing Entities. At March 31, 2024, the Company operates 34 wholly-owned risk-bearing entities (“RBEs”) for the purpose of entering into risk-bearing contracts with payors. Each RBE’s equity at risk is considered insufficient to finance its activities without additional support, and, therefore, each RBE is considered a VIE. The Company consolidates the RBEs as it has determined that it is the primary beneficiary because it has: (i) the ability to control the activities that most significantly impact the RBEs’ economic performance; and (ii) the obligation to absorb losses or right to receive benefits that could potentially be significant to the RBEs. Specifically, the Company has the unilateral ability and authority, through the RBE governance and management agreements, to make significant decisions about strategic and operating activities of the RBEs, including negotiating and entering into risk-bearing contracts with payors, and approving the RBEs’ annual operating budgets. The Company also has the obligation to fund losses of the RBEs and the right to receive a significant percentage of any financial surplus generated by the RBEs. The assets of the RBEs primarily consist of cash and cash equivalents, receivables, net, intangible assets, net, and other assets. Its obligations primarily consist of medical claims and related payables as well as operating expenses of the RBEs (accounts payable and accrued expenses), including incentive compensation obligations to the Company’s physician partners. On February 18, 2021, the Company executed the Credit Facility, which is guaranteed by certain of the Company’s VIEs. Assets generated by the RBEs (primarily from medical services revenues) may be used, in certain limited circumstances, to settle the Company’s contractual debt obligations.
Unconsolidated Variable Interest Entities
As of March 31, 2024, the Company had 11 equity method investees that were deemed to be VIEs. The Company has determined that the activities that most significantly impact the performance of these VIEs consist of the allocation of resources to and other decisions related to clinical activities and provider contracting decisions. Because the Company does not have the ability to control these activities due to another party’s control of the VIEs’ board of directors, the Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs. The Company provided support to assist its CMS ACO Models investments in obtaining surety bonds related to risk-bearing capital contributions to CMS. As of March 31, 2024 and December 31, 2023, the ACOs had $103.0 million and $38.5 million outstanding surety bonds. The Company's maximum loss exposure as a result of the Company’s involvement with the VIEs cannot be quantified as the Company has the obligation to provide ongoing operational support to the unconsolidated VIEs, as needed.
Equity Method Investments
The following table summarizes the Company’s equity method investees (in thousands):
 March 31,
2024		December 31,
2023
Equity method investments - Other(1)
$9,477 $9,148 
Equity method investments - CMS ACO Models(1)
44,195 35,605 
Equity method liabilities - CMS ACO Models(2)
(2,284)(1,199)
___________________________________________
(1)Included in Other assets, net in the condensed consolidated balance sheets.
(2)Included in Other liabilities in the condensed consolidated balance sheets.
The Company is a partner in 10 wholly-owned CMS ACO Models entities in collaboration with 15 of its physician group partners operating in 13 geographies. The combined summarized operating results of the Company’s CMS ACO Models entities are as follows (in thousands):
 Three Months Ended
March 31,
 20242023
Medical services revenue$440,160 $280,529 
Medical services expense(398,792)(257,477)
Other medical expenses(1)
(25,405)(15,744)
Income (loss) from operations9,532 2,001 
Net income (loss)(2)
5,631 1,334 
___________________________________________
(1)For the three months ended March 31, 2024 and 2023, includes physician incentive expenses of $16.7 million and $9.7 million, respectively.
(2)Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.
The combined summarized balance sheet of the Company’s CMS ACO Models entities are as follows (in thousands):
 March 31,
2024		December 31,
2023
Current assets$294,399 $174,967 
Noncurrent assets3,341 3,341 
Total assets297,740 178,308 
Current and total liabilities255,829 142,027 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Discontinued Operations
 3 Months Ended
Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations
NOTE 15. Discontinued Operations
Discontinued operations is a component of an entity that has either been disposed of or is deemed held-for-sale and, (i) the operations and cash flows of the component have been or will be eliminated from ongoing operations as a result of the disposal transaction, and (ii) the entity will not have any significant continuing involvement in the operations of the component after the disposal transaction. On October 31, 2023, the Company completed the disposition of MDX Hawaii, Inc. and its related operations. The Company’s decision to exit Hawaii and the Independent Practice Association line of business represents a strategic shift that will have a major effect on its operations and financial results. As such, the Company’s Hawaii operations are reflected in the consolidated financial statements as discontinued operations for all periods presented.
The results of discontinued operations are as follows (in thousands):
Three Months Ended
March 31,
20242023
Revenues:
Medical services revenue$— $81,711 
Other operating revenue— 124 
Total revenues— 81,835 
Expenses:
Medical services expense— 75,255 
Other medical expenses— 2,407 
General and administrative518 (2,906)
Depreciation and amortization— 1,235 
Income (loss) from operations(518)5,844 
Other income (expense), net— 204 
Gain (loss) on sales of assets, net(8,763)— 
Interest expense— (40)
Net income (loss) from discontinued operations attributable to common shares$(9,281)$6,008 
The following table provides significant non-cash operating items for discontinued operations that are included in the consolidated statements of cash flows for the three months ended March 31, 2023 (in thousands):
Non-cash operating activities from discontinued operations:
Depreciation and amortization$1,235 
Stock-based compensation expense87 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net income (loss) $ (6,064) $ 16,022
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
shares
Trading Arrangements, by Individual  
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Veeral Desai [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On March 15, 2024, Veeral Desai, the registrant’s Chief Strategy and Development Officer, adopted a Rule 10b5-1 plan intended to satisfy the affirmative defense of SEC Rule 10b5-1(c). The trading plan commences June 15, 2024, ends August 30, 2024 and covers 1,000,000 options to purchase common stock of the registrant.
Name Veeral Desai
Title Chief Strategy and Development Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 15, 2024
Arrangement Duration 76 days
Aggregate Available 1,000,000
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and both joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included.
Use of Estimates
Use of Estimates
Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (“IBNR”) claims), and valuation of long-lived assets, goodwill and intangible assets (acquired in business combinations and analysis of impairment). Management’s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.
Income Taxes
Income Taxes
The Company determines the income tax provision for interim periods using an estimate of the Company’s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In November of 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting—Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which amends certain reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. Additionally, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The amendments in ASU 2023-07 are required to be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-07 on the disclosures in its condensed consolidated financial statements.
In December of 2023, the FASB issued ASU 2023-09, Income Taxes—Improvements to Income Tax Disclosures (“ASU 2023-09”), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on the disclosures in its condensed consolidated financial statements.
Medical Services Revenue
Medical Services Revenue
Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (“payors”). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (“PMPM”) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (“members”) attributed to the Company’s contracted primary care physicians. PMPM fees are determined as a percent of the premium payors receive from the Centers for Medicare & Medicaid Services’ (“CMS”) for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers (“ASC 606”), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.
The transaction price for the Company’s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS’s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member’s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available
diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company’s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved.
Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.
Receivables
Receivables
Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management’s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue, Receivables, and Concentration of Credit Risk (Tables)
 3 Months Ended
Mar. 31, 2024
Risks and Uncertainties [Abstract]  
Schedules of Concentration of Risk as a Percentage of Revenues and Receivables
The following table provides the Company’s revenue concentration with respect to major payors as a percentage of the Company’s total revenues:
 Three Months Ended
March 31,
 20242023
Payor A22 %20 %
Payor B15 %17 %
Payor C14 %13 %
Payor D*10 %
___________________________________________
*Less than 10% of total revenues.
The following table provides the Company’s concentration of credit risk with respect to major payors as a percentage of receivables, net:
 March 31,
2024		December 31,
2023
Payor A14 %13 %
Payor B14 %11 %
Payor C12 % *
Payor D13 %21 %
___________________________________________
*Less than 10% of total receivables.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2024
Debt Securities [Abstract]  
Summary of Marketable Securities
The following table summarizes the Company’s marketable securities (in thousands):
 March 31, 2024December 31, 2023
 Amortized CostGross Unrealized GainsGross Unrealized Losses Fair ValueAmortized CostGross Unrealized GainsGross Unrealized Losses Fair Value
Marketable securities:
Corporate debt securities$184,107 $63 $(1,547)$182,623 $234,821 $180 $(1,604)$233,397 
U.S. Treasury notes126,085 53 (1,402)124,736 138,329 261 (1,206)137,384 
Other— — — — 10,000 — (8)9,992 
 $310,192 $116 $(2,949)$307,359 $383,150 $441 $(2,818)$380,773 
The following table summarizes the Company’s marketable securities maturity as of March 31, 2024 (in thousands):
YearAmortized CostFair Value
2024$92,005 $91,495 
2025176,926 174,802 
202641,261 41,062 
 $310,192 $307,359 
Summary of Marketable Securities, Unrealized Loss Position
The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of March 31, 2024 (in thousands):
Less Than 12 Months12 Months or Greater
Fair ValueGross Unrealized Losses Fair ValueGross Unrealized Losses
Marketable securities:
Corporate debt securities$50,514 $212 $101,513 $1,335 
U.S. Treasury notes49,359 615 63,494 787 
$99,873 $827 $165,007 $2,122 
The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December 31, 2023 (in thousands):
Less Than 12 Months12 Months or Greater
Fair ValueGross Unrealized Losses Fair ValueGross Unrealized Losses
Marketable securities:
Corporate debt securities$55,343 $167 $126,189 $1,437 
U.S. Treasury notes37,486 303 75,980 903 
Other9,992 8 — — 
$102,821 $478 $202,169 $2,340 
Summary of Fair Value Assets Measured on Recurring Basis
The table below summarizes the Company’s financial instruments measured at fair value on a recurring basis (in thousands):
 March 31, 2024December 31, 2023
 Level 1Level 2Level 3Level 1Level 2Level 3
Marketable securities:
Corporate debt securities$— $182,623 $— $— $233,397 $— 
U.S. Treasury notes124,736 — — 137,384 — — 
Other— — — 9,992 — — 
 $124,736 $182,623 $— $147,376 $233,397 $— 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Assets (Tables)
 3 Months Ended
Mar. 31, 2024
Other Assets [Abstract]  
Schedule of Other Assets
The following table summarizes the Company’s other assets (in thousands):
 March 31,
2024		December 31,
2023
Loans to physician partners$71,561 $71,862 
Health plan deposits2,051 2,051 
Equity method investments(1)
53,672 44,753 
Right-of-use lease assets13,092 13,411 
Other15,530 13,235 
 $155,906 $145,312 
___________________________________________
(1)See Note 14 for additional discussion related to the Company's equity method investments.
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Medical Claims and Related Payables (Tables)
 3 Months Ended
Mar. 31, 2024
Insurance [Abstract]  
Summary Changes in Medical Claims and Related Payables
The following table presents the components of changes in medical claims and related payables (in thousands):
 March 31,
 20242023
Medical claims and related payables, beginning of the year$723,071 $339,749 
Components of incurred costs related to:
Current year1,427,328 872,973 
Prior years16,514 24,599 
Discontinued operations - current year— 71,333 
Discontinued operations - prior years— 3,922 
 1,443,842 972,827 
Claims paid related to:
Current year(316,779)(223,425)
Prior years(595,250)(278,688)
Discontinued operations - current year— (34,793)
Discontinued operations - prior years— (42,140)
 (912,029)(579,046)
Medical claims and related payables, end of the period$1,254,884 $733,530 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Liabilities (Tables)
 3 Months Ended
Mar. 31, 2024
Other Liabilities [Abstract]  
Summary of Other Liabilities
The following table summarizes the Company’s other liabilities (in thousands):
 March 31,
2024		December 31,
2023
Other long-term contingencies$49,000 $49,000 
Lease liabilities, long-term10,618 10,905 
Equity method liabilities – CMS ACO Models2,284 1,199 
Other9,593 9,277 
 $71,495 $70,381 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Income (Loss) Per Common Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Summery of Net Income (Loss) Per Share Attributable to Common Stockholder
The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):
 Three Months Ended
March 31,
 20242023
Numerator
Income (loss) from continuing operations$3,247 $9,951 
Noncontrolling interests’ share in (earnings) loss from continuing operations(30)63 
Net income (loss) attributable to common stockholders before discontinued operations3,217 10,014 
Income (loss) from discontinued operations(9,281)6,008 
Net income (loss) attributable to common stockholders$(6,064)$16,022 
Denominator
Weighted average shares outstanding – basic408,938413,136
Weighted average shares outstanding – diluted413,437426,586
Net income (loss) per share attributable to common stockholders
Net income (loss) per common share from continuing operations, basic and diluted$0.01 $0.02 
Net income (loss) per common share from discontinued operations, basic and diluted$(0.02)$0.02 
Schedule of Antidilutive Securities
The following table provides the weighted-average potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):
 March 31,
 20242023
Stock options6,6162,098
Restricted stock units9,6574,592
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Cash Flow Information (Tables)
 3 Months Ended
Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]  
Summary of Supplemental Cash Flow Information
The following table provides supplemental cash flow information (in thousands):
 Three Months Ended
March 31,
 20242023
Supplemental cash flow information:
Interest paid$1,069 $1,352 
Income taxes paid227 171 
Supplemental disclosure of non-cash investing and financing activities:  
Right-of-use asset obtained in exchange for new operating lease liability326 435 
Settlement of liabilities through issuance of stock15,230 — 
Summary of Restricted Cash Equivalents from Continuing Operations
The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):
 March 31,
2024		December 31,
2023
Cash and cash equivalents$111,706 $107,570 
Restricted cash and equivalents(1)
6,844 6,759 
Cash, cash equivalents and restricted cash equivalents$118,550 $114,329 
___________________________________________
(1)Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.
Schedule of Cash and Cash Equivalents from Continuing Operations
The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):
 March 31,
2024		December 31,
2023
Cash and cash equivalents$111,706 $107,570 
Restricted cash and equivalents(1)
6,844 6,759 
Cash, cash equivalents and restricted cash equivalents$118,550 $114,329 
___________________________________________
(1)Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Variable Interest Entities (Tables)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Consolidated Asset and Liabilities Include VIE Assets and Liabilities
agilon health, inc.’s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):
 March 31,
2024		December 31,
2023
Assets
Cash and cash equivalents$59,680 $62,154 
Restricted cash equivalents6,842 6,757 
Receivables, net1,569,319 940,618 
Prepaid expenses and other current assets, net21,926 21,907 
Property and equipment, net1,636 1,754 
Intangible assets, net46,578 25,561 
Other assets, net6,144 6,334 
Liabilities
Medical claims and related payables1,266,651 737,724 
Accounts payable and accrued expenses219,407 188,671 
Other liabilities5,062 4,184 
Schedule of Equity Method Investments
The following table summarizes the Company’s equity method investees (in thousands):
 March 31,
2024		December 31,
2023
Equity method investments - Other(1)
$9,477 $9,148 
Equity method investments - CMS ACO Models(1)
44,195 35,605 
Equity method liabilities - CMS ACO Models(2)
(2,284)(1,199)
___________________________________________
(1)Included in Other assets, net in the condensed consolidated balance sheets.
(2)Included in Other liabilities in the condensed consolidated balance sheets.
Summary of Operating Results The combined summarized operating results of the Company’s CMS ACO Models entities are as follows (in thousands):
 Three Months Ended
March 31,
 20242023
Medical services revenue$440,160 $280,529 
Medical services expense(398,792)(257,477)
Other medical expenses(1)
(25,405)(15,744)
Income (loss) from operations9,532 2,001 
Net income (loss)(2)
5,631 1,334 
___________________________________________
(1)For the three months ended March 31, 2024 and 2023, includes physician incentive expenses of $16.7 million and $9.7 million, respectively.
(2)Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.
Summarized Balance Sheet
The combined summarized balance sheet of the Company’s CMS ACO Models entities are as follows (in thousands):
 March 31,
2024		December 31,
2023
Current assets$294,399 $174,967 
Noncurrent assets3,341 3,341 
Total assets297,740 178,308 
Current and total liabilities255,829 142,027 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Discontinued Operations (Tables)
 3 Months Ended
Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Summary of Financial Statements Related to Discontinued Operations
The results of discontinued operations are as follows (in thousands):
Three Months Ended
March 31,
20242023
Revenues:
Medical services revenue$— $81,711 
Other operating revenue— 124 
Total revenues— 81,835 
Expenses:
Medical services expense— 75,255 
Other medical expenses— 2,407 
General and administrative518 (2,906)
Depreciation and amortization— 1,235 
Income (loss) from operations(518)5,844 
Other income (expense), net— 204 
Gain (loss) on sales of assets, net(8,763)— 
Interest expense— (40)
Net income (loss) from discontinued operations attributable to common shares$(9,281)$6,008 
The following table provides significant non-cash operating items for discontinued operations that are included in the consolidated statements of cash flows for the three months ended March 31, 2023 (in thousands):
Non-cash operating activities from discontinued operations:
Depreciation and amortization$1,235 
Stock-based compensation expense87 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business (Details)
Mar. 31, 2024
member
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of medicare advantage members enrolled with private health plans 522,800
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Accounting Policies [Abstract]      
Gross carrying amount of property and equipment $ 44.3   $ 41.9
Accumulated amortization 16.8   $ 14.3
Depreciation expense $ 2.8 $ 1.7  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue, Receivables, and Concentration of Credit Risk (Details) - Medicare Advantage Payors
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Revenue from Contract with Customer Benchmark | Payor A      
Concentration Risk [Line Items]      
Concentration risk, percentage 22.00% 20.00%  
Revenue from Contract with Customer Benchmark | Payor B      
Concentration Risk [Line Items]      
Concentration risk, percentage 15.00% 17.00%  
Revenue from Contract with Customer Benchmark | Payor C      
Concentration Risk [Line Items]      
Concentration risk, percentage 14.00% 13.00%  
Revenue from Contract with Customer Benchmark | Payor D      
Concentration Risk [Line Items]      
Concentration risk, percentage   10.00%  
Receivables | Payor A      
Concentration Risk [Line Items]      
Concentration risk, percentage 14.00%   13.00%
Receivables | Payor B      
Concentration Risk [Line Items]      
Concentration risk, percentage 14.00%   11.00%
Receivables | Payor C      
Concentration Risk [Line Items]      
Concentration risk, percentage 12.00%    
Receivables | Payor D      
Concentration Risk [Line Items]      
Concentration risk, percentage 13.00%   21.00%
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Fair Value Measurements - Summary of Marketable Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Marketable debt securities [Line Items]    
Amortized Cost $ 310,192 $ 383,150
Gross Unrealized Gains 116 441
Gross Unrealized Losses (2,949) (2,818)
Fair Value 307,359 380,773
Corporate debt securities    
Marketable debt securities [Line Items]    
Amortized Cost 184,107 234,821
Gross Unrealized Gains 63 180
Gross Unrealized Losses (1,547) (1,604)
Fair Value 182,623 233,397
U.S. Treasury notes    
Marketable debt securities [Line Items]    
Amortized Cost 126,085 138,329
Gross Unrealized Gains 53 261
Gross Unrealized Losses (1,402) (1,206)
Fair Value 124,736 137,384
Other    
Marketable debt securities [Line Items]    
Amortized Cost 0 10,000
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 (8)
Fair Value $ 0 $ 9,992
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Fair Value Measurements - Narrative (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]      
Investment income $ 5,400,000 $ 8,300,000  
Allowances for credit losses 0   $ 0
Debt Securities      
Debt Securities, Available-for-Sale [Line Items]      
Investment income 4,000,000 4,900,000  
Cash and Cash Equivalents      
Debt Securities, Available-for-Sale [Line Items]      
Investment income $ 1,400,000 $ 3,400,000  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Fair Value Measurements - Summarizes Marketable Securities Maturity (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Amortized Cost    
2024 $ 92,005  
2025 176,926  
2026 41,261  
Amortized Cost 310,192 $ 383,150
Fair Value    
2024 91,495  
2025 174,802  
2026 41,062  
Fair Value $ 307,359 $ 380,773
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Fair Value Measurements - Summary of Marketable Securities, Unrealized Loss Position (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Fair Value    
Less Than 12 Months $ 99,873 $ 102,821
12 Months or Greater 165,007 202,169
Gross Unrealized Losses    
Less Than 12 Months 827 478
12 Months or Greater 2,122 2,340
Corporate debt securities    
Fair Value    
Less Than 12 Months 50,514 55,343
12 Months or Greater 101,513 126,189
Gross Unrealized Losses    
Less Than 12 Months 212 167
12 Months or Greater 1,335 1,437
U.S. Treasury notes    
Fair Value    
Less Than 12 Months 49,359 37,486
12 Months or Greater 63,494 75,980
Gross Unrealized Losses    
Less Than 12 Months 615 303
12 Months or Greater $ 787 903
Other    
Fair Value    
Less Than 12 Months   9,992
12 Months or Greater   0
Gross Unrealized Losses    
Less Than 12 Months   8
12 Months or Greater   $ 0
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]    
Fair Value $ 307,359 $ 380,773
Level 1    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 124,736 147,376
Level 2    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 182,623 233,397
Level 3    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 0 0
Corporate debt securities    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 182,623 233,397
Corporate debt securities | Level 1    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 0 0
Corporate debt securities | Level 2    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 182,623 233,397
Corporate debt securities | Level 3    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 0 0
U.S. Treasury notes    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 124,736 137,384
U.S. Treasury notes | Level 1    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 124,736 137,384
U.S. Treasury notes | Level 2    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 0 0
U.S. Treasury notes | Level 3    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 0 0
Other    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 0 9,992
Other | Level 1    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 0 9,992
Other | Level 2    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value 0 0
Other | Level 3    
Debt Securities, Available-for-Sale [Line Items]    
Fair Value $ 0 $ 0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Other Assets [Abstract]    
Loans to physician partners $ 71,561 $ 71,862
Health plan deposits 2,051 2,051
Equity method investments 53,672 44,753
Right-of-use lease assets 13,092 13,411
Other 15,530 13,235
Other assets $ 155,906 $ 145,312
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Medical Claims and Related Payables - Summary Changes in Medical Claims and Related Payables (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]    
Medical claims and related payables, beginning of the year $ 723,071 $ 339,749
Components of incurred costs related to:    
Incurred cost related to claims 1,443,842 972,827
Claims paid related to:    
Claims paid related (912,029) (579,046)
Medical claims and related payables, end of the period 1,254,884 733,530
Continuing Operations    
Components of incurred costs related to:    
Current year 1,427,328 872,973
Prior years 16,514 24,599
Claims paid related to:    
Current year (316,779) (223,425)
Prior years (595,250) (278,688)
Discontinued Operations    
Components of incurred costs related to:    
Current year 0 71,333
Prior years 0 3,922
Claims paid related to:    
Current year 0 (34,793)
Prior years $ 0 $ (42,140)
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Medical Claims and Related Payables - Narrative (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Insurance [Abstract]    
Related payables associated with retained liability $ 11.8 $ 14.7
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Liabilities - Summary of Other Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Other Liabilities [Abstract]    
Other long-term contingencies $ 49,000 $ 49,000
Lease liabilities, long-term $ 10,618 $ 10,905
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other liabilities Other liabilities
Equity method liabilities – CMS ACO Models $ 2,284 $ 1,199
Other 9,593 9,277
Other liabilities $ 71,495 $ 70,381
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Liabilities - Narrative (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Other Liabilities [Line Items]    
Other long-term contingencies $ 49,000 $ 49,000
Unasserted Claim    
Other Liabilities [Line Items]    
Other long-term contingencies $ 49,000 $ 49,000
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt (Details) - USD ($)
 3 Months Ended
May 25, 2023
Feb. 18, 2021
Mar. 31, 2024
Dec. 31, 2023
Surety Bond        
Debt Instrument [Line Items]        
Long-term debt     $ 25,100,000 $ 25,100,000
Secured Term Loan Facility        
Debt Instrument [Line Items]        
Credit facility remaining borrowing capacity   $ 100,000,000    
Line of credit facility, accordion feature, increase limit   50,000,000    
Long-term debt     $ 37,500,000  
Weighted average effective interest rate     9.394%  
Secured Term Loan Facility | Secured Overnight Financing Rate (SOFR)        
Debt Instrument [Line Items]        
Debt instrument, basis spread on variable rate 1.00%      
Secured Term Loan Facility | Overnight Federal Funds Rate        
Debt Instrument [Line Items]        
Debt instrument, basis spread on variable rate 0.50%      
Secured Term Loan Facility | Maximum | Secured Overnight Financing Rate (SOFR)        
Debt Instrument [Line Items]        
Debt instrument, basis spread on variable rate 3.50%      
Secured Term Loan Facility | Maximum | Base Rate Loans        
Debt Instrument [Line Items]        
Debt instrument, basis spread on variable rate 2.50%      
Secured Term Loan Facility | Minimum | Secured Overnight Financing Rate (SOFR)        
Debt Instrument [Line Items]        
Debt instrument, basis spread on variable rate 0.00%      
Secured Term Loan Facility | Minimum | Base Rate Loans        
Debt Instrument [Line Items]        
Debt instrument, basis spread on variable rate 0.00%      
Secured Revolving Facility        
Debt Instrument [Line Items]        
Credit facility remaining borrowing capacity   100,000,000    
Credit facility remaining borrowing capacity     $ 60,700,000  
Secured Revolving Facility | Minimum        
Debt Instrument [Line Items]        
Line of credit facility, unused capacity, commitment fee percentage 0.375%      
Standby Letters of Credit        
Debt Instrument [Line Items]        
Credit facility remaining borrowing capacity   $ 100,000,000    
Long-term debt     0  
Total outstanding letters of credit     $ 39,300,000  
Extended term of letters of credit     1 year  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies (Details)
 2 Months Ended
Mar. 31, 2024
lawsuit
Commitments and Contingencies Disclosure [Abstract]  
Loss contingency, new claims filed 3
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock (Details) - Common Stock - shares
shares in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Subsidiary Sale Of Stock [Line Items]    
Number of shares issued under share-based awards (in shares) 2.5 2.1
Number of shares issued to settle liabilities (in shares) 2.0  
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Income (Loss) Per Common Share - Computation of Basic and Diluted EPS (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Numerator    
Income (loss) from continuing operations $ 3,247 $ 9,951
Noncontrolling interests’ share in (earnings) loss from continuing operations (30) 63
Net income (loss) attributable to common stockholders before discontinued operations 3,217 10,014
Income (loss) from discontinued operations (9,281) 6,008
Net income (loss) attributable to common shares $ (6,064) $ 16,022
Denominator    
Weighted average shares outstanding – basic (in shares) 408,938 413,136
Weighted average shares outstanding – diluted (in shares) 413,437 426,586
Net income (loss) per share attributable to common stockholders    
Continuing operations, basic (in dollars per share) $ 0.01 $ 0.02
Continuing operations, diluted (in dollars per share) 0.01 0.02
Discontinued operations, basic (in dollars per share) (0.02) 0.02
Discontinued operations, diluted (in dollars per share) $ (0.02) $ 0.02
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Stock options    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 6,616 2,098
Restricted stock units    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 9,657 4,592
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Amortizable Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended
Feb. 28, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Indefinite-Lived Intangible Assets [Line Items]        
Goodwill   $ 24,133   $ 24,133
Gross carrying amount of amortizable intangible assets   119,200   108,000
Accumulated amortization   47,100   $ 44,200
Amortization expense   2,900 $ 1,300  
Net cash paid in business combination   $ 0 $ 44,367  
Weighted-average life 10 years      
mphrX        
Indefinite-Lived Intangible Assets [Line Items]        
Net cash paid in business combination $ 45,300      
mphrX | Developed Technology        
Indefinite-Lived Intangible Assets [Line Items]        
Assets acquired 27,500      
mphrX | Customer Relationships        
Indefinite-Lived Intangible Assets [Line Items]        
Goodwill 21,600      
Net liabilities assumed $ 3,800      
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Cash Flow Information - Summary of Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Supplemental cash flow information:    
Interest paid $ 1,069 $ 1,352
Income taxes paid 227 171
Supplemental disclosure of non-cash investing and financing activities:    
Right-of-use asset obtained in exchange for new operating lease liability 326 435
Settlement of liabilities through issuance of stock $ 15,230 $ 0
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Cash Flow Information - Summary of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]        
Cash and cash equivalents $ 111,706 $ 107,570    
Restricted cash and equivalents 6,844 6,759    
Cash, cash equivalents and restricted cash equivalents $ 118,550 $ 114,329 $ 397,023 $ 475,912
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Variable Interest Entities - Summary of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets    
Cash and cash equivalents $ 111,706 $ 107,570
Receivables, net 1,571,143 942,461
Prepaid expenses and other current assets, net 39,757 42,513
Property and equipment, net 27,539 27,576
Intangible assets, net 72,076 63,769
Liabilities    
Medical claims and related payables 1,266,651 737,724
Accounts payable and accrued expenses 252,497 233,182
Variable Interest Entity    
Assets    
Cash and cash equivalents 59,680 62,154
Restricted cash equivalents 6,842 6,757
Receivables, net 1,569,319 940,618
Prepaid expenses and other current assets, net 21,926 21,907
Property and equipment, net 1,636 1,754
Intangible assets, net 46,578 25,561
Other assets, net 6,144 6,334
Liabilities    
Medical claims and related payables 1,266,651 737,724
Accounts payable and accrued expenses 219,407 188,671
Other liabilities $ 5,062 $ 4,184
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Variable Interest Entities - Narrative (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
investment
entity
partner
geography
Dec. 31, 2023
USD ($)
Variable Interest Entity [Line Items]    
Number of geographies | geography 13  
Surety Bond    
Variable Interest Entity [Line Items]    
Long-term debt | $ $ 25.1 $ 25.1
Variable Interest Entity, Primary Beneficiary    
Variable Interest Entity [Line Items]    
Number of wholly-owned risk-bearing entities | entity 34  
Number of direct contracting entities | entity 10  
Number of physician group partners | partner 15  
Variable Interest Entity, Not Primary Beneficiary    
Variable Interest Entity [Line Items]    
Number of equity method investments for VIEs | investment 11  
Variable Interest Entity, Not Primary Beneficiary | Surety Bond    
Variable Interest Entity [Line Items]    
Long-term debt | $ $ 103.0 $ 38.5
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Variable Interest Entities - Schedule of Equity Method Investments (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Variable Interest Entity [Line Items]    
Equity method investments $ 53,672 $ 44,753
Equity method liabilities (2,284) (1,199)
Other Equity Methods    
Variable Interest Entity [Line Items]    
Equity method investments 9,477 9,148
ACO REACH    
Variable Interest Entity [Line Items]    
Equity method investments $ 44,195 $ 35,605
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Variable Interest Entities - Summary of Operating Results (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Variable Interest Entity [Line Items]    
Medical services revenue $ 1,604,354 $ 1,054,312
Income (loss) from operations (7,178) 417
Net income (loss) (6,064) 16,022
Equity Method Investment, Nonconsolidated Investee or Group of Investees    
Variable Interest Entity [Line Items]    
Income (loss) from operations 9,532 2,001
Net income (loss) 5,631 1,334
Physician compensation expense 16,700 9,700
Medical services revenue    
Variable Interest Entity [Line Items]    
Medical services revenue 1,601,195 1,053,119
Expenses (1,443,842) (897,572)
Medical services revenue | Equity Method Investment, Nonconsolidated Investee or Group of Investees    
Variable Interest Entity [Line Items]    
Medical services revenue 440,160 280,529
Expenses (398,792) (257,477)
Other operating revenue    
Variable Interest Entity [Line Items]    
Medical services revenue 3,159 1,193
Expenses (85,424) (83,617)
Other operating revenue | Equity Method Investment, Nonconsolidated Investee or Group of Investees    
Variable Interest Entity [Line Items]    
Expenses $ (25,405) $ (15,744)
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Variable Interest Entities - Summarized Balance Sheet (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Variable Interest Entity [Line Items]    
Current assets $ 2,036,809 $ 1,480,076
Total assets 2,316,463 1,740,866
Current and total liabilities 1,627,977 1,079,845
Equity Method Investment, Nonconsolidated Investee or Group of Investees    
Variable Interest Entity [Line Items]    
Current assets 294,399 174,967
Noncurrent assets 3,341 3,341
Total assets 297,740 178,308
Current and total liabilities $ 255,829 $ 142,027
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Discontinued Operations - Summary of Results of Discontinued Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]    
Gain (loss) on sales of assets, net $ (8,763) $ 0
Discontinued Operations, Disposed of by Sale    
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]    
Revenues 0 81,835
General and administrative 518 (2,906)
Depreciation and amortization 0 1,235
Income (loss) from operations (518) 5,844
Other income (expense), net 0 204
Gain (loss) on sales of assets, net (8,763) 0
Interest expense 0 (40)
Net income (loss) from discontinued operations attributable to common shares (9,281) 6,008
Medical services revenue | Discontinued Operations, Disposed of by Sale    
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]    
Revenues 0 81,711
Expenses 0 75,255
Other Operating | Discontinued Operations, Disposed of by Sale    
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]    
Revenues 0 124
Expenses $ 0 $ 2,407
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Discontinued Operations - Summary of Significant Non-Cash Operating Items for Discontinued Operations (Details) - Discontinued Operations, Disposed of by Sale - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Non-cash operating activities from discontinued operations:    
Depreciation and amortization $ 0 $ 1,235
Stock-based compensation expense   $ 87
EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 79 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 147 252 1 false 47 0 false 10 false false R1.htm 0000001 - Document - Cover Sheet http://agilonhealth.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://agilonhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 7 false false R8.htm 0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 0000009 - Disclosure - Business Sheet http://agilonhealth.com/role/Business Business Notes 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://agilonhealth.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk Sheet http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRisk Revenue, Receivables, and Concentration of Credit Risk Notes 11 false false R12.htm 0000012 - Disclosure - Marketable Securities and Fair Value Measurements Sheet http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurements Marketable Securities and Fair Value Measurements Notes 12 false false R13.htm 0000013 - Disclosure - Other Assets Sheet http://agilonhealth.com/role/OtherAssets Other Assets Notes 13 false false R14.htm 0000014 - Disclosure - Medical Claims and Related Payables Sheet http://agilonhealth.com/role/MedicalClaimsandRelatedPayables Medical Claims and Related Payables Notes 14 false false R15.htm 0000015 - Disclosure - Other Liabilities Sheet http://agilonhealth.com/role/OtherLiabilities Other Liabilities Notes 15 false false R16.htm 0000016 - Disclosure - Debt Sheet http://agilonhealth.com/role/Debt Debt Notes 16 false false R17.htm 0000017 - Disclosure - Commitments and Contingencies Sheet http://agilonhealth.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 17 false false R18.htm 0000018 - Disclosure - Common Stock Sheet http://agilonhealth.com/role/CommonStock Common Stock Notes 18 false false R19.htm 0000019 - Disclosure - Net Income (Loss) Per Common Share Sheet http://agilonhealth.com/role/NetIncomeLossPerCommonShare Net Income (Loss) Per Common Share Notes 19 false false R20.htm 0000020 - Disclosure - Goodwill and Amortizable Intangible Assets Sheet http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssets Goodwill and Amortizable Intangible Assets Notes 20 false false R21.htm 0000021 - Disclosure - Supplemental Cash Flow Information Sheet http://agilonhealth.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 21 false false R22.htm 0000022 - Disclosure - Variable Interest Entities Sheet http://agilonhealth.com/role/VariableInterestEntities Variable Interest Entities Notes 22 false false R23.htm 0000023 - Disclosure - Discontinued Operations Sheet http://agilonhealth.com/role/DiscontinuedOperations Discontinued Operations Notes 23 false false R24.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 24 false false R25.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 25 false false R26.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://agilonhealth.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 9954472 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Tables) Sheet http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskTables Revenue, Receivables, and Concentration of Credit Risk (Tables) Tables http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRisk 27 false false R28.htm 9954473 - Disclosure - Marketable Securities and Fair Value Measurements (Tables) Sheet http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables Marketable Securities and Fair Value Measurements (Tables) Tables http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurements 28 false false R29.htm 9954474 - Disclosure - Other Assets (Tables) Sheet http://agilonhealth.com/role/OtherAssetsTables Other Assets (Tables) Tables http://agilonhealth.com/role/OtherAssets 29 false false R30.htm 9954475 - Disclosure - Medical Claims and Related Payables (Tables) Sheet http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesTables Medical Claims and Related Payables (Tables) Tables http://agilonhealth.com/role/MedicalClaimsandRelatedPayables 30 false false R31.htm 9954476 - Disclosure - Other Liabilities (Tables) Sheet http://agilonhealth.com/role/OtherLiabilitiesTables Other Liabilities (Tables) Tables http://agilonhealth.com/role/OtherLiabilities 31 false false R32.htm 9954477 - Disclosure - Net Income (Loss) Per Common Share (Tables) Sheet http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables Net Income (Loss) Per Common Share (Tables) Tables http://agilonhealth.com/role/NetIncomeLossPerCommonShare 32 false false R33.htm 9954478 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://agilonhealth.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://agilonhealth.com/role/SupplementalCashFlowInformation 33 false false R34.htm 9954479 - Disclosure - Variable Interest Entities (Tables) Sheet http://agilonhealth.com/role/VariableInterestEntitiesTables Variable Interest Entities (Tables) Tables http://agilonhealth.com/role/VariableInterestEntities 34 false false R35.htm 9954480 - Disclosure - Discontinued Operations (Tables) Sheet http://agilonhealth.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://agilonhealth.com/role/DiscontinuedOperations 35 false false R36.htm 9954481 - Disclosure - Business (Details) Sheet http://agilonhealth.com/role/BusinessDetails Business (Details) Details http://agilonhealth.com/role/Business 36 false false R37.htm 9954482 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies 37 false false R38.htm 9954483 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Details) Sheet http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails Revenue, Receivables, and Concentration of Credit Risk (Details) Details http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskTables 38 false false R39.htm 9954484 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Marketable Securities (Details) Sheet http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails Marketable Securities and Fair Value Measurements - Summary of Marketable Securities (Details) Details 39 false false R40.htm 9954485 - Disclosure - Marketable Securities and Fair Value Measurements - Narrative (Details) Sheet http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails Marketable Securities and Fair Value Measurements - Narrative (Details) Details http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables 40 false false R41.htm 9954486 - Disclosure - Marketable Securities and Fair Value Measurements - Summarizes Marketable Securities Maturity (Details) Sheet http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails Marketable Securities and Fair Value Measurements - Summarizes Marketable Securities Maturity (Details) Details 41 false false R42.htm 9954487 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Marketable Securities, Unrealized Loss Position (Details) Sheet http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails Marketable Securities and Fair Value Measurements - Summary of Marketable Securities, Unrealized Loss Position (Details) Details 42 false false R43.htm 9954488 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details) Sheet http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails Marketable Securities and Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details) Details 43 false false R44.htm 9954489 - Disclosure - Other Assets (Details) Sheet http://agilonhealth.com/role/OtherAssetsDetails Other Assets (Details) Details http://agilonhealth.com/role/OtherAssetsTables 44 false false R45.htm 9954490 - Disclosure - Medical Claims and Related Payables - Summary Changes in Medical Claims and Related Payables (Details) Sheet http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails Medical Claims and Related Payables - Summary Changes in Medical Claims and Related Payables (Details) Details 45 false false R46.htm 9954491 - Disclosure - Medical Claims and Related Payables - Narrative (Details) Sheet http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesNarrativeDetails Medical Claims and Related Payables - Narrative (Details) Details 46 false false R47.htm 9954492 - Disclosure - Other Liabilities - Summary of Other Liabilities (Details) Sheet http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails Other Liabilities - Summary of Other Liabilities (Details) Details 47 false false R48.htm 9954493 - Disclosure - Other Liabilities - Narrative (Details) Sheet http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails Other Liabilities - Narrative (Details) Details 48 false false R49.htm 9954494 - Disclosure - Debt (Details) Sheet http://agilonhealth.com/role/DebtDetails Debt (Details) Details http://agilonhealth.com/role/Debt 49 false false R50.htm 9954495 - Disclosure - Commitments and Contingencies (Details) Sheet http://agilonhealth.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://agilonhealth.com/role/CommitmentsandContingencies 50 false false R51.htm 9954496 - Disclosure - Common Stock (Details) Sheet http://agilonhealth.com/role/CommonStockDetails Common Stock (Details) Details http://agilonhealth.com/role/CommonStock 51 false false R52.htm 9954497 - Disclosure - Net Income (Loss) Per Common Share - Computation of Basic and Diluted EPS (Details) Sheet http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails Net Income (Loss) Per Common Share - Computation of Basic and Diluted EPS (Details) Details http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables 52 false false R53.htm 9954498 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details) Sheet http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details) Details http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables 53 false false R54.htm 9954499 - Disclosure - Goodwill and Amortizable Intangible Assets (Details) Sheet http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails Goodwill and Amortizable Intangible Assets (Details) Details http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssets 54 false false R55.htm 9954500 - Disclosure - Supplemental Cash Flow Information - Summary of Supplemental Cash Flow Information (Details) Sheet http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofSupplementalCashFlowInformationDetails Supplemental Cash Flow Information - Summary of Supplemental Cash Flow Information (Details) Details 55 false false R56.htm 9954501 - Disclosure - Supplemental Cash Flow Information - Summary of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details) Sheet http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails Supplemental Cash Flow Information - Summary of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details) Details 56 false false R57.htm 9954502 - Disclosure - Variable Interest Entities - Summary of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details) Sheet http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails Variable Interest Entities - Summary of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details) Details 57 false false R58.htm 9954503 - Disclosure - Variable Interest Entities - Narrative (Details) Sheet http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails Variable Interest Entities - Narrative (Details) Details 58 false false R59.htm 9954504 - Disclosure - Variable Interest Entities - Schedule of Equity Method Investments (Details) Sheet http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails Variable Interest Entities - Schedule of Equity Method Investments (Details) Details 59 false false R60.htm 9954505 - Disclosure - Variable Interest Entities - Summary of Operating Results (Details) Sheet http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails Variable Interest Entities - Summary of Operating Results (Details) Details 60 false false R61.htm 9954506 - Disclosure - Variable Interest Entities - Summarized Balance Sheet (Details) Sheet http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails Variable Interest Entities - Summarized Balance Sheet (Details) Details 61 false false R62.htm 9954507 - Disclosure - Discontinued Operations - Summary of Results of Discontinued Operations (Details) Sheet http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails Discontinued Operations - Summary of Results of Discontinued Operations (Details) Details 62 false false R63.htm 9954508 - Disclosure - Discontinued Operations - Summary of Significant Non-Cash Operating Items for Discontinued Operations (Details) Sheet http://agilonhealth.com/role/DiscontinuedOperationsSummaryofSignificantNonCashOperatingItemsforDiscontinuedOperationsDetails Discontinued Operations - Summary of Significant Non-Cash Operating Items for Discontinued Operations (Details) Details 63 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration - agl-20240331.htm 4 agl-20240331.htm agl-20240331.xsd agl-20240331_cal.xml agl-20240331_def.xml agl-20240331_lab.xml agl-20240331_pre.xml http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 82 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "agl-20240331.htm": { "nsprefix": "agl", "nsuri": "http://agilonhealth.com/20240331", "dts": { "inline": { "local": [ "agl-20240331.htm" ] }, "schema": { "local": [ "agl-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "agl-20240331_cal.xml" ] }, "definitionLink": { "local": [ "agl-20240331_def.xml" ] }, "labelLink": { "local": [ "agl-20240331_lab.xml" ] }, "presentationLink": { "local": [ "agl-20240331_pre.xml" ] } }, "keyStandard": 229, "keyCustom": 23, "axisStandard": 22, "axisCustom": 0, "memberStandard": 33, "memberCustom": 14, "hidden": { "total": 8, "http://xbrl.sec.gov/ecd/2023": 1, "http://fasb.org/us-gaap/2023": 2, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 147, "entityCount": 1, "segmentCount": 47, "elementCount": 498, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 583, "http://xbrl.sec.gov/dei/2023": 30, "http://xbrl.sec.gov/ecd/2023": 10, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://agilonhealth.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R3": { "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R5": { "role": "http://agilonhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSParenthetical", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R7": { "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-27", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R9": { "role": "http://agilonhealth.com/role/Business", "longName": "0000009 - Disclosure - Business", "shortName": "Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://agilonhealth.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRisk", "longName": "0000011 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk", "shortName": "Revenue, Receivables, and Concentration of Credit Risk", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurements", "longName": "0000012 - Disclosure - Marketable Securities and Fair Value Measurements", "shortName": "Marketable Securities and Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://agilonhealth.com/role/OtherAssets", "longName": "0000013 - Disclosure - Other Assets", "shortName": "Other Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://agilonhealth.com/role/MedicalClaimsandRelatedPayables", "longName": "0000014 - Disclosure - Medical Claims and Related Payables", "shortName": "Medical Claims and Related Payables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://agilonhealth.com/role/OtherLiabilities", "longName": "0000015 - Disclosure - Other Liabilities", "shortName": "Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://agilonhealth.com/role/Debt", "longName": "0000016 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://agilonhealth.com/role/CommitmentsandContingencies", "longName": "0000017 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://agilonhealth.com/role/CommonStock", "longName": "0000018 - Disclosure - Common Stock", "shortName": "Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://agilonhealth.com/role/NetIncomeLossPerCommonShare", "longName": "0000019 - Disclosure - Net Income (Loss) Per Common Share", "shortName": "Net Income (Loss) Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssets", "longName": "0000020 - Disclosure - Goodwill and Amortizable Intangible Assets", "shortName": "Goodwill and Amortizable Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://agilonhealth.com/role/SupplementalCashFlowInformation", "longName": "0000021 - Disclosure - Supplemental Cash Flow Information", "shortName": "Supplemental Cash Flow Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://agilonhealth.com/role/VariableInterestEntities", "longName": "0000022 - Disclosure - Variable Interest Entities", "shortName": "Variable Interest Entities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://agilonhealth.com/role/DiscontinuedOperations", "longName": "0000023 - Disclosure - Discontinued Operations", "shortName": "Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "ecd:MtrlTermsOfTrdArrTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "ecd:MtrlTermsOfTrdArrTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskTables", "longName": "9954472 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Tables)", "shortName": "Revenue, Receivables, and Concentration of Credit Risk (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables", "longName": "9954473 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)", "shortName": "Marketable Securities and Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://agilonhealth.com/role/OtherAssetsTables", "longName": "9954474 - Disclosure - Other Assets (Tables)", "shortName": "Other Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesTables", "longName": "9954475 - Disclosure - Medical Claims and Related Payables (Tables)", "shortName": "Medical Claims and Related Payables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://agilonhealth.com/role/OtherLiabilitiesTables", "longName": "9954476 - Disclosure - Other Liabilities (Tables)", "shortName": "Other Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables", "longName": "9954477 - Disclosure - Net Income (Loss) Per Common Share (Tables)", "shortName": "Net Income (Loss) Per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://agilonhealth.com/role/SupplementalCashFlowInformationTables", "longName": "9954478 - Disclosure - Supplemental Cash Flow Information (Tables)", "shortName": "Supplemental Cash Flow Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://agilonhealth.com/role/VariableInterestEntitiesTables", "longName": "9954479 - Disclosure - Variable Interest Entities (Tables)", "shortName": "Variable Interest Entities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:VariableInterestEntityDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:VariableInterestEntityDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://agilonhealth.com/role/DiscontinuedOperationsTables", "longName": "9954480 - Disclosure - Discontinued Operations (Tables)", "shortName": "Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://agilonhealth.com/role/BusinessDetails", "longName": "9954481 - Disclosure - Business (Details)", "shortName": "Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "agl:NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans", "unitRef": "member", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": [ "span", "div", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "agl:NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans", "unitRef": "member", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": [ "span", "div", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails", "longName": "9954483 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Details)", "shortName": "Revenue, Receivables, and Concentration of Credit Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-44", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-44", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails", "longName": "9954484 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Marketable Securities (Details)", "shortName": "Marketable Securities and Fair Value Measurements - Summary of Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R40": { "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails", "longName": "9954485 - Disclosure - Marketable Securities and Fair Value Measurements - Narrative (Details)", "shortName": "Marketable Securities and Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentIncomeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentIncomeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails", "longName": "9954486 - Disclosure - Marketable Securities and Fair Value Measurements - Summarizes Marketable Securities Maturity (Details)", "shortName": "Marketable Securities and Fair Value Measurements - Summarizes Marketable Securities Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails", "longName": "9954487 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Marketable Securities, Unrealized Loss Position (Details)", "shortName": "Marketable Securities and Fair Value Measurements - Summary of Marketable Securities, Unrealized Loss Position (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails", "longName": "9954488 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details)", "shortName": "Marketable Securities and Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-86", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R44": { "role": "http://agilonhealth.com/role/OtherAssetsDetails", "longName": "9954489 - Disclosure - Other Assets (Details)", "shortName": "Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "agl:LoansToPhysiciansPartners", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "agl:LoansToPhysiciansPartners", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails", "longName": "9954490 - Disclosure - Medical Claims and Related Payables - Summary Changes in Medical Claims and Related Payables (Details)", "shortName": "Medical Claims and Related Payables - Summary Changes in Medical Claims and Related Payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-4", "name": "agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesNarrativeDetails", "longName": "9954491 - Disclosure - Medical Claims and Related Payables - Narrative (Details)", "shortName": "Medical Claims and Related Payables - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "agl:LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "agl:LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails", "longName": "9954492 - Disclosure - Other Liabilities - Summary of Other Liabilities (Details)", "shortName": "Other Liabilities - Summary of Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LossContingencyAccrualCarryingValueNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseLiabilityNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R48": { "role": "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails", "longName": "9954493 - Disclosure - Other Liabilities - Narrative (Details)", "shortName": "Other Liabilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LossContingencyAccrualCarryingValueNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:LossContingencyAccrualCarryingValueNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:LossContingencyAccrualCarryingValueNoncurrent", "span", "div", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R49": { "role": "http://agilonhealth.com/role/DebtDetails", "longName": "9954494 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-113", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-98", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R50": { "role": "http://agilonhealth.com/role/CommitmentsandContingenciesDetails", "longName": "9954495 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-115", "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "unitRef": "lawsuit", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-115", "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "unitRef": "lawsuit", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://agilonhealth.com/role/CommonStockDetails", "longName": "9954496 - Disclosure - Common Stock (Details)", "shortName": "Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-20", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-20", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails", "longName": "9954497 - Disclosure - Net Income (Loss) Per Common Share - Computation of Basic and Diluted EPS (Details)", "shortName": "Net Income (Loss) Per Common Share - Computation of Basic and Diluted EPS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R53": { "role": "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails", "longName": "9954498 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details)", "shortName": "Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-116", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-116", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails", "longName": "9954499 - Disclosure - Goodwill and Amortizable Intangible Assets (Details)", "shortName": "Goodwill and Amortizable Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R55": { "role": "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofSupplementalCashFlowInformationDetails", "longName": "9954500 - Disclosure - Supplemental Cash Flow Information - Summary of Supplemental Cash Flow Information (Details)", "shortName": "Supplemental Cash Flow Information - Summary of Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails", "longName": "9954501 - Disclosure - Supplemental Cash Flow Information - Summary of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details)", "shortName": "Supplemental Cash Flow Information - Summary of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails", "longName": "9954502 - Disclosure - Variable Interest Entities - Summary of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details)", "shortName": "Variable Interest Entities - Summary of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "us-gaap:VariableInterestEntityDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R58": { "role": "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails", "longName": "9954503 - Disclosure - Variable Interest Entities - Narrative (Details)", "shortName": "Variable Interest Entities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "agl:NumberOfGeographicalLocation", "unitRef": "geography", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "agl:NumberOfGeographicalLocation", "unitRef": "geography", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails", "longName": "9954504 - Disclosure - Variable Interest Entities - Schedule of Equity Method Investments (Details)", "shortName": "Variable Interest Entities - Schedule of Equity Method Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "agl:EquityMethodLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R60": { "role": "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails", "longName": "9954505 - Disclosure - Variable Interest Entities - Summary of Operating Results (Details)", "shortName": "Variable Interest Entities - Summary of Operating Results (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-136", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R61": { "role": "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails", "longName": "9954506 - Disclosure - Variable Interest Entities - Summarized Balance Sheet (Details)", "shortName": "Variable Interest Entities - Summarized Balance Sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-138", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R62": { "role": "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails", "longName": "9954507 - Disclosure - Discontinued Operations - Summary of Results of Discontinued Operations (Details)", "shortName": "Discontinued Operations - Summary of Results of Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-144", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } }, "R63": { "role": "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofSignificantNonCashOperatingItemsforDiscontinuedOperationsDetails", "longName": "9954508 - Disclosure - Discontinued Operations - Summary of Significant Non-Cash Operating Items for Discontinued Operations (Details)", "shortName": "Discontinued Operations - Summary of Significant Non-Cash Operating Items for Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-144", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-145", "name": "agl:DisposalGroupIncludingDiscontinuedOperationSharedBasedPaymentArrangementExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240331.htm", "unique": true } } }, "tag": { "agl_ACOREACHMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "ACOREACHMember", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ACO REACH", "label": "ACO REACH [Member]", "documentation": "ACO REACH" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r28" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r650" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r65", "r200", "r548" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r37", "r38", "r129", "r207", "r544", "r575", "r576" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r14", "r38", "r467", "r470", "r491", "r571", "r572", "r791", "r792", "r793", "r799", "r800", "r801" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r150" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r732" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r124" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r443", "r444", "r445", "r585", "r799", "r800", "r801", "r839", "r863" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r738" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r738" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r738" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r738" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares withheld related to net share settlement", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r69", "r70", "r415" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r703", "r714", "r724", "r749" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r706", "r717", "r727", "r752" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r738" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r745" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r710", "r718", "r728", "r745", "r753", "r757", "r765" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r763" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r442", "r446" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11", "r59", "r63" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r260" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r48" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r48" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r168", "r204", "r238", "r264", "r274", "r278", "r318", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r460", "r464", "r477", "r541", "r609", "r681", "r694", "r830", "r831", "r842" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "verboseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "terseLabel": "Current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r196", "r208", "r238", "r318", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r460", "r464", "r477", "r681", "r830", "r831", "r842" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r238", "r318", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r460", "r464", "r477", "r830", "r831", "r842" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r287" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r288" ] }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r328", "r662" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r809" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r291", "r537" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r760" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r756" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r759" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r758" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r757" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r757" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate Loans", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r458", "r675", "r676" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r71", "r72", "r458", "r675", "r676" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r73", "r74" ] }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://agilonhealth.com/role/Business" ], "lang": { "en-us": { "role": { "terseLabel": "Business", "label": "Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r146", "r147" ] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r43", "r198", "r657" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities and Fair Value Measurements", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": [ "r807" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 1.0 }, "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash and equivalents from continuing operations, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash and equivalents from continuing operations, end of period", "totalLabel": "Cash, cash equivalents and restricted cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r43", "r143", "r234" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash and equivalents from discontinued operations, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash and equivalents from discontinued operations, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r43", "r143", "r234" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash and equivalents, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash and equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r43", "r143", "r234" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r143" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://agilonhealth.com/role/SupplementalCashFlowInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r141" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r736" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r737" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r737" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r34", "r97", "r542", "r596" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://agilonhealth.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r155", "r338", "r339", "r651", "r823" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://agilonhealth.com/role/CommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r684", "r685", "r686", "r688", "r689", "r690", "r691", "r799", "r800", "r839", "r860", "r863" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r123" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r123", "r597" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r123" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance, (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r123", "r597", "r615", "r863", "r864" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value: 2,000,000 shares authorized; 410,843 and 406,387 shares issued and outstanding, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r123", "r543", "r681" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r742" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r741" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r743" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r740" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income (loss) attributable to agilon health, inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r39", "r214", "r216", "r225", "r534", "r560" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedLabel": "Comprehensive (income) loss attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r8", "r79", "r87", "r214", "r216", "r224", "r533", "r559" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r87", "r162", "r214", "r216", "r223", "r532", "r558" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r50", "r52", "r90", "r91", "r282", "r650" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r50", "r52", "r90", "r91", "r282", "r577", "r650" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r50", "r52", "r90", "r91", "r282", "r650", "r772" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRisk" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Receivables, and Concentration of Credit Risk", "label": "Concentration Risk Disclosure [Text Block]", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r147" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r650" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r50", "r52", "r90", "r91", "r282" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r49", "r50", "r52", "r53", "r90", "r165", "r650" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r50", "r52", "r90", "r91", "r282", "r650" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities", "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": [ "r191", "r239", "r460", "r461", "r464", "r465", "r492", "r652", "r784", "r785", "r786", "r829", "r832", "r833" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities", "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": [ "r191", "r239", "r460", "r461", "r464", "r465", "r492", "r652", "r784", "r785", "r786", "r829", "r832", "r833" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r672", "r674", "r857" ] }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses", "negatedLabel": "Expenses", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization." } } }, "auth_ref": [ "r774", "r775" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r134" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare Advantage Payors", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r51", "r282" ] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r75" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://agilonhealth.com/role/Debt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r156", "r236", "r355", "r361", "r362", "r363", "r364", "r365", "r366", "r371", "r378", "r379", "r381" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r239", "r356", "r357", "r358", "r359", "r360", "r362", "r367", "r368", "r369", "r370", "r372", "r373", "r374", "r375", "r376", "r377", "r380", "r486", "r664", "r665", "r666", "r667", "r668", "r796" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r32", "r67", "r68", "r92", "r93", "r95", "r98", "r158", "r159", "r239", "r356", "r357", "r358", "r359", "r360", "r362", "r367", "r368", "r369", "r370", "r372", "r373", "r374", "r375", "r376", "r377", "r380", "r486", "r664", "r665", "r666", "r667", "r668", "r796" ] }, "us-gaap_DebtSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Securities [Abstract]", "label": "Debt Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowances for credit losses", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest", "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r326" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss", "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r817" ] }, "agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Three", "documentation": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Three" } } }, "auth_ref": [] }, "agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Two", "documentation": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Two" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "12 Months or Greater", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r183", "r329", "r662" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "12 Months or Greater", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r183", "r329" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less Than 12 Months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r183", "r329", "r662" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less Than 12 Months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r183", "r329" ] }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0, "order": 3.0 }, "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "totalLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest", "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r817" ] }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current", "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r817" ] }, "agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Three", "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Three" } } }, "auth_ref": [] }, "agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Two", "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Two" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r328", "r662" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Marketable Securities, Unrealized Loss Position", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r182", "r662", "r818" ] }, "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable debt securities [Line Items]", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r816" ] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesMember", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities", "label": "Debt Securities [Member]", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } }, "auth_ref": [ "r57", "r686", "r865" ] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average effective interest rate", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r11", "r64" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r11", "r64" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r11", "r268" ] }, "agl_DevelopedTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "DevelopedTechnologyMember", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed Technology", "label": "Developed Technology [Member]", "documentation": "Developed Technology [Member]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationAlternativeCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationAlternativeCashFlowInformationAbstract", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofSignificantNonCashOperatingItemsforDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating activities from discontinued operations:", "label": "Discontinued Operation, Alternative Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0, "order": 2.0 }, "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on sales of assets, net", "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax", "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": [ "r105", "r107", "r109" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, basic (in dollars per share)", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, diluted (in dollars per share)", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]", "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails", "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofSignificantNonCashOperatingItemsforDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Disposed of by Sale", "label": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results." } } }, "auth_ref": [ "r6" ] }, "agl_DiscontinuedOperationsIncomeLossBeforeImpairmentsGainLossOnSalesAndIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "DiscontinuedOperationsIncomeLossBeforeImpairmentsGainLossOnSalesAndIncomeTaxes", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) before gain (loss) on sales", "label": "Discontinued Operations Income (Loss) Before Impairments Gain (Loss) On Sales And Income Taxes", "documentation": "Discontinued operations income loss before impairments gain loss on Sales and income taxes." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails", "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofSignificantNonCashOperatingItemsforDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r194" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails", "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofSignificantNonCashOperatingItemsforDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails", "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofSignificantNonCashOperatingItemsforDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "terseLabel": "Depreciation and amortization", "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization", "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r116" ] }, "agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "Disposal Group, Including Discontinued Operation, General And Administrative Expense, Net Of Adjustments", "documentation": "Disposal Group, Including Discontinued Operation, General And Administrative Expense, Net Of Adjustments" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Disposal Group, Including Discontinued Operation, Interest Expense", "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r23", "r24", "r26", "r116" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r116" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from operations", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r116" ] }, "agl_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense)", "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense)" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Disposal Group, Including Discontinued Operation, Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r116", "r195" ] }, "agl_DisposalGroupIncludingDiscontinuedOperationSharedBasedPaymentArrangementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "DisposalGroupIncludingDiscontinuedOperationSharedBasedPaymentArrangementExpense", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofSignificantNonCashOperatingItemsforDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Disposal Group, Including Discontinued Operation, Shared Based Payment Arrangement, Expense", "documentation": "Disposal Group, Including Discontinued Operation, Shared Based Payment Arrangement, Expense" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r100", "r152" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r698" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r731" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per common share, basic and diluted", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) Per Common Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r252", "r260", "r261", "r262" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r696" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r696" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r696" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r770" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r696" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r696" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r696" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r696" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://agilonhealth.com/role/CommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r192", "r218", "r219", "r220", "r240", "r241", "r242", "r244", "r249", "r251", "r263", "r319", "r320", "r396", "r443", "r444", "r445", "r454", "r455", "r466", "r467", "r468", "r469", "r470", "r471", "r474", "r478", "r480", "r481", "r482", "r483", "r484", "r491", "r571", "r572", "r573", "r585", "r635" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r315", "r316", "r317" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r195", "r238", "r318", "r477" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r195", "r238", "r318", "r477" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees", "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]", "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r787", "r797", "r815", "r841" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/OtherAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/OtherAssetsDetails", "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r271", "r313", "r789", "r814" ] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r314" ] }, "agl_EquityMethodLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "EquityMethodLiabilities", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Equity method liabilities", "label": "Equity Method Liabilities", "documentation": "Equity Method Liabilities" } } }, "auth_ref": [] }, "agl_EquityMethodLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "EquityMethodLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method liabilities \u2013 CMS ACO Models", "label": "Equity Method Liabilities, Noncurrent", "documentation": "Equity Method Liabilities, Noncurrent" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r739" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r703", "r714", "r724", "r749" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r700", "r711", "r721", "r746" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r745" ] }, "agl_ExtendedTermOfLettersOfCredit": { "xbrltype": "durationItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "ExtendedTermOfLettersOfCredit", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extended term of letters of credit", "label": "Extended Term Of Letters Of Credit", "documentation": "Extended term of letters of credit." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value Assets Measured on Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r88", "r164" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r16" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r88", "r89" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r369", "r408", "r409", "r410", "r411", "r412", "r413", "r476", "r496", "r497", "r498", "r665", "r666", "r672", "r673", "r674" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r369", "r408", "r413", "r476", "r496", "r672", "r673", "r674" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r369", "r408", "r413", "r476", "r497", "r665", "r666", "r672", "r673", "r674" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r369", "r408", "r409", "r410", "r411", "r412", "r413", "r476", "r498", "r665", "r666", "r672", "r673", "r674" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r369", "r408", "r409", "r410", "r411", "r412", "r413", "r496", "r497", "r498", "r665", "r666", "r672", "r673", "r674" ] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Overnight Federal Funds Rate", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": [ "r838" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r321", "r322", "r323", "r324", "r325", "r327", "r330", "r331", "r380", "r394", "r472", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r557", "r662", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r810", "r811", "r812", "r813" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r202", "r336" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r333", "r335", "r336", "r337", "r528", "r529" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r60", "r62" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets acquired", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r334" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r707", "r718", "r728", "r753" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r707", "r718", "r728", "r753" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r707", "r718", "r728", "r753" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r707", "r718", "r728", "r753" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r707", "r718", "r728", "r753" ] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Gain) loss on sale of assets, net", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r794" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative (including noncash stock-based compensation expense of $16,909 and $13,585, respectively)", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r137", "r619" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r201", "r332", "r530", "r663", "r681", "r820", "r821" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Amortizable Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r149" ] }, "agl_HealthPlanDepositsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "HealthPlanDepositsNoncurrent", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/OtherAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://agilonhealth.com/role/OtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Health plan deposits", "label": "Health Plan Deposits, Noncurrent", "documentation": "Health Plan Deposits, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummarizesMarketableSecuritiesMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to common stockholders before discontinued operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r78", "r135", "r145", "r245", "r246", "r247", "r248", "r256", "r259" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r131", "r175", "r264", "r273", "r277", "r279", "r536", "r551", "r660" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from continuing operations", "terseLabel": "Income (loss) from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r162", "r238", "r243", "r264", "r273", "r277", "r279", "r318", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r475", "r477", "r551", "r660", "r830" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing operations, basic (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r130", "r173", "r176", "r226", "r243", "r245", "r246", "r247", "r248", "r255", "r257", "r258", "r475", "r535", "r854" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing operations, diluted (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r130", "r226", "r243", "r245", "r246", "r247", "r248", "r255", "r257", "r258", "r259", "r475", "r535", "r854" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) from discontinued operations attributable to common shares", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r105", "r106", "r107", "r108", "r109", "r118", "r195", "r457", "r552" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations:", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total discontinued operations", "terseLabel": "Income (loss) from discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r105", "r106", "r107", "r108", "r109", "r115", "r118", "r162" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from equity method investments", "negatedLabel": "Loss (income) from equity method investments", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r11", "r132", "r174", "r269", "r313", "r550" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails", "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofSignificantNonCashOperatingItemsforDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails", "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofSignificantNonCashOperatingItemsforDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r13", "r17", "r25", "r101", "r110", "r111", "r112", "r113", "r114", "r117", "r119", "r120", "r154" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax benefit (expense)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r184", "r189", "r250", "r251", "r270", "r449", "r456", "r561" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r217", "r447", "r448", "r450", "r451", "r452", "r453", "r579" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r44" ] }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapital", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital", "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r710", "r718", "r728", "r745", "r753", "r757", "r765" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r763" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r699", "r769" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r699", "r769" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r699", "r769" ] }, "us-gaap_InsuranceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InsuranceAbstract", "lang": { "en-us": { "role": { "terseLabel": "Insurance [Abstract]", "label": "Insurance [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross carrying amount of amortizable intangible assets", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r201" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r58", "r61" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r94", "r178", "r221", "r267", "r485", "r620", "r692", "r862" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r229", "r232", "r233" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNet", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment income", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r138", "r140" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total outstanding letters of credit", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "terseLabel": "Liabilities", "verboseLabel": "Current and total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r29", "r238", "r318", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r461", "r464", "r465", "r477", "r595", "r659", "r694", "r830", "r842", "r843" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r128", "r172", "r547", "r681", "r797", "r815", "r841" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r31", "r197", "r238", "r318", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r461", "r464", "r465", "r477", "r681", "r830", "r842", "r843" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical claims and related payables", "label": "Liability for Claims and Claims Adjustment Expense", "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date." } } }, "auth_ref": [ "r99", "r181" ] }, "agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related payables associated with retained liability", "label": "Liability For Claims And Claims Adjustment Expense, Amounts Recoverable", "documentation": "Liability For Claims And Claims Adjustment Expense, Amounts Recoverable under risk sharing arrangements" } } }, "auth_ref": [] }, "agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Medical claims and related payables, beginning of the year", "periodEndLabel": "Medical claims and related payables, end of the period", "label": "Liability For Claims And Claims Adjustment Expense, Including Amounts Recoverable", "documentation": "Liability For Claims And Claims Adjustment Expense, Including Amounts Recoverable" } } }, "auth_ref": [] }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability For Claims And Claims Adjustment Expense [Line Items]", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability For Claims And Claims Adjustment Expense [Table]", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "documentation": "Disclosure of information about the liability for claims and claims adjustment expense." } } }, "auth_ref": [] }, "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayables" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Claims and Related Payables", "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]", "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments." } } }, "auth_ref": [ "r568" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Claims paid related to:", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails": { "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Current year", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs." } } }, "auth_ref": [ "r19" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails": { "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Prior years", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs." } } }, "auth_ref": [ "r19" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Incurred cost related to claims", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process." } } }, "auth_ref": [ "r180" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of incurred costs related to:", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, accordion feature, increase limit", "label": "Line Of Credit Facility, Accordion Feature, Increase Limit", "documentation": "Line Of Credit Facility, Accordion Feature, Increase Limit" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility remaining borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r27" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r27" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "agl_LoansToPhysiciansPartners": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "LoansToPhysiciansPartners", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/OtherAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://agilonhealth.com/role/OtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans to physician partners", "label": "Loans To Physicians Partners", "documentation": "Loans To Physicians Partners" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/DebtDetails", "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r22", "r170", "r368", "r382", "r665", "r666", "r852" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r205" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of current portion", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r206" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://agilonhealth.com/role/DebtDetails", "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r32" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://agilonhealth.com/role/DebtDetails", "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r32", "r66" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r340", "r341", "r342", "r345", "r824", "r825" ] }, "us-gaap_LossContingencyAccrualCarryingValueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualCarryingValueNoncurrent", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails", "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term contingencies", "label": "Loss Contingency, Accrual, Noncurrent", "documentation": "Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r340" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r340", "r341", "r342", "r345", "r824", "r825" ] }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNewClaimsFiledNumber", "presentation": [ "http://agilonhealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, new claims filed", "label": "Loss Contingency, New Claims Filed, Number", "documentation": "The total number of new claims filed pertaining to a loss contingency during the period." } } }, "auth_ref": [ "r824", "r825" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r282", "r671", "r835", "r855", "r856" ] }, "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTable", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities [Table]", "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Marketable Securities", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r414", "r526", "r570", "r587", "r588", "r640", "r641", "r642", "r643", "r644", "r653", "r654", "r661", "r669", "r677", "r683", "r834", "r844", "r845", "r846", "r847", "r848", "r849" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r737" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r737" ] }, "agl_MedicalServicesRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "MedicalServicesRevenueMember", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical services revenue", "label": "Medical Services Revenue [Member]", "documentation": "Medical services revenue." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r414", "r526", "r570", "r587", "r588", "r640", "r641", "r642", "r643", "r644", "r653", "r654", "r661", "r669", "r677", "r683", "r834", "r844", "r845", "r846", "r847", "r848", "r849" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r36", "r171", "r238", "r318", "r346", "r348", "r349", "r350", "r353", "r354", "r477", "r546", "r599" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r756" ] }, "agl_MphrxMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "MphrxMember", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "mphrX", "label": "mphrX [Member]", "documentation": "mphrX [Member]" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r764" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r282", "r671", "r835", "r855", "r856" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r738" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r231" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r231" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r143", "r144", "r145" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to common shares", "terseLabel": "Net income (loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r133", "r145", "r177", "r195", "r212", "r215", "r220", "r238", "r243", "r245", "r246", "r247", "r248", "r250", "r251", "r256", "r264", "r273", "r277", "r279", "r318", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r475", "r477", "r555", "r617", "r633", "r634", "r660", "r692", "r830" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 1.0 }, "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Noncontrolling interests\u2019 share in (earnings) loss", "negatedLabel": "Noncontrolling interests\u2019 share in (earnings) loss from continuing operations", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r86", "r163", "r212", "r215", "r250", "r251", "r554", "r793" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share attributable to common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r737" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r707", "r718", "r728", "r745", "r753" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r735" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r734" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r745" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r764" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r76", "r396", "r799", "r800", "r801", "r863" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r139" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "agl_NumberOfDirectContractingEntities": { "xbrltype": "integerItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "NumberOfDirectContractingEntities", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of direct contracting entities", "label": "Number Of Direct Contracting Entities", "documentation": "Number of Direct Contracting Entities." } } }, "auth_ref": [] }, "agl_NumberOfEquityMethodInvestments": { "xbrltype": "integerItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "NumberOfEquityMethodInvestments", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of equity method investments for VIEs", "label": "Number Of Equity Method Investments", "documentation": "Number of equity method investments." } } }, "auth_ref": [] }, "agl_NumberOfGeographicalLocation": { "xbrltype": "integerItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "NumberOfGeographicalLocation", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of geographies", "label": "Number of Geographical Location", "documentation": "Number of geographical location." } } }, "auth_ref": [] }, "agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans": { "xbrltype": "integerItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans", "presentation": [ "http://agilonhealth.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of medicare advantage members enrolled with private health plans", "label": "Number Of Medicare Advantage Members Enrolled With Private Health Plans", "documentation": "Number of Medicare Advantage members enrolled with private health plans." } } }, "auth_ref": [] }, "agl_NumberOfPhysicianGroupPartners": { "xbrltype": "integerItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "NumberOfPhysicianGroupPartners", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of physician group partners", "label": "Number Of Physician Group Partners", "documentation": "Number of physician group partners." } } }, "auth_ref": [] }, "agl_NumberOfWhollyOwnedRiskBearingEntities": { "xbrltype": "integerItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "NumberOfWhollyOwnedRiskBearingEntities", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of wholly-owned risk-bearing entities", "label": "Number Of Wholly Owned Risk Bearing Entities", "documentation": "Number of wholly-owned risk-bearing entities." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from operations", "terseLabel": "Income (loss) from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r264", "r273", "r277", "r279", "r660" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities, long-term", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r488" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r489" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/OtherAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/OtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use lease assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r487" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets, net", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r167", "r203", "r540", "r694" ] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Assets [Abstract]", "label": "Other Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://agilonhealth.com/role/OtherAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousNoncurrent", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/OtherAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/OtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Assets, Miscellaneous, Noncurrent", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://agilonhealth.com/role/OtherAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/OtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "totalLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r203" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gain (loss) on marketable securities, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r209", "r210", "r211" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r15", "r21", "r213", "r216", "r222", "r478", "r479", "r484", "r531", "r556", "r791", "r792" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDebtSecuritiesMember", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Debt Obligations [Member]", "documentation": "Investments in debt securities classified as other." } } }, "auth_ref": [ "r819", "r837", "r840" ] }, "agl_OtherEquityMethodInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "OtherEquityMethodInvestmentsMember", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Equity Methods", "label": "Other Equity Method Investments [Member]", "documentation": "Other Equity Method Investments" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r96", "r539", "r591", "r592", "r694", "r861" ] }, "us-gaap_OtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities [Abstract]", "label": "Other Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://agilonhealth.com/role/OtherLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities", "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r30" ] }, "agl_OtherLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "OtherLiabilitiesLineItems", "presentation": [ "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities [Line Items]", "label": "Other Liabilities [Line Items]", "documentation": "Other liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 }, "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "totalLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r33" ] }, "agl_OtherLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "OtherLiabilitiesTable", "presentation": [ "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities [Table]", "label": "Other Liabilities [Table]", "documentation": "Other liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesTableTextBlock", "presentation": [ "http://agilonhealth.com/role/OtherLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Liabilities", "label": "Other Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other noncash items", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r145" ] }, "agl_OtherOperatingRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "OtherOperatingRevenueMember", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other operating revenue", "label": "Other Operating Revenue [Member]", "documentation": "Other operating revenue." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r737" ] }, "us-gaap_OtherSundryLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSundryLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://agilonhealth.com/role/OtherLiabilitiesSummaryofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Liabilities, Noncurrent", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date." } } }, "auth_ref": [ "r121", "r169" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r705", "r716", "r726", "r751" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r733" ] }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForLossesAndLossAdjustmentExpense", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Claims paid related", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process." } } }, "auth_ref": [ "r9", "r19" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net cash paid in business combination", "terseLabel": "Net cash paid in business combination", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r41" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r142" ] }, "us-gaap_PaymentsToAcquireLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireLoansReceivable", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Funding of loans receivable and other", "label": "Payments to Acquire Loans Receivable", "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services." } } }, "auth_ref": [ "r40" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Investments in marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r808" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r142" ] }, "agl_PayorAMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "PayorAMember", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payor A", "label": "Payor A [Member]", "documentation": "Payor A." } } }, "auth_ref": [] }, "agl_PayorBMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "PayorBMember", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payor B", "label": "Payor B [Member]", "documentation": "Payor B." } } }, "auth_ref": [] }, "agl_PayorCMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "PayorCMember", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payor C", "label": "Payor C [Member]", "documentation": "Payor C." } } }, "auth_ref": [] }, "agl_PayorDMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "PayorDMember", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payor D", "label": "Payor D [Member]", "documentation": "Payor D." } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r736" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r736" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r735" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r745" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r738" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r734" ] }, "agl_PhysicianCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "PhysicianCompensationExpense", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Physician compensation expense", "label": "Physician Compensation Expense", "documentation": "Physician compensation expense." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets, net", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r790" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from equity issuances, net", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of marketable securities and other", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r227", "r228", "r808" ] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Operating", "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r836" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r280", "r527", "r562", "r563", "r564", "r565", "r566", "r567", "r656", "r670", "r682", "r773", "r826", "r827", "r835", "r855" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/DiscontinuedOperationsSummaryofResultsofDiscontinuedOperationsDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r280", "r527", "r562", "r563", "r564", "r565", "r566", "r567", "r656", "r670", "r682", "r773", "r826", "r827", "r835", "r855" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r195", "r212", "r215", "r230", "r238", "r243", "r250", "r251", "r264", "r273", "r277", "r279", "r318", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r459", "r462", "r463", "r475", "r477", "r536", "r553", "r584", "r617", "r633", "r634", "r660", "r678", "r679", "r693", "r793", "r830" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross carrying amount of property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r153", "r199", "r549" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r538", "r549", "r681" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r733" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r733" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r407", "r414", "r438", "r439", "r440", "r499", "r526", "r570", "r587", "r588", "r640", "r641", "r642", "r643", "r644", "r653", "r654", "r661", "r669", "r677", "r683", "r686", "r822", "r834", "r845", "r846", "r847", "r848", "r849" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r407", "r414", "r438", "r439", "r440", "r499", "r526", "r570", "r587", "r588", "r640", "r641", "r642", "r643", "r644", "r653", "r654", "r661", "r669", "r677", "r683", "r686", "r822", "r834", "r845", "r846", "r847", "r848", "r849" ] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables, net", "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r681" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables", "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r803", "r804", "r805", "r806" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r700", "r711", "r721", "r746" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r42", "r581" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r701", "r712", "r722", "r747" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r702", "r713", "r723", "r748" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "us-gaap_RestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash equivalents", "label": "Restricted Cash Equivalents", "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r648", "r649", "r795", "r850", "r853" ] }, "us-gaap_RestrictedCashEquivalentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashEquivalentsCurrent", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash and equivalents", "label": "Restricted Cash Equivalents, Current", "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r648", "r649", "r788", "r795" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r125", "r160", "r545", "r574", "r576", "r582", "r598", "r681" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r192", "r240", "r241", "r242", "r244", "r249", "r251", "r319", "r320", "r443", "r444", "r445", "r454", "r455", "r466", "r468", "r469", "r471", "r474", "r571", "r573", "r585", "r863" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "verboseLabel": "Medical services revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r265", "r266", "r272", "r275", "r276", "r280", "r281", "r282", "r405", "r406", "r527" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r282", "r771" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Services Revenue", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r190", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r655" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset obtained in exchange for new operating lease liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r490", "r680" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties [Abstract]", "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r764" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://agilonhealth.com/role/SupplementalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents from Continuing Operations", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://agilonhealth.com/role/SupplementalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Supplemental Cash Flow Information", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summarized Balance Sheet", "label": "Condensed Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r783", "r798" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://agilonhealth.com/role/DiscontinuedOperationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Statements Related to Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r13", "r17", "r25", "r101", "r110", "r111", "r112", "r113", "r114", "r117", "r119", "r120", "r154" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summery of Net Income (Loss) Per Share Attributable to Common Stockholder", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r802" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r315", "r316", "r317" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r18", "r151" ] }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Changes in Medical Claims and Related Payables", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims." } } }, "auth_ref": [ "r179" ] }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": [ "http://agilonhealth.com/role/OtherAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Assets", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Operating Results", "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]", "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement." } } }, "auth_ref": [ "r136" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://agilonhealth.com/role/SupplementalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Cash Equivalents from Continuing Operations", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r20", "r166", "r853" ] }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails", "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Variable Interest Entities [Table]", "label": "Schedule of Variable Interest Entities [Table]", "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r80", "r81", "r82", "r83", "r84", "r460", "r461", "r464", "r465", "r507", "r508", "r509" ] }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Consolidated Asset and Liabilities Include VIE Assets and Liabilities", "label": "Schedule of Variable Interest Entities [Table Text Block]", "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r80", "r81", "r82", "r83", "r84" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedules of Concentration of Risk as a Percentage of Revenues and Receivables", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r49", "r50", "r52", "r53", "r90", "r165" ] }, "agl_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "agl_SecuredRevolvingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "SecuredRevolvingFacilityMember", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Revolving Facility", "label": "Secured Revolving Facility [Member]", "documentation": "Secured Revolving Facility [Member]" } } }, "auth_ref": [] }, "agl_SecuredTermLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "SecuredTermLoanFacilityMember", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Term Loan Facility", "label": "Secured Term Loan Facility [Member]", "documentation": "Secured Term Loan Facility [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r695" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r697" ] }, "us-gaap_SegmentContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentContinuingOperationsMember", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing Operations", "label": "Continuing Operations [Member]", "documentation": "Component of an entity expected to operate in the foreseeable future." } } }, "auth_ref": [] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDiscontinuedOperationsMember", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Discontinued Operations [Member]", "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale." } } }, "auth_ref": [ "r7", "r102", "r103", "r104" ] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentOperatingActivitiesDomain", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities [Domain]", "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares withheld related to net share settlement (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://agilonhealth.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r146", "r235" ] }, "us-gaap_StandbyLettersOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandbyLettersOfCreditMember", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standby Letters of Credit", "label": "Standby Letters of Credit [Member]", "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation." } } }, "auth_ref": [ "r0", "r828", "r858", "r859" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://agilonhealth.com/role/CommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r35", "r192", "r218", "r219", "r220", "r240", "r241", "r242", "r244", "r249", "r251", "r263", "r319", "r320", "r396", "r443", "r444", "r445", "r454", "r455", "r466", "r467", "r468", "r469", "r470", "r471", "r474", "r478", "r480", "r481", "r482", "r483", "r484", "r491", "r571", "r572", "r573", "r585", "r635" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r240", "r241", "r242", "r263", "r527", "r578", "r586", "r589", "r590", "r591", "r592", "r593", "r594", "r597", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r614", "r616", "r618", "r619", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r635", "r687" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOperatingActivitiesSegmentAxis", "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities [Axis]", "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r240", "r241", "r242", "r263", "r527", "r578", "r586", "r589", "r590", "r591", "r592", "r593", "r594", "r597", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r614", "r616", "r618", "r619", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r635", "r687" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r704", "r715", "r725", "r750" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement of liabilities through issuance of stock", "label": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r45", "r46", "r47" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://agilonhealth.com/role/CommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued to settle liabilities (in shares)", "label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r15", "r122", "r123", "r160", "r580", "r635", "r645" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r15", "r122", "r123", "r160" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://agilonhealth.com/role/CommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued under share-based awards (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r15", "r122", "r123", "r160" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r15", "r122", "r123", "r160", "r424" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r15", "r122", "r123", "r160", "r585", "r635", "r645", "r693" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r15", "r160" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r15", "r35", "r160" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total agilon health, inc. stockholders' equity (deficit)", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r123", "r126", "r127", "r148", "r599", "r615", "r636", "r637", "r681", "r694", "r797", "r815", "r841", "r863" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity (deficit)", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r76", "r77", "r85", "r192", "r193", "r219", "r240", "r241", "r242", "r244", "r249", "r319", "r320", "r396", "r443", "r444", "r445", "r454", "r455", "r466", "r467", "r468", "r469", "r470", "r471", "r474", "r478", "r480", "r484", "r491", "r572", "r573", "r583", "r599", "r615", "r636", "r637", "r646", "r693", "r797", "r815", "r841", "r863" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity (deficit):", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://agilonhealth.com/role/CommonStock" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r157", "r237", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r395", "r396", "r473", "r638", "r639", "r647" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://agilonhealth.com/role/CommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://agilonhealth.com/role/CommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary Sale Of Stock [Line Items]", "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Elements [Abstract]", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://agilonhealth.com/role/SupplementalCashFlowInformationSummaryofSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current year", "label": "Current Year Claims and Claims Adjustment Expense", "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs." } } }, "auth_ref": [ "r569" ] }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesSummaryChangesinMedicalClaimsandRelatedPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior years", "label": "Prior Year Claims and Claims Adjustment Expense", "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs." } } }, "auth_ref": [ "r569" ] }, "us-gaap_SuretyBondMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SuretyBondMember", "presentation": [ "http://agilonhealth.com/role/DebtDetails", "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surety Bond", "label": "Surety Bond [Member]", "documentation": "An obligation arising from a three-party agreement that legally binds together a principal who needs the bond, an obligee who requires the bond and a surety company that sells the bond." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r744" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r736" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r743" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r763" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r765" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r380", "r394", "r472", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r557", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r810", "r811", "r812", "r813" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r766" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r767" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r765" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r765" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r768" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r766" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFairValueAssetsMeasuredonRecurringBasisDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesDetails", "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofMarketableSecuritiesUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury notes", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r658", "r672", "r674", "r851" ] }, "us-gaap_UnassertedClaimMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnassertedClaimMember", "presentation": [ "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unasserted Claim", "label": "Unasserted Claim [Member]", "documentation": "A claim for damages that is likely to be made and for which it is reasonably possible that there will be an unfavorable outcome, such as a likelihood that lawsuits from parties as yet unidentified will be filed alleging injury from using a product when other parties have successfully sued the entity for such use." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r762" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r54", "r55", "r56", "r185", "r186", "r187", "r188" ] }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityDisclosureTextBlock", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntities" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Variable Interest Entity Disclosure [Text Block]", "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss." } } }, "auth_ref": [ "r161" ] }, "us-gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityLineItems", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails", "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummarizedBalanceSheetDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofOperatingResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity [Line Items]", "label": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r460", "r461", "r464", "r465", "r507", "r508", "r509" ] }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "presentation": [ "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity, Not Primary Beneficiary", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity." } } }, "auth_ref": [] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails", "http://agilonhealth.com/role/VariableInterestEntitiesSummaryofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity, Primary Beneficiary", "verboseLabel": "Variable Interest Entity", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r80", "r460", "r461", "r464", "r465" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://agilonhealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "agl_VeeralDesaiMember": { "xbrltype": "domainItemType", "nsuri": "http://agilonhealth.com/20240331", "localname": "VeeralDesaiMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Veeral Desai [Member]", "documentation": "Veeral Desai" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in shares)", "terseLabel": "Weighted average shares outstanding \u2013 diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r254", "r259" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted average shares outstanding \u2013 basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r253", "r259" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://agilonhealth.com/role/NetIncomeLossPerCommonShareComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average shares outstanding", "terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "12", "Subparagraph": "(f)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481410/810-10-15-12" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-6" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-7" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//230/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(cc)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "4", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//944-40/tableOfContent" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "(a)", "Publisher": "SEC" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-15" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-16" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" } } } ZIP 83 0001628280-24-021088-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-021088-xbrl.zip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end XML 85 agl-20240331_htm.xml IDEA: XBRL DOCUMENT 0001831097 2024-01-01 2024-03-31 0001831097 2024-05-01 0001831097 2024-03-31 0001831097 2023-12-31 0001831097 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-03-31 0001831097 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-12-31 0001831097 agl:MedicalServicesRevenueMember 2024-01-01 2024-03-31 0001831097 agl:MedicalServicesRevenueMember 2023-01-01 2023-03-31 0001831097 agl:OtherOperatingRevenueMember 2024-01-01 2024-03-31 0001831097 agl:OtherOperatingRevenueMember 2023-01-01 2023-03-31 0001831097 2023-01-01 2023-03-31 0001831097 us-gaap:CommonStockMember 2023-12-31 0001831097 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001831097 us-gaap:RetainedEarningsMember 2023-12-31 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001831097 us-gaap:NoncontrollingInterestMember 2023-12-31 0001831097 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001831097 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001831097 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001831097 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001831097 us-gaap:CommonStockMember 2024-03-31 0001831097 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001831097 us-gaap:RetainedEarningsMember 2024-03-31 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001831097 us-gaap:NoncontrollingInterestMember 2024-03-31 0001831097 us-gaap:CommonStockMember 2022-12-31 0001831097 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001831097 us-gaap:RetainedEarningsMember 2022-12-31 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001831097 us-gaap:NoncontrollingInterestMember 2022-12-31 0001831097 2022-12-31 0001831097 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001831097 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001831097 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001831097 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001831097 us-gaap:CommonStockMember 2023-03-31 0001831097 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001831097 us-gaap:RetainedEarningsMember 2023-03-31 0001831097 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001831097 us-gaap:NoncontrollingInterestMember 2023-03-31 0001831097 2023-03-31 0001831097 agl:PayorAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001831097 agl:PayorAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001831097 agl:PayorBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001831097 agl:PayorBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001831097 agl:PayorCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001831097 agl:PayorCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001831097 agl:PayorDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001831097 agl:PayorAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001831097 agl:PayorAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001831097 agl:PayorBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001831097 agl:PayorBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001831097 agl:PayorCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001831097 agl:PayorDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001831097 agl:PayorDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001831097 us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001831097 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001831097 us-gaap:USTreasurySecuritiesMember 2024-03-31 0001831097 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001831097 us-gaap:OtherDebtSecuritiesMember 2024-03-31 0001831097 us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001831097 us-gaap:DebtSecuritiesMember 2024-01-01 2024-03-31 0001831097 us-gaap:CashAndCashEquivalentsMember 2024-01-01 2024-03-31 0001831097 us-gaap:DebtSecuritiesMember 2023-01-01 2023-03-31 0001831097 us-gaap:CashAndCashEquivalentsMember 2023-01-01 2023-03-31 0001831097 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001831097 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001831097 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001831097 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001831097 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001831097 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001831097 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2024-03-31 0001831097 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2024-03-31 0001831097 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2024-03-31 0001831097 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001831097 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001831097 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001831097 us-gaap:FairValueInputsLevel1Member us-gaap:OtherDebtSecuritiesMember 2024-03-31 0001831097 us-gaap:FairValueInputsLevel2Member us-gaap:OtherDebtSecuritiesMember 2024-03-31 0001831097 us-gaap:FairValueInputsLevel3Member us-gaap:OtherDebtSecuritiesMember 2024-03-31 0001831097 us-gaap:FairValueInputsLevel1Member us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001831097 us-gaap:FairValueInputsLevel2Member us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001831097 us-gaap:FairValueInputsLevel3Member us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001831097 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001831097 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001831097 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001831097 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001831097 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001831097 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001831097 us-gaap:SegmentContinuingOperationsMember 2024-01-01 2024-03-31 0001831097 us-gaap:SegmentContinuingOperationsMember 2023-01-01 2023-03-31 0001831097 us-gaap:SegmentDiscontinuedOperationsMember 2024-01-01 2024-03-31 0001831097 us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-03-31 0001831097 us-gaap:UnassertedClaimMember 2023-12-31 0001831097 us-gaap:UnassertedClaimMember 2024-03-31 0001831097 agl:SecuredTermLoanFacilityMember 2021-02-18 0001831097 agl:SecuredRevolvingFacilityMember 2021-02-18 0001831097 us-gaap:StandbyLettersOfCreditMember 2021-02-18 0001831097 agl:SecuredTermLoanFacilityMember 2021-02-18 2021-02-18 0001831097 agl:SecuredTermLoanFacilityMember 2024-03-31 0001831097 agl:SecuredRevolvingFacilityMember 2024-03-31 0001831097 us-gaap:StandbyLettersOfCreditMember 2024-03-31 0001831097 us-gaap:StandbyLettersOfCreditMember 2024-01-01 2024-03-31 0001831097 srt:MaximumMember agl:SecuredTermLoanFacilityMember agl:SecuredOvernightFinancingRateSOFRMember 2023-05-25 2023-05-25 0001831097 srt:MinimumMember agl:SecuredTermLoanFacilityMember agl:SecuredOvernightFinancingRateSOFRMember 2023-05-25 2023-05-25 0001831097 srt:MaximumMember agl:SecuredTermLoanFacilityMember us-gaap:BaseRateMember 2023-05-25 2023-05-25 0001831097 agl:SecuredTermLoanFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2023-05-25 2023-05-25 0001831097 agl:SecuredTermLoanFacilityMember agl:SecuredOvernightFinancingRateSOFRMember 2023-05-25 2023-05-25 0001831097 srt:MinimumMember agl:SecuredTermLoanFacilityMember us-gaap:BaseRateMember 2023-05-25 2023-05-25 0001831097 srt:MinimumMember agl:SecuredRevolvingFacilityMember 2023-05-25 2023-05-25 0001831097 us-gaap:SuretyBondMember 2024-03-31 0001831097 us-gaap:SuretyBondMember 2023-12-31 0001831097 2024-02-01 2024-03-31 0001831097 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001831097 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001831097 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001831097 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001831097 agl:MphrxMember 2023-02-28 2023-02-28 0001831097 agl:MphrxMember agl:DevelopedTechnologyMember 2023-02-28 2023-02-28 0001831097 agl:MphrxMember us-gaap:CustomerRelationshipsMember 2023-02-28 0001831097 2023-02-28 2023-02-28 0001831097 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2024-03-31 0001831097 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:SuretyBondMember 2024-03-31 0001831097 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:SuretyBondMember 2023-12-31 0001831097 agl:OtherEquityMethodInvestmentsMember 2024-03-31 0001831097 agl:OtherEquityMethodInvestmentsMember 2023-12-31 0001831097 agl:ACOREACHMember 2024-03-31 0001831097 agl:ACOREACHMember 2023-12-31 0001831097 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-01-01 2024-03-31 0001831097 agl:MedicalServicesRevenueMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-01-01 2024-03-31 0001831097 agl:MedicalServicesRevenueMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2023-01-01 2023-03-31 0001831097 agl:OtherOperatingRevenueMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-01-01 2024-03-31 0001831097 agl:OtherOperatingRevenueMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2023-01-01 2023-03-31 0001831097 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-01-01 2024-03-31 0001831097 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2023-01-01 2023-03-31 0001831097 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-03-31 0001831097 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2023-12-31 0001831097 agl:MedicalServicesRevenueMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2024-01-01 2024-03-31 0001831097 agl:MedicalServicesRevenueMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-01-01 2023-03-31 0001831097 us-gaap:ProductAndServiceOtherMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2024-01-01 2024-03-31 0001831097 us-gaap:ProductAndServiceOtherMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-01-01 2023-03-31 0001831097 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2024-01-01 2024-03-31 0001831097 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-01-01 2023-03-31 0001831097 agl:VeeralDesaiMember 2024-01-01 2024-03-31 0001831097 agl:VeeralDesaiMember 2024-03-31 shares iso4217:USD iso4217:USD shares agl:member pure agl:lawsuit agl:entity agl:investment agl:partner agl:geography 0001831097 --12-31 2024 Q1 false http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent P76D 10-Q true 2024-03-31 false 001-40332 agilon health, inc. DE 37-1915147 6210 E Hwy 290 Suite 450 Austin TX 78723 (562) 256-3800 Common stock, $0.01 par value AGL NYSE Yes Yes Large Accelerated Filer false false false 411261609 111706000 107570000 6844000 6759000 307359000 380773000 1571143000 942461000 39757000 42513000 2036809000 1480076000 27539000 27576000 72076000 63769000 24133000 24133000 155906000 145312000 2316463000 1740866000 1266651000 737724000 252497000 233182000 7500000 6250000 1526648000 977156000 29834000 32308000 71495000 70381000 1627977000 1079845000 0.01 0.01 2000000000 2000000000 410843000 410843000 406387000 406387000 4108000 4064000 2020803000 1986899000 -1332890000 -1326826000 -2747000 -2298000 689274000 661839000 -788000 -818000 688486000 661021000 2316463000 1740866000 1710000000 1070000000.00 1490000000 930600000 1601195000 1053119000 3159000 1193000 1604354000 1054312000 1443842000 897572000 85424000 83617000 16909000 13585000 76422000 69752000 5844000 2954000 1611532000 1053895000 -7178000 417000 5684000 1376000 5892000 7892000 1284000 1493000 3114000 8192000 -133000 -1759000 3247000 9951000 -518000 6008000 -8763000 0 -9281000 6008000 -6034000 15959000 30000 -63000 -6064000 16022000 0.01 0.01 0.02 0.02 -0.02 -0.02 0.02 0.02 408938000 413136000 413437000 426586000 -6034000 15959000 -457000 1896000 8000 115000 -6483000 17970000 30000 -63000 -6513000 18033000 406387000 4064000 1986899000 -1326826000 -2298000 -818000 661021000 -6064000 30000 -6034000 -449000 -449000 1434000 14000 2441000 2455000 1170000 11000 -11000 0 122000 1000 645000 646000 1974000 20000 15210000 15230000 16909000 16909000 410843000 4108000 2020803000 -1332890000 -2747000 -788000 688486000 412385000 4124000 2106886000 -1064230000 -5560000 -611000 1040609000 16022000 -63000 15959000 2011000 2011000 2002000 20000 9597000 9617000 79000 1000 -1000 0 1000 28000 28000 13672000 13672000 414465000 4145000 2130126000 -1048208000 -3549000 -674000 1081840000 -6034000 15959000 5844000 4189000 16909000 13672000 5684000 1376000 -4996000 0 472000 1785000 63335000 91470000 -47776000 -60811000 3139000 3717000 11438000 0 8508000 1301000 0 29969000 74523000 28540000 0 44367000 51438000 -50814000 1809000 9589000 1250000 1250000 559000 8339000 4221000 -103286000 114329000 475912000 0 31768000 114329000 507680000 118550000 397023000 0 7371000 118550000 404394000 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. Business</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc., through its partnerships and platform, provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. As of March 31, 2024, the Company, through its contracted physician networks, provided care to approximately 522,800 Medicare Advantage members enrolled with private health plans. Beginning January 1, 2024, the Company expanded its operations into: (i) Lexington, Kentucky and (ii) Augusta, Georgia, along with additional partnerships in the Company’s existing Texas, Pennsylvania, and Michigan markets. Additionally, beginning January 1, 2024, the Company began participating in the Centers for Medicare &amp; Medicaid Services' (“CMS”) Shared Savings Program (“MSSP”), along with its existing participation in the Accountable Care Organization Realizing Equity, Access, and Community Health (“ACO REACH”) Model, (collectively, “CMS ACO Models”). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 14 for additional discussions related to the Company’s involvement with VIEs. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s largest shareholder is an investment fund associated with Clayton Dubilier &amp; Rice, LLC (“CD&amp;R”), a private equity firm. All funds affiliated with CD&amp;R are considered related parties.</span></div> 522800 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:24pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. Summary of Significant Accounting Policies</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and both joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The accompanying condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.</span></div><div style="margin-bottom:12pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (“IBNR”) claims), and valuation of long-lived assets, goodwill and intangible assets (acquired in business combinations and analysis of impairment). Management’s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the Company’s gross carrying amount of property and equipment was $44.3 million and $41.9 million, with accumulated depreciation of $16.8 million and $14.3 million, respectively. For the three months ended March 31, 2024 and 2023, the Company recognized $2.8 million and $1.7 million, respectively, in </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the income tax provision for interim periods using an estimate of the Company’s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November of 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting—Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2023-07”), which amends certain reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. Additionally, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The amendments in ASU 2023-07 are required to be applied retrospectively to all prior periods presented in the financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-07 on the disclosures in its condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December of 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes—Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-09”), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on the disclosures in its condensed consolidated financial statements.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div>The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and both joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included. <div style="margin-bottom:12pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (“IBNR”) claims), and valuation of long-lived assets, goodwill and intangible assets (acquired in business combinations and analysis of impairment). Management’s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.</span></div> 44300000 41900000 16800000 14300000 2800000 1700000 <div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the income tax provision for interim periods using an estimate of the Company’s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.</span></div> <div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November of 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting—Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2023-07”), which amends certain reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. Additionally, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The amendments in ASU 2023-07 are required to be applied retrospectively to all prior periods presented in the financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-07 on the disclosures in its condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December of 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes—Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-09”), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on the disclosures in its condensed consolidated financial statements.</span></div> <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:24pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. Revenue, Receivables, and Concentration of Credit Risk</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Services Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (“payors”). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (“PMPM”) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (“members”) attributed to the Company’s contracted primary care physicians. PMPM fees are determined as a percent of the premium payors receive from the Centers for Medicare &amp; Medicaid Services’ (“CMS”) for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (“ASC”) 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price for the Company’s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS’s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member’s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company’s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management’s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company contracts with various payors whereby the Company is entitled to monthly PMPM fees to provide a defined range of healthcare services for members attributed to its contracted primary care physicians. The Company generally accepts full financial risk for such members and therefore is responsible for the cost of all healthcare services required by them. Substantially all of the Company’s receivable balances are from a small number of payors. Revenue from Medicare Advantage payors constitutes substantially all of the Company’s total revenue for the three months ended March 31, 2024 and 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the Company’s revenue concentration with respect to major payors as a percentage of the Company’s total revenues: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the Company’s concentration of credit risk with respect to major payors as a percentage of receivables, net:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> * </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total receivables.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Services Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (“payors”). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (“PMPM”) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (“members”) attributed to the Company’s contracted primary care physicians. PMPM fees are determined as a percent of the premium payors receive from the Centers for Medicare &amp; Medicaid Services’ (“CMS”) for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (“ASC”) 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price for the Company’s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS’s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member’s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company’s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.</span></div> <div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span></div>Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management’s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized. <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the Company’s revenue concentration with respect to major payors as a percentage of the Company’s total revenues: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the Company’s concentration of credit risk with respect to major payors as a percentage of receivables, net:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> * </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total receivables.</span></div> 0.22 0.20 0.15 0.17 0.14 0.13 0.10 0.14 0.13 0.14 0.11 0.12 0.13 0.21 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. Marketable Securities and Fair Value Measurements</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,547)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310,192 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,949)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,359 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">383,150 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">441 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,818)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">380,773 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the Company recognized total interest income of $5.4 million, of which $4.0 million was related to its marketable securities investments and $1.4 million was related to interest on cash and cash equivalent balances. For the three months ended March 31, 2023, the Company recognized total interest income of $8.3 million, of which $4.9 million was related to its marketable securities investments and $3.4 million was related to interest on cash and cash equivalent balances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities maturity as of March 31, 2024 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310,192 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,359 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of March 31, 2024 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">827 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165,007 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,122 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December 31, 2023 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,821 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">478 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202,169 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,340 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unrealized losses from marketable securities as of March 31, 2024 and December 31, 2023 were caused primarily by interest rate increases. The Company does not intend to sell marketable securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. There was no allowance for credit losses on available-for-sale marketable securities at March 31, 2024 and December 31, 2023.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist of cash and cash equivalents, restricted cash and cash equivalents, marketable securities, receivables, other liabilities, accounts payable, certain accrued expenses, and borrowings which consist of a term loan and a revolving credit facility. The carrying values of the financial instruments classified as current in the consolidated balance sheets approximate their fair values due to their short-term maturities. The Company's cash and cash equivalents are classified within Level 1 of the fair value hierarchy. The Company may be required, from time to time, to measure its loans to physician partner groups, primarily in connection with taxes payable on shares distributed to them upon completion of the Company's initial public offering ("IPO"), at fair value on a nonrecurring basis. Such measurements are classified within Level 2 of the fair value hierarchy. The carrying values of the term loan and revolving credit facility are a reasonable estimate of fair value because the interest rates on such borrowings approximate market rates as of the reporting date. Such borrowings are classified within Level 2 of the fair value hierarchy. During the three months ended March 31, 2024 and 2023, there were no material transfers of financial assets or liabilities within the fair value hierarchy. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1—quoted prices for identical instruments in active markets; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2—quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3—fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company’s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,736 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,623 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147,376 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233,397 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,547)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310,192 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,949)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,359 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">383,150 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">441 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,818)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">380,773 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities maturity as of March 31, 2024 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310,192 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,359 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 184107000 63000 1547000 182623000 234821000 180000 1604000 233397000 126085000 53000 1402000 124736000 138329000 261000 1206000 137384000 0 0 0 0 10000000 0 8000 9992000 310192000 116000 2949000 307359000 383150000 441000 2818000 380773000 5400000 4000000 1400000 8300000 4900000 3400000 92005000 91495000 176926000 174802000 41261000 41062000 310192000 307359000 <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of March 31, 2024 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">827 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165,007 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,122 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December 31, 2023 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,821 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">478 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202,169 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,340 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 50514000 212000 101513000 1335000 49359000 615000 63494000 787000 99873000 827000 165007000 2122000 55343000 167000 126189000 1437000 37486000 303000 75980000 903000 9992000 8000 0 0 102821000 478000 202169000 2340000 0 0 <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company’s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,736 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,623 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147,376 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233,397 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 182623000 0 0 233397000 0 124736000 0 0 137384000 0 0 0 0 0 9992000 0 0 124736000 182623000 0 147376000 233397000 0 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:12pt;padding-right:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. Other Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s other assets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans to physician partners</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,862 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health plan deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,906 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145,312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">See Note 14 for additional discussion related to the Company's equity method investments.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans to Physician Partners</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans to physician partners primarily represent loans in connection with taxes payable on shares distributed to them in connection with the IPO. These loans mature between 2026 and 2031 with nominal interest compounding annually and no prepayment penalties. Such loans are stated at the amount expected to be collected.</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s other assets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans to physician partners</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,862 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health plan deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,906 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145,312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">See Note 14 for additional discussion related to the Company's equity method investments.</span></div> 71561000 71862000 2051000 2051000 53672000 44753000 13092000 13411000 15530000 13235000 155906000 145312000 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. Medical Claims and Related Payables</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense represents costs incurred for medical services provided to members by physicians, hospitals and other ancillary providers for which the Company is financially responsible and that are paid either directly by the Company or by payors with whom the Company has contracted. Medical services expenses are recognized in the period in which services are provided and include estimates of claims that have been incurred but have either not yet been received, processed, or paid and as such, not reported.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such estimates are developed using actuarial methods commonly used by health insurance actuaries that include a number of factors and assumptions including medical service utilization trends, changes in membership, observed medical cost trends, historical claim payment patterns and other factors. Generally, for the most recent months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average PMPM medical costs incurred in prior months for which more complete claims data are available.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each period, the Company re-examines previously established medical claims payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claims information becomes available, the Company adjusts its estimates and recognizes those changes in estimates in the period in which the change is identified. The difference between the estimated liability and the actual settlements of claims is recognized in the period the claims are settled. The Company’s medical claims payable balance represents management’s best estimate of its liability for unpaid medical costs as of March 31, 2024 and 2023. The Company uses judgment to determine the appropriate assumptions for developing the required estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of changes in medical claims and related payables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical claims and related payables, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">723,071 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339,749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of incurred costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,427,328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">872,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations - current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations - prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,443,842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">972,827 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(316,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(223,425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(595,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(278,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations - current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations - prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(912,029)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(579,046)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical claims and related payables, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,254,884 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">733,530 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Medical claims and related payables also include $11.8 million and $14.7 million, as of March 31, 2024 and December 31, 2023, respectively, that is recoverable from other parties under risk sharing arrangements and is presented as prepaid expenses and other current assets, net in the condensed consolidated balance sheets. Medical claims and related payables presented in the periods above include immaterial balances related to claims liabilities associated with certain divested California businesses for which the Company has retained the liability for claims incurred prior to the date of divestiture. <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of changes in medical claims and related payables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical claims and related payables, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">723,071 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339,749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of incurred costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,427,328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">872,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations - current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations - prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,443,842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">972,827 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(316,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(223,425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(595,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(278,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations - current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations - prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(912,029)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(579,046)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical claims and related payables, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,254,884 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">733,530 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 723071000 339749000 1427328000 872973000 16514000 24599000 0 71333000 0 3922000 1443842000 972827000 316779000 223425000 595250000 278688000 0 34793000 0 42140000 912029000 579046000 1254884000 733530000 11800000 14700000 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. Other Liabilities</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s other liabilities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term contingencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">L<span style="-sec-ix-hidden:f-465"><span style="-sec-ix-hidden:f-466">ease liabilities, long-term</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,905 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method liabilities – CMS ACO Models</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,495 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,381 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both March 31, 2024 and December 31, 2023, the Company’s accruals for contingent liabilities related to unasserted claims were $49.0 million. The accrued amounts represent the Company’s estimate of probable losses in accordance with ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 14 for equity method liabilities related to the Company's CMS ACO Models investments.</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s other liabilities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term contingencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">L<span style="-sec-ix-hidden:f-465"><span style="-sec-ix-hidden:f-466">ease liabilities, long-term</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,905 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method liabilities – CMS ACO Models</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,495 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,381 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 49000000 49000000 10618000 10905000 2284000 1199000 9593000 9277000 71495000 70381000 49000000 49000000 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. Debt</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2021, the Company executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the “Credit Facility”). The Credit Facility includes: (i) a $100.0 million secured term loan (the “Secured Term Loan Facility”) and (ii) a $100.0 million senior secured revolving credit facility (the “Secured Revolving Facility”) with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $100.0 million. Subject to specified </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $50.0 million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of the Company’s indebtedness. The maturity date of the Credit Facility is February 18, 2026.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company had $37.5 million outstanding under the Secured Term Loan Facility and availability under the Secured Revolving Facility was $60.7 million, as the Company had outstanding letters of credit totaling $39.3 million. The standby letters of credit are automatically extended without amendment for one-year periods, unless the Company notifies the institution in advance of the expiration date that the letter will be terminated. No amounts have been drawn on the outstanding letters of credit as of March 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective with the Second Amendment to Credit Agreement on May 25, 2023, the Company transitioned to the Secured Overnight Financing Rate ("SOFR") as a benchmark interest rate used in the Credit Agreement. At the Company’s option, borrowings under the Credit Agreement can be either: (i) SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans. Daily Simple SOFR Rate Loans and SOFR Rate Loans bear interest at a rate equal to the sum of 3.50% and the higher of (a) SOFR, as defined in the credit agreement, and (b) 0%. Base Rate Loans bear interest at a rate equal to the sum of 2.50% and the highest of: (a) 0.50% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus 1.00% and (d) 0%. Additionally, the Company pays a commitment fee on the unfunded Secured Revolving Facility amount of 0.375%. The Company must also pay customary letter of credit fees. As of March 31, 2024, the effective interest rate on the Secured Term Loan Facility was 9.394%.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility is guaranteed by certain of the Company’s subsidiaries, including those identified as VIEs, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios. Failure to meet any of these covenants could result in an event of default under the Credit Agreement. If an event of default occurs, the lenders could elect to declare all amounts outstanding under the Credit Agreement to be immediately due and payable. The Company was in compliance with all covenants under the Credit Facilities.</span></div>As of both March 31, 2024 and December 31, 2023, the Company had $25.1 million outstanding surety bonds related to health plan payor risk-bearing capital contributions. 100000000 100000000 100000000 50000000 37500000 60700000 39300000 P1Y 0 0.0350 0 0.0250 0.0050 0.0100 0 0.00375 0.09394 25100000 25100000 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;padding-right:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. Commitments and Contingencies</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to, or has a significant relationship to, legal proceedings, lawsuits, and other claims that arise in the ordinary course of the Company's business. Except as described in this Note 9, the Company is not aware of any other legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company's business, prospects, financial condition, results of operations or cash flows. The Company’s policy is to expense legal costs as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February and March 2024, three putative class action lawsuits, (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Teamsters Pension Fund v. agilon health, inc. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 1:24-cv-00297 (W.D. Tex., March 19, 2024); (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hope v. agilon health, inc. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 1:24-cv-00305 (W.D. Tex., March 25, 2024); and (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indiana Public Retirement System v. agilon health et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 1:24-cv-02506 (S.D.N.Y., April 2, 2024), were filed. The lawsuits name the Company and certain current and former members of the Company’s executive team and Board of Directors as defendants. The lawsuits generally assert securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended, in connection with statements made in the Company’s annual and quarterly reports and earnings releases related to, among other things, the Company’s medical utilization and claims rates, medical margin, incurred but not reported reserve, and profit margins between April 2021 to February 2024. The lawsuits seek compensatory damages, attorney’s fees and other unspecified equitable and/or injunctive relief. The Company is unable to estimate the ultimate individual or aggregate amount of monetary liability or financial impact due to the early stages of the litigation.</span></div> 3 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. Common Stock</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the three months ended March 31, 2024, the Company issued approximately 2.5 million shares of common stock primarily in connection with exercises and vesting of stock-based awards. Additionally, during the three months ended March 31, 2024, the Company issued approximately 2.0 million shares of common stock to settle liabilities related to the exchange of common stock for reduced physician partner compensation percentage in certain ACO REACH entities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023</span>. During the three months ended March 31, 2023, the Company issued approximately 2.1 million shares of common stock primarily in connection with exercises and vesting of stock-based awards. 2500000 2000000 2100000 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. Net Income (Loss) Per Common Share</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share (“EPS”) is computed based upon the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed based upon the weighted average number of common shares outstanding plus the impact of common shares issuable from the assumed conversion of stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on basic net income (loss) per share are included in diluted net income (loss) per share during the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests’ share in (earnings) loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to common stockholders before discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,217 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,014 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,064)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,022 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding – basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">408,938</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413,136</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding – diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413,437</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">426,586</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) per share attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per common share from continuing operations, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per common share from discontinued operations, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the weighted-average potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,616</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,098</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,657</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,592</span></td></tr></table></div> <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests’ share in (earnings) loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to common stockholders before discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,217 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,014 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,064)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,022 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding – basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">408,938</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413,136</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding – diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413,437</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">426,586</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) per share attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per common share from continuing operations, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per common share from discontinued operations, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 3247000 9951000 30000 -63000 3217000 10014000 -9281000 6008000 -6064000 16022000 408938000 413136000 413437000 426586000 0.01 0.01 0.02 0.02 -0.02 -0.02 0.02 0.02 <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the weighted-average potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,616</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,098</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,657</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,592</span></td></tr></table></div> 6616000 2098000 9657000 4592000 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. Goodwill and Amortizable Intangible Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both March 31, 2024 and December 31, 2023, the Company’s goodwill balance was $24.1 million. There were no events or circumstances that warranted an interim impairment test for goodwill during the three months ended March 31, 2024. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the Company’s gross carrying amount of amortizable intangible assets was $119.2 million and $108.0 million, with accumulated amortization of $47.1 million and $44.2 million, respectively. For the three months ended March 31, 2024 and 2023, the Company recognized $2.9 million and $1.3 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition</span></div>On February 28, 2023, the Company completed the acquisition of My Personal Health Record Express, Inc. (the “Acquisition”), a leading provider of value-based care technology and interoperability solutions for cash consideration of $45.3 million, net of cash acquired and subject to certain post-closing adjustments. The Company accounted for the Acquisition utilizing the acquisition method of accounting, which requires assets and liabilities to be recognized based on estimates of their acquisition date fair values. The determination of the values of the acquired assets and assumed liabilities, including other intangible assets and deferred taxes, requires significant judgment. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, the Company estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Measurement period adjustments are recorded in the period in which they are determined, as if they had been completed at the acquisition date. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within the Company's consolidated results of operations. The following allocation of the purchase price related to the Acquisition based upon the fair value of assets, which primarily included developed technology of $27.5 million, and assumed net liabilities of $3.8 million, with the residual amount being recorded as goodwill of $21.6 million. The intangible assets acquired have a weighted-average life of 10 years. 24100000 24100000 119200000 108000000 47100000 44200000 2900000 1300000 45300000 27500000 3800000 21600000 P10Y <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. Supplemental Cash Flow Information</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental cash flow information (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset obtained in exchange for new operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement of liabilities through issuance of stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107,570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,550 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,329 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span>Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors. <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental cash flow information (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset obtained in exchange for new operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement of liabilities through issuance of stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1069000 1352000 227000 171000 326000 435000 15230000 0 <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107,570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,550 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,329 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span>Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors. <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107,570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,550 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,329 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span>Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors. 111706000 107570000 6844000 6759000 118550000 114329000 <div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. Variable Interest Entities</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc.’s consolidated assets and liabilities as of March 31, 2024 and December 31, 2023 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to agilon health, inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc.’s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,569,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">940,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and related payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,266,651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">737,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-bearing Entities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At March 31, 2024, the Company operates 34 wholly-owned risk-bearing entities (“RBEs”) for the purpose of entering into risk-bearing contracts with payors. Each RBE’s equity at risk is considered insufficient to finance its activities without additional support, and, therefore, each RBE is considered a VIE. The Company consolidates the RBEs as it has determined that it is the primary beneficiary because it has: (i) the ability to control the activities that most significantly impact the RBEs’ economic performance; and (ii) the obligation to absorb losses or right to receive benefits that could potentially be significant to the RBEs. Specifically, the Company has the unilateral ability and authority, through the RBE governance and management agreements, to make significant decisions about strategic and operating activities of the RBEs, including negotiating and entering into risk-bearing contracts with payors, and approving the RBEs’ annual operating budgets. The Company also has the obligation to fund losses of the RBEs and the right to receive a significant percentage of any financial surplus generated by the RBEs. The assets of the RBEs primarily consist of cash and cash equivalents, receivables, net, intangible assets, net, and other assets. Its obligations primarily consist of medical claims and related payables as well as operating expenses of the RBEs (accounts payable and accrued expenses), including incentive compensation obligations to the Company’s physician partners. On February 18, 2021, the Company executed the Credit Facility, which is guaranteed by certain of the Company’s VIEs. Assets generated by the RBEs (primarily from medical services revenues) may be used, in certain limited circumstances, to settle the Company’s contractual debt obligations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company had 11 equity method investees that were deemed to be VIEs. The Company has determined that the activities that most significantly impact the performance of these VIEs consist of the allocation of resources to and other decisions related to clinical activities and provider contracting decisions. Because the Company does not have the ability to control these activities due to another party’s control of the VIEs’ board of directors, the Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs. The Company provided support to assist its CMS ACO Models investments in obtaining surety bonds related to risk-bearing capital contributions to CMS. As of March 31, 2024 and December 31, 2023, the ACOs had $103.0 million and $38.5 million outstanding surety bonds. The Company's maximum loss exposure as a result of the Company’s involvement with the VIEs cannot be quantified as the Company has the obligation to provide ongoing operational support to the unconsolidated VIEs, as needed.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s equity method investees (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments - Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments - CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method liabilities - CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Other assets, net in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Other liabilities in the condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a partner in 10 wholly-owned CMS ACO Models entities in collaboration with 15 of its physician group partners operating in 13 geographies. The combined summarized operating results of the Company’s CMS ACO Models entities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">440,160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">280,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(398,792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(257,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,744)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:26.68pt">For the three months ended March 31, 2024 and 2023, includes physician incentive expenses of $16.7 million and $9.7 million, respectively. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combined summarized balance sheet of the Company’s CMS ACO Models entities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174,967 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">297,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">178,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc.’s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,569,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">940,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and related payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,266,651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">737,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 59680000 62154000 6842000 6757000 1569319000 940618000 21926000 21907000 1636000 1754000 46578000 25561000 6144000 6334000 1266651000 737724000 219407000 188671000 5062000 4184000 34 11 103000000 38500000 <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s equity method investees (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments - Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments - CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method liabilities - CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Other assets, net in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Other liabilities in the condensed consolidated balance sheets.</span></div> 9477000 9148000 44195000 35605000 2284000 1199000 10 15 13 The combined summarized operating results of the Company’s CMS ACO Models entities are as follows (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">440,160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">280,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(398,792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(257,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,744)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:26.68pt">For the three months ended March 31, 2024 and 2023, includes physician incentive expenses of $16.7 million and $9.7 million, respectively. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.</span></div> 440160000 280529000 398792000 257477000 25405000 15744000 9532000 2001000 5631000 1334000 16700000 9700000 <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combined summarized balance sheet of the Company’s CMS ACO Models entities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174,967 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">297,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">178,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 294399000 174967000 3341000 3341000 297740000 178308000 255829000 142027000 <div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. Discontinued Operations</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations is a component of an entity that has either been disposed of or is deemed held-for-sale and, (i) the operations and cash flows of the component have been or will be eliminated from ongoing operations as a result of the disposal transaction, and (ii) the entity will not have any significant continuing involvement in the operations of the component after the disposal transaction. On October 31, 2023, the Company completed the disposition of MDX Hawaii, Inc. and its related operations. The Company’s decision to exit Hawaii and the Independent Practice Association line of business represents a strategic shift that will have a major effect on its operations and financial results. As such, the Company’s Hawaii operations are reflected in the consolidated financial statements as discontinued operations for all periods presented. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of discontinued operations are as follows (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,835 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(518)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sales of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) from discontinued operations attributable to common shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,281)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides significant non-cash operating items for discontinued operations that are included in the consolidated statements of cash flows for the three months ended March 31, 2023 (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-cash operating activities from discontinued operations:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of discontinued operations are as follows (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,835 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(518)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sales of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) from discontinued operations attributable to common shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,281)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides significant non-cash operating items for discontinued operations that are included in the consolidated statements of cash flows for the three months ended March 31, 2023 (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-cash operating activities from discontinued operations:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 81711000 0 124000 0 81835000 0 75255000 0 2407000 518000 -2906000 0 1235000 -518000 5844000 0 204000 -8763000 0 0 40000 -9281000 6008000 1235000 87000 <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2024, Veeral Desai, the registrant’s Chief Strategy and Development Officer, adopted a Rule 10b5-1 plan intended to satisfy the affirmative defense of SEC Rule 10b5-1(c). The trading plan commences June 15, 2024, ends August 30, 2024 and covers 1,000,000 options to purchase common stock of the registrant.</span></div> March 15, 2024 Veeral Desai Chief Strategy and Development Officer true false false false 1000000